PMC1180449|S63|3a|Trial Design|Design|This is an observer-blind prospective, controlled and randomised parallel group study.
PMC1180449|S95|7a|Sample Size Determination|Sample size|A trial with 20 patients in each treatment group will provide us with a power (1-β) of 80% to detect a relative reduction in number of patients with persisting PDPH after 24 hours of 50% (OR = 12) and a power of 99% to detect a relative risk reduction of 80%, (OR = 81, at the usual significance level α = 5%, taking into account that in approximately 10% of the patients the PDPH will have resolved spontaneously after one day.
PMC125317|S32|4a|Eligibility Criteria|Patients|After approval by the faculty ethics committee, patients with severe sepsis (temperature >38°C or <36°C, heart rate >90 beats/min, respiratory rate >20/min or PaCO2 < 32 mmHg, white blood cell count >12,000/mm3 or <4000/mm3, documented infection and dysfunction of an organ or hypotension) were enrolled in the study.
PMC1386726|S50|5|Interventions|Interventions|Details of the interventions used have previously been published[18], but a brief description is given below.
PMC1403777|S62|3a|Trial Design|Study design|The proposed study is a randomised controlled trial, with blinded treatment allocation, assessment and analysis, in which 70 patients undergoing a scheduled unilateral TKA will be evaluated to assess the added value of CPM at home, using function and mobility as the main outcomes.
PMC1458347|S91|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Data were analysed by Statistical Package for the Social Sciences (SPSS) version 10.0, × 2 test for qualitative variables, and Student's t test for quantitative variables.
PMC1459128|S46|3a|Trial Design|Design|The study was a randomised controlled trial of a solution-focused follow-up versus regular follow-up.
PMC1513567|S41|3a|Trial Design|Study design|We conducted a single blind RCT with individuals randomly allocated to intervention (receipt of immediate welfare rights assessment, advice and active assistance with claims) or control condition (receipt of the intervention after a six month delay).
PMC1550238|S100|6a|Outcomes|Assessments|Assessments take place at baseline (T0), start of the programme (T1), at three (T2), six (T3), nine (T4) and twelve months (T5) and then at eighteen = follow-up1 (T6) and twenty-four = follow-up2 (T7) months.
PMC1594582|S97|3a|Trial Design|Study design|Randomized, double blind, placebo-controlled, cross-over clinical trial (Figure 2).
PMC1610114|S41|3a|Trial Design|Design|Singleblinded Radomized Clinical Trial.
PMC1904445|S87|9|Allocation Concealment Mechanism|Allocation concealment|Given the cluster design participant concealment was not possible but data extraction and analysis was carried out in blind fashion by one of us (DM).
PMC1904445|S89|12a|Statistical Methods for Outcome Comparison|Statistical methods|We carried out comparisons of primary outcomes between the intervention and control arms at cluster (GP) level as this was the unit of randomisation [22] and data were analysed using a cluster specific method, Generalised Estimating Equation (GEE) model [23,24].
PMC1976105|S80|4a|Eligibility Criteria|Exclusion criteria|Exclusion criteria: breech presentation, twin pregnancies, maternal age < 18 years or absent informed consent.
PMC2001290|S99|11a|Blinding Procedure|Blinding|The study was single blind (participant unaware of product applied).
PMC200974|S137|7a|Sample Size Determination|Sample size|Assuming a conservative estimate of 30% attrition at 1 year (a lower attrition would increase the power of the study) due to death and loss to follow-up (15% in Jolly 1999 [66]), a sample size of 650 patients (450 evaluable at 1 year) would have 90% power, at the 5% significance level, to detect the differences tabulated (table 3) (population standard deviations estimated from Jolly 1999 [66]).
PMC2040506|S81|7a|Sample Size Determination|Sample size calculation|Assuming a risk of recrudescence adjusted by genotyping of 6% for MAS3 and 1% for DHA-PPQ group, we calculated that a minimum of 250 patients would be needed in each treatment arm to detect a significant difference at 5% significance level and 80% power.
PMC2111052|S51|5|Interventions|Interventions|Participants were randomized to receive a standard dose of AS and SP (AS+SP) over three days, or AS+SP over the first three days plus primaquine (PQ) administered on the fourth day.
PMC2111052|S82|11a|Blinding Procedure|Blinding|The trial was not blinded; however laboratory staff performing the PCR assays were unaware of the treatment allocation.
PMC2216688|S115|8a|Random Allocation Sequence Generation|Randomization—Sequence generation|Using SAS, a randomization list was prepared in advance of vaccination activities with randomized block of N = 2 (one subject receiving saline and the other Alhydrogel formulated vaccine) for the August 2002 cohorts.
PMC2228299|S65|4a|Eligibility Criteria|Study population|All patients between 16–65 years with an acute lateral ankle sprain (less than 1 week since injury) will be considered for participation in the study.
PMC222984|S59|9|Allocation Concealment Mechanism|Allocation concealment|The randomization code of the monotherapy arms of the study remained concealed until all patients had completed their follow up and the database had been verified and closed.
PMC2258152|S128|9|Allocation Concealment Mechanism|Randomization−Allocation concealment|This was an open-label study.
PMC2258152|S130|10|Randomization Implementation|Randomization−Implementation|Scratch cards were provided to clinicians and were selected consecutively on patient enrolment to reveal treatment allocation.
PMC2276521|S163|11a|Blinding Procedure|Blinding|The clinicians, those administering the trial medication, the caregivers, the relatives, the patients themselves, and those assessing the outcomes were all blinded to treatment allocation.
PMC2329664|S117|6a|Outcomes|Outcome measures|Outcome measures and assessment moments are presented in table 2.
PMC2359503|S66|12a|Statistical Methods for Outcome Comparison|Statistical Analyses|We compared baseline sociodemographic, diagnostic, and symptom severity variables by recruitment strategy using t tests for continuous data and chi-square analyses for categorical data.
PMC2361459|S84|7a|Sample Size Determination|Sample size|Safety and tolerability was assessed on the basis of a sample size of 10 patients per dose level.
PMC2364646|S76|11a|Blinding Procedure|Blinding|Participants and those administering interventions were not blinded to the interventions, but participants were not informed of the specific nature of the other interventions applied to other participating households.
PMC2374894|S120|11a|Blinding Procedure|Blinding|This study was conducted as an open study.
PMC2375887|S62|3a|Trial Design|Study design|The study was carried out in three phases: the first was translation into Spanish and cultural adaptation of the NDI and COM; the second was a pilot study to assess the comprehensibility and reproducibility of those Spanish versions; and the third was a validation study to determine their metric characteristics and to compare them with those of the NPQ.
PMC2386789|S69|3a|Trial Design|Study design|A randomised controlled trial, with blinded treatment allocation, assessment and analysis, was carried out, with local medical ethics committee approval, to assess the added value of prolonged CPM use at home, using function and mobility as the main outcomes.
PMC2405770|S103|7a|Sample Size Determination|Sample size|Adopting the results of karyotyping as the gold standard and assuming that MLPA and karyotyping do not produce different test results, that not more than 1/500 missed cases of Down syndrome are accepted, and that the proportion of discordant test results is 0.002, we need at least 4500 paired test results to test the null-hypothesis of clinical equivalence (one-sided alpha 0.05, power = 1-beta = 0.90).
PMC2405936|S99|10|Randomization Implementation|Randomization—Implementation|The nurse administered treatment by opening an envelope with a matching treatment number sequentially assigned by the study physician.
PMC2409316|S236|12a|Statistical Methods for Outcome Comparison|Analysis|The relative risks of outcomes between the intensive care with cooling group and the intensive care group will be calculated, along with 95% confidence intervals.
PMC2409363|S55|3a|Trial Design|Study design|The study was designed as a double blind, placebo controlled study to compare the antipyretic efficacy of ibuprofen versus placebo in children with uncomplicated falciparum malaria.
PMC2440367|S52|4b|Data Collection Setting|Data collection|Demographic and arrest data is collected according to Utstein guidelines and stored in a database designed with Microsoft access software (Microsoft Inc., Redmond, WA).
PMC2447850|S83|11a|Blinding Procedure|Blinding|An independent physiotherapist blinded to group allocation will assess all participants using the battery of outcome assessments on entry to the study, on completion of the eight-week trial and finally at the three month follow-up stage.
PMC2453103|S63|8b,10|Randomization Type,Randomization Implementation|Randomisation|Randomisation is performed by a web-based randomisation program, using a computer program with stratification for hospital and serum hCG concentration (< 1,000 IU/l versus 1,000–2,000 IU/l).
PMC2464580|S117|12b|Statistical Methods for Other Analyses|Subgroup analyses|Pre conceived subgroup analyses are planned for age (under and over 30 years), history of a previous EP, pre-operative serum hCG-level (< 3,000 IU/l, 3,000–6,000 IU/l, and > 6,000 IU/l), and size of the ectopic mass (less or more than 4 cm).
PMC2467399|S117|12a|Statistical Methods for Outcome Comparison|Statistical analysis|The analysis will be performed in accordance with the intention to treat principle.
PMC2481397|S60|8a|Random Allocation Sequence Generation|Randomization—Sequence generation|Randomisation was performed following consent using computer minimisation on age (>70 years), delay from ischaemic event, ischaemic event (stroke or TIA) and baseline systolic blood pressure (SBP).
PMC2481397|S64|10|Randomization Implementation|Randomization—Implementation|Patients were identified and enrolled by research nurses (with consent obtained by clinical research fellows); treatment assignment was performed by a third party.
PMC2486263|S36|3a|Trial Design|Study design|Multicenter, double blind, randomized and placebo controlled trial.
PMC2529300|S108|5|Interventions|Intervention|Forty ambulatory patients with KOA are randomly assigned to receive Tai Chi (n = 20) or attention control (wellness education and stretching) (n = 20) in twice-weekly one-hour group sessions for 12 weeks (Figure 1).
PMC2532999|S49|3a|Trial Design|Study design|The REACT-trial is a prospective, patient-randomized study that will compare the clinical work-up of trauma patients in a setting where the CT scanner is located in the shockroom (AMC) with the standard situation where CT scanning takes place at the Radiology Department (VUmc).
PMC2551629|S54|6a|Outcomes|Outcomes|The primary outcome was the comparison of A1C change and the proportion of subjects who reached the treatment target (A1C ≤7.0 or ≤6.5% at 6 and 12 months, respectively).
PMC2566605|S42|3a|Trial Design|Study design|The study was an investigator-initiated, single-centre, randomized, double-masked, parallel trial of metformin versus placebo treatments.
PMC2567972|S57|3a|Trial Design|Design|Quasi-experimental, prospective, multi-centre study, with a concurrent control group, conducted between 2003 and late 2006, focusing on public home care services delivered by Primary Health Care in four districts in Andalusia (Spain), namely Malaga (DSM), Almeria (DSA), Granada (DSG) and Costa del Sol (DSCS).
PMC2575590|S49|3a|Trial Design|Study design|We conducted a prospective, randomized, double-blind, placebo-controlled, single-center trial with the approval of the institutional ethics committee.
PMC2583045|S45|4a|Eligibility Criteria|Participants|Our service targeted primary care providers in Family Health Networks (FHNs) and Family Health Groups (FHGs), two recently introduced models for primary care service delivery in Ontario.
PMC2640375|S34|4b|Data Collection Setting|Setting|Lazio is a region of about 5,3 million inhabitants, located in Central Italy, that include Rome (3 million inhabitants).
PMC2642861|S74|12a|Statistical Methods for Outcome Comparison|Statistical analyses|An independent statistician analysed the data using t-tests (for single between-group comparisons), ANCOVA (for between-group comparisons at specific timepoints, using baseline score as a covariate) and a mixed linear regression model on repeated measures data (for between-group comparisons across all timepoints) to analyze data for an Intent to Treat Group (including all subjects enrolled and treated in this trial with values imputed for their Last Observation Carried Forward (LOCF) for any subjects who did not complete the trial) and a Completer's Group (including only data from subjects who completed the trial per protocol).
PMC2644264|S59|7a|Sample Size Determination|Sample size|In order to detect a 15% difference in adequate parasite clearance by day 28 between symptomatic 6–59 month old children and asymptomatic 2–10 month old children with 80% power at the 5% significance level using a ratio of 2 symptomatic cases to 1 asymptomatic case, we estimated that 292 symptomatic children and 146 asymptomatic infants would be required.
PMC2645389|S51|4a|Eligibility Criteria|Inclusion criteria|• Age ≥ 40 years           • Premenopausal patients           • Patients who do not want conception any more           • Patients who agree to the current study protocol with informed consent           • Patients with more than 2 cm sized uterine fibroids on ultrasonography (USG)           • Patients with symptomatic uterine fibroids such as menorrhagia, dysmenorrhea, lower abdominal discomfort or pain, lower back pain and urological symptoms including dysuria and frequency           • Patients without underlying disease affecting QOL           • At least six months interval after last medication if patients have been treated with GnRH agonists.
PMC2646129|S50|7a|Sample Size Determination|Sample Size|Sample size calculations were based on other studies with similar design and allow for a detection of standardized effect sizes of 0.9 with 80% power to detect changes in intramuscular phosphocreatine (PCr) levels.
PMC2653461|S87|4a|Eligibility Criteria|Participants|Potential participants will be recruited from the physiotherapy waiting lists in the four participating hospitals if they meet the inclusion criteria as shown in Table 1.
PMC2653463|S78|3a|Trial Design|Study Design|Multicentred randomised, double blind, placebo-controlled trial.
PMC2656923|S62|6a|Outcomes|Outcomes|The primary end points were all cause mortality and adverse events leading to an interruption of trial drug.
PMC2656923|S76|7a|Sample Size Determination|Sample size|Assuming a death rate of 15 per 100 person years in the previously untreated participants (based on a death rate of 18/100 person years in a trial in a similar population of patients in Lusaka15), a total of 1408 person years of observation would be needed to show a 35% reduction in death rate in patients receiving co-trimoxazole, at the 5% level of significance with 80% power; a 40% reduction would require 1045 person years.
PMC2660319|S121|4a|Eligibility Criteria|Patients|Patients diagnosed with TS, aged 7–14 years, either sex, with a minimum score of 40 points on the Yale Global Tic Severity Scale (YGTSS) [29], among whom the onset of clinical exacerbation has been observed.
PMC2662878|S38|4b|Data Collection Setting|Setting|This project was carried out in the city of Lawrence, Massachusetts, a primarily Latino community characterized by families struggling with high levels of poverty, limited access to jobs, and limited access to resources families need to prosper [11].
PMC2664964|S135|6a|Outcomes|Outcomes|Outcome measures were changes in anthropometry (BMI, weight, waist, waist-to-hip ratio), VO2max, self-reported physical activity, blood pressure, triglycerides, cholesterols (total, HDL, and LDL), fasting blood glucose, glucose tolerance, and HbA1c.
PMC2667489|S61|5|Interventions|Interventions|Data on the treatment effects of liraglutide 1.2 mg and 1.8 mg or rosiglitazone added to glimepiride were extracted from the LEAD-1 study (Table 1).
PMC2669069|S37|3a|Trial Design|Design|A two-arm parallel group, multi-centre, randomised controlled trial with outcome data collection every 12 weeks to 48 weeks post-randomisation.
PMC270093|S58|4a|Eligibility Criteria|Exclusion criteria|• Pregnant or lactating women         • Women planning on becoming pregnant within the next year         • Any illness or reason where the GP feels that the patient should not be taking part in a clinical trial.
PMC2701554|S41|3a|Trial Design|Design|A multiprofessional team comprising a consultant diabetologist, diabetes specialist nurse, specialist diabetes dietician and clinical health psychologist designed the BITES intervention.
PMC2705367|S43|3a|Trial Design|Study Design|Randomized, double-blinded, placebo-controlled, phase II clinical trial.
PMC2706243|S99|7a|Sample Size Determination|Sample size|Based on a recent systematic review and meta-analysis of 26 randomized controlled trials, we anticipate an incidence of CIN at 48 to 96 hours of approximately 15%[16] In order to detect a 30% relative risk reduction (RRR), with 90% statistical power, and a two-tailed alpha of 5%, we will need to include at least 2,300 patients.
PMC2714003|S74|4b|Data Collection Setting|Setting|A sample of patients will be recruited in Dublin, Ireland through the physiotherapy departments of acute public hospitals that provide physiotherapy treatment for people with CLBP.
PMC2716313|S57|7a|Sample Size Determination|Sample size|900 patients including 450 patients randomised for OPCAB and 450 randomized for CCABG.
PMC2724683|S95|8a|Random Allocation Sequence Generation|Randomization − Sequence generation|GlaxoSmithKline generated the randomization schedule comprising blocks of six patients by center.
PMC2724683|S100|11a|Blinding Procedure|Blinding|Investigators, technicians performing microbiological assessments and patients were blinded to study treatments.
PMC2724738|S116|7a|Sample Size Determination|Sample Size|Using data from the pilot study, we estimated we would need about 750 to 800 participants per group to achieve 80% power to test each one of the three hypotheses at 0.0167 alpha level (after applying a Bonferroni correction).
PMC2729073|S99|6a|Outcomes|Measures|The primary outcome was weight in kilograms measured in the research offices using a calibrated scale.
PMC2731082|S106|12a|Statistical Methods for Outcome Comparison|Data analysis|In order to examine the feasibility of the trial methodology, the following were examined: response rates to the trial; response rates to the individual questionnaires and items; comments relating to the trial functioning made during interviews with patients, carers, referrers and BIS providers; and, researcher fieldwork notes.
PMC2736167|S42|4a|Eligibility Criteria|Participants|A consecutive sample of 24 male patients with an idiopathic Parkinson disease diagnosed by a neurologist, with the following criteria were entered into the study: age ≤ 65 years, stage 2 to 3 of the Hoehn and Yahr scales [16], no cardiovascular, orthopaedic, or other neurological disease, no cognitive impairment (MMSE score >24; [17]), and had not received exercise therapy within the 6 months prior to the study.
PMC2753618|S59|4b|Data Collection Setting|Setting|Five acute older persons' care wards at Nottingham University Hospitals NHS Trust (NUH).
PMC2760547|S97|11a|Blinding Procedure|Blinding|This is an open-label study.
PMC2761912|S33|3a|Trial Design|Design|A two-arm parallel group randomised controlled trial with outcome data collection every 4 weeks to 32 weeks post-randomisation.
PMC2767482|S85|7a|Sample Size Determination|Sample size|Based on existing default rates of 13%, we calculated that we needed to enrol 270 patients to detect a reduction in the primary outcome (default rate) to an acceptable 3%, with 80% power and an α of 0.05.
PMC2770987|S79|3a|Trial Design|Study Design|Multicentered randomised, double-blind, placebo-controlled trial.
PMC2774677|S57|4b|Data Collection Setting|Setting|Patients were recruited from the practices of 11 general practitioners in the northern part of the Netherlands.
PMC2782970|S26|7a|Sample Size Determination|Sample size|Based on differences in the postprandial responses of triglycerides in the chylomicrons and VLDL fractions between diabetic and control subjects (0.7 mmol/l per 6 h, SD 0.85 mmol/l) (12), we considered as clinically relevant a 30% difference between the two treatments of the primary end point (postprandial incremental area of triglycerides content in chylomicrons and VLDL fraction).
PMC2789586|S38|4a|Eligibility Criteria|Patients|In brief, patients aged 12–75 years, who fulfilled ACR criteria [19], with a diagnosis of SLE and histologically confirmed LN (Classes III–V with active or active/chronic lesions, International Society of Nephrology/Renal Pathology Society classification [20]) were enrolled at 88 hospital clinics in 20 countries in Asia, Australia, Europe, Latin America, USA and Canada between July 2005 and October 2006.
PMC2790457|S146|6a|Outcomes|Primary outcomes|There are three primary study outcomes 1) telephone calls to CIS (call volume); 2) timely completion of medical follow-up (within 6 months); 3) patient satisfaction with doctor-patient communication at medical follow-up.
PMC2803175|S89|4a|Eligibility Criteria|Inclusion and Exclusion Criteria|• Histologically or cytologically confirmed gastric adenocarcinoma with or without prior resection of the primary or metastatic disease           • Limited metastatic disease that is measurable by CT, mandatory PET scan and/or MRI:           - Esophageal invasion <4 cm that does not require thoracotomy (Seiwert II and III lesions)           - Hepatic metastases (unilateral or bilateral, ≤ 5 lesions, ≤ 15 cm total diameter)           - Primary peritoneal metastases (small disease load, ≤ P2 disease) without clinically significant ascites or intestinal obstruction           - Lung metastases (≤ 3 unilateral/bilateral, 9 cm total diameter)           - Patients who present with both hepatic and peritoneal metastases must have no evidence of extensive para-aortic/retro-pancreatic lymph node metastases           • All disease should be deemed resectable to negative margins (NED) based on imaging studies           • Patients with or without prior chemotherapy treatments for metastatic disease will be eligible           • Age greater than 18 years           • Clinical performance status of ECOG ≤ 2           • Life expectancy of greater than three months           • No history of prior/other malignancies within the 2 years prior to enrollment with the exception of basal cell carcinoma           • Laboratory parameters within acceptable limits to undergo surgical resection and/or systemic chemotherapy                             Exclusion Criteria
PMC2804565|S81|8b,10|Randomization Type,Randomization Implementation|Randomisation|Randomisation is performed by accessing a central internet-based randomisation program and is stratified for hospital.
PMC2805643|S116|7b|Interim Analyses/Stopping Guidelines|Interim Analyses|During the study interim analyses will be performed every year with the scope of verifying the correctness of the assumptions made for sample size estimation with regard to the primary end point event rate (this information can influence the duration of follow up) and to avoid unforecast excess of event rate in the treatment group.
PMC2819992|S124|9|Allocation Concealment Mechanism|Allocation concealment|The allocation schedule will be concealed through the use of a centralised web-based randomisation service.
PMC2819992|S129|11a|Blinding Procedure|Blinding|Data analysts will be blind to treatment allocation, but the study manager, research assistants and participants (who are also outcome assessors) will not be blinded.
PMC2828415|S48|3a|Trial Design|Study design|This will be a single-blind 2 arm pragmatic randomised controlled trial of individually prescribed exercise in a class setting versus usual care.
PMC2829558|S71|4b|Data Collection Setting|Study setting|The study will take place within Primary care practices in the geographical care covered by the North Thames Dementias and Neurodegenerative Diseases Research Network (NT DeNDRoN); Metropolitan North London, Essex, Hertfordshire and Bedfordshire.
PMC2841104|S47|3a|Trial Design|Study design|The FINALE programme consists of 3 randomized controlled trials (RCT) and 1 exploratory case-control study involving several workplaces.
PMC2841161|S140|7a|Sample Size Determination|Sample size|Under the assumption of four successful follow-up assessments and a within-subject correlation of r = 0.40, 72 participants in total would yield, at a two-sided alpha < 0.05, a power of 0.81 to detect a medium effect size of d = 0.35 for main effects [62], i.e. a difference of 0.35 of the pooled standard deviation.
PMC2846886|S49|3a|Trial Design|Study design|The study is designed as a mono center, single arm phase I/II pilot trial.
PMC2851683|S95|3a|Trial Design|Study design|Cross-sectional and multicentre study.
PMC2854122|S90|6a|Outcomes|Outcomes|Outcome measurements encompassed: a) the number of mf present in skin snip biopsies taken at baseline, 4, 12 and 21 months after the start of treatment, b) the quantity of a Wolbachia single copy gene (Wolbachia surface protein; wsp) within extirpated nodule tissue 21 months after the start of treatment and the immunohistochemical staining of Wolbachia within adult O. volvulus tissues 21 months after the start of treatment, c) the histological assessment of the frequency of embryonic stages present within female O. volvulus uteri 21 months after the start of treatment, d) the detection of adult O. volvulus motility within onchocercomas using ultrasonography e) histological assessment of parasite viability, f) the clinical monitoring and assessment of adverse reactions during primary drug allocation (doxycycline) or secondary drug allocation (ivermectin) in patients singly infected with O. volvulus or co-infected with L. loa and g) the number of L. loa and M. perstans mf present in 50 µl thick blood smears taken at baseline, 4, 12 and 21 months after the start of treatment.
PMC2858116|S37|3a|Trial Design|Design|A single arm Phase 2a study examining the efficacy of a liquid nicotine cigarette as an aid to smoking cessation.
PMC2859488|S47|3a|Trial Design|Design|Multicenter randomized clinical trial designed to compare antibiotic prescription in patients with acute pharyngitis in two groups of physicians, one with the use of RADT and the other without these tests.
PMC2859488|S49|4b|Data Collection Setting|Setting|The trial will be conducted in Primary Health Care Centers in Catalonia (Spain) in which the clinical history records are accessed electronically.
PMC2859488|S110|7a|Sample Size Determination|Sample size|Two hundred seventy-six patients are required in each arm to detect a reduction of 10% in antibiotic prescription from 85% in the control group to 75% in the intervention group, assuming a rate of 85% of prescription in the control group, allowing 10% for losses in the follow-up visits, with a power of 90% and a level of significance of 5% (2-sided) and performance values of the RADT given by the manufacturer.
PMC2869159|S73|4b|Data Collection Setting|Data collection|Data were collected at baseline and after 12 months from the following two sources: (i) a self-completed postal patient questionnaire (comprising questions on demographic and socioeconomic status, a questionnaire to ascertain patient satisfaction (Grunfeld et al, 1999), the Short Form-36 (SF-36) questionnaire (Ware, 1993) and the Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983)) and (ii) patients' general practice-held medical records for information about the initial melanoma diagnosis as well as treatment and use of primary and secondary care services in the previous 12 months.
PMC2873461|S50|4b|Data Collection Setting|Setting|A sample of patients will be recruited in Beaumont Hospital physiotherapy department that provides physiotherapy treatment for people with CLBP in the Northside of Dublin City.
PMC2874544|S73|4a|Eligibility Criteria|Inclusion Criteria|Patients must fulfill all of the following inclusion criteria:         • Peripheral or central intravenous catheter and urinary catheter         • Early AKI         • ≥ 2 criteria for the systemic inflammatory response syndrome (SIRS) within 24 hours         • Achieved immediate resuscitation goals (as directed by the treating physician) including fluid resuscitation AND/OR vasoactive therapy to achieve mean arterial pressure ≥65 mmHg, central venous pressure ≥8 cmH2O, central venous oxygen saturation ≥70% (if measured) AND/OR cardiac index ≥2.5 L/min/1.73 m2 (if measured).
PMC2875414|S56|12a|Statistical Methods for Outcome Comparison|Statistical methods|Differences between participants assigned to the ILI and DSE treatments were compared at baseline and 1-year using Student t test for unpaired data for continuous variables and a χ2 test for categorical variables.
PMC2877663|S124|6a|Outcomes|Measures|The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) Axis I Disorders, Clinical Version (SCID-I) and the Structured Clinical Interview for DSM-IV Personality Disorders (SIDP-IV) were used for diagnostic screening for PTSD and BPD, respectively.
PMC2880231|S48|8b,10|Randomization Type,Randomization Implementation|Randomisation|Randomisation was done at the level of the pathology laboratories (clusters).
PMC2888743|S49|3a|Trial Design|Study Design|We will conduct a comparative study with retrospective and prospective parts, in which we will compare the redesigned stroke service in the intervention region with a comparable region that offers the usual stroke care.
PMC2890338|S35|12a|Statistical Methods for Outcome Comparison|Statistical analyses|The main analyses included all subjects in the groups to which they were randomized.
PMC2890350|S39|6a|Outcomes|Outcome measures|There were two main objectives of the Cycloset Safety Trial: 1) assessment of overall safety of bromocriptine-QR by measuring the frequency of serious adverse events (SAEs) among patients taking bromocriptine-QR and placebo, and 2) cardiovascular safety assessed by determining the frequency of major cardiovascular events, defined as a composite of first myocardial infarction, stroke, coronary revascularization, or hospitalization for angina or congestive heart failure that occurred after randomization.
PMC2890362|S44|6a|Outcomes|Outcome measures|The outcomes were all-cause and CVD mortality (adjudicated by a blinded panel using predefined adjudication processes).
PMC2901361|S95|4b|Data Collection Setting|Data collection|Data were collected on Case Report Forms by the investigators, and entered in a data base using the Clininfo SA software (Clininfo SA, 99 rue de Gerland, 69007 Lyon, France).
PMC2902456|S56|5|Interventions|Interventions|After the diagnostic assessments, the patients are allocated for one of the following groups of treatment:         Group I: lithium + valproic acid         Group II: lithium + carbamazepine         Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability         Valproic acid: Starting at 500 mg daily, dose weekly adjusted according to blood serum level (50 and 125 μg/ml), efficacy and tolerability         Carbamazepine: Starting at 200 mg daily and getting 600 mg daily at the end of the first week.
PMC2903577|S32|3a|Trial Design|Study design|Two simultaneous multicentre parallel group double-blind randomised placebo controlled trials of Propranolol and Pizotifen.
PMC2903577|S34|4b|Data Collection Setting|Setting|Secondary care paediatric headache or neurology clinics.
PMC2905353|S84|4b|Data Collection Setting|Setting|The trial is taking place in three centres (Poole, Bristol, Southampton/Portsmouth) and each centre has a team of trained facilitators to deliver the fatigue management programme.
PMC2912827|S62|3a|Trial Design|Design|The study is a double blind randomised controlled clinical trial with two parallel groups.
PMC2913910|S47|4a|Eligibility Criteria|Study population|Female or male patients over 18 years old undergoing an elective repair for a midline incisional hernia are eligible for participation (table 3).
PMC2918573|S91|12a|Statistical Methods for Outcome Comparison|Statistical methods|Statistical differences between groups were analyzed using the Student's t-test and the Fisher exact test with two-tailed p < 0.05 considered significant.
PMC2919451|S116|12a|Statistical Methods for Outcome Comparison|Statistics|STATA10.1 was used for the calculations [16].
PMC2921105|S53|4b|Data Collection Setting|Setting|Patients were recruited from the practices of 20 general practitioners in the northern part of the Netherlands.
PMC2921106|S55|3a|Trial Design|Design|This controlled clinical trial was named Support for Increased Physical Activity (Stöd till Aktivare Motion or STAM in Swedish).
PMC2925820|S64|4a|Eligibility Criteria|Exclusion criteria|1) co-morbid conditions that limit physical activity such as severe cardiac disease, recent myocardial infarction, severe asthma or breathlessness, uncontrolled hypertension (blood pressure > 160/95 mm/Hg), or severe pain; 2) medical conditions that require a reduced fruit and vegetable diet (e.g. kidney failure); 3) history of insulin dependent diabetes; 4) treated with any type of steroid hormone; 5) treated for any other cancer; and 6) life expectancy of less than 2 years.
PMC293467|S58|4b|Data Collection Setting|Setting|The setting of the study is the Department of General-, Visceral-, Trauma Surgery and Outpatient Clinic of the University of Heidelberg, Medical School.
PMC2936282|S130|8b,10|Randomization Type,Randomization Implementation|Randomization|A minimization algorithm is used to randomize patients, with the factors region, Hoehn & Yahr stage, age, gender and current level of physical activity.
PMC2936306|S76|11a|Blinding Procedure|Masking|The dermatopathologists (JTS and JWP) were unaware of the study group during the primary assessments.
PMC2939600|S64|4a|Eligibility Criteria|Exclusion criteria|Patients who live in a nursing home, have a clinical diagnosis of dementia, have a score of 29 or higher on the Kokmen Short Test of Mental Status, cannot give informed consent, or do not have the ability to use the Intel Health Guide (due to severe visual impairment and lack of a caregiver, an unwillingness to use the device, or lack of a grounded outlet or 3G mobile communications coverage) are excluded from the study.
PMC2940902|S73|7a|Sample Size Determination|Sample size|This was calculated using the data published by Guarino [18], who described the effects of a product that combined three probiotics in children with rotavirus diarrhoea and found that diarrhoea decreased from 120 ± 30 to 96 ± 30 (24 hours decrease); using 0.8 power, 0.05 (one-sided) significance and assuming 24 hours difference between the experimental and control groups the sample size was calculated as 20 cases per group.
PMC2945119|S68|4b|Data Collection Setting|Data collection|Demographic data, co-morbidities, APACHE II (Acute Physiology and Chronic Health Evaluation, SOFA score [4], treatment data, ICU and hospital length of stay (LOS), and hospital mortality were registered.
PMC2949787|S45|4b|Data Collection Setting|Data collection|Sociodemographic variables were collected either from women's medical records or self-completed questionnaires at trial entry and included: maternal age, ethnicity, body mass index, social-economic status as measured by Socio-Economic Indexes for Area (SEIFA) score [11], maternal education, smoking status and blood pressure at trial entry.
PMC2956226|S84|6a|Outcomes|Outcomes|The key outcomes derived from the web-logs were:                                 Total time spent on site                                   Total number of main content pages accessed on site                                   Time spent viewing each module (“The PSA Test,”’ “It’s your Choice,” “Prostate Cancer”)                                   Time spent viewing each section (eg, “What is the PSA test?” and “PSA test results”                                   Time spent viewing each page (eg, “Why is the PSA test done?”)                                   Number of pages accessed in each module and section and actual pages accessed                                   Total number of interactive elements used (ie, videos and animations)                                   Whether the participant tracked their decision using the “Decision Stacker”                                   Whether the participant used the integrated print function                             The 3 components of informed decision making assessed were: (1) knowledge of PSA testing and prostate cancer-related issues; (2) attitudes toward testing; (3) behavior, for which a proxy measure was the declared intention to have the PSA test.
PMC2956331|S65|3a|Trial Design|Study Design|A Web-based randomized controlled trial (RCT) was designed, composed of four groups: two intervention groups and two control groups.
PMC2956331|S67|4b|Data Collection Setting|Setting|Men were invited to participate by their general practitioners (GPs) in South Wales, United Kingdom.
PMC2958953|S73|4b|Data Collection Setting|Setting|Patients will be enrolled in 28 Dutch hospitals and 3 Swedish centers.
PMC2958954|S66|4a|Eligibility Criteria|Patient selection|• Histologically confirmed or surgically removed malignant tumour of the salivary glands (head and neck)           • Inoperable tumour           • G2/3           • Macroscopic or microscopic residual tumour (R2/R1) or           • ≥T3/T4 or           • perineural invasion (Pn+)           • written informed consent           • pts aged 18 - 80 years           • effective contraception for pts in childbearing age (< 12 months post beginning of menopause)                             Exclusion criteria
PMC2964698|S60|3a|Trial Design|Design|This is a feasibility study for a randomised controlled trial (RCT).
PMC2965705|S58|3a|Trial Design|Design|The investigation was as a case-control study.
PMC2972594|S45|6a|Outcomes|Assessments|Participants were assessed at baseline and at the end of the treatment by an investigator (physiotherapist) who was blinded to the randomization, the severity of pain, functional disability, and TrA activation capacity.
PMC2974661|S43|3a|Trial Design|Design|As we wanted to assess how the HHF worked over time, we embedded this RCT in a longitudinal cohort study which aimed to describe the course of breathlessness over time [7].
PMC2987886|S62|8b,10|Randomization Type,Randomization Implementation|Randomisation|After enrolment, women will be randomised to one of two arms using a 1:1 computer-generated randomisation sequence attributed to each centre by the Omniview-SisPorto® 3.5 program.
PMC2987886|S90|6a|Outcomes|Secondary outcome measures|The secondary outcomes are: overall rates of caesarean section and of caesarean section for non-reassuring fetal state; overall rates of instrumental vaginal delivery and of instrumental vaginal delivery for non-reassuring fetal state; fetal blood sampling rates; incidence of 5-minute Apgar score < 7; need for neonatal intensive care unit admission; incidence of moderate and severe neonatal encephalopathy with a hypoxic marker; perinatal death; rate of delayed interventions (interval between red alerts - offline analysis in the control arm - and delivery in metabolic acidosis cases); internal FHR monitoring rates; tracing quality and signal loss.
PMC2987889|S116|8a|Random Allocation Sequence Generation|Allocation sequence|Sequentially numbered, opaque and sealed envelopes were opened by one researcher (BJ) after the participants was deemed appropriate fulfilling all inclusion criteria and no exclusion criteria as stated above.
PMC2988774|S57|4b|Data Collection Setting|Recruitment|Participants were recruited by advertisements in public and private institutions.
PMC2993045|S42|4a|Eligibility Criteria|Exclusion criteria|Exclusion criteria included age (<45 years or >80 years), ill defined diagnosis of cardiovascular disease, inability or unwillingness to comply with study treatment, and disease or treatment that might interfere with metabolism of homocysteine or omega 3 fatty acids, in particular methotrexate for treating cancer or rheumatoid arthritis and chronic renal failure (plasma creatinine concentration >200 μmol/l or creatinine clearance <40 ml/min).
PMC2995791|S76|7a|Sample Size Determination|Sample size|The study planned to recruit 90 subjects in each cross-over study, based on an expected standardized mean difference of placebo effect on continuous subjective outcome of 0.36[2], type I error of 0.05, type II error of 0.1, paired design, and 10% dropout rate.
PMC3004878|S82|4b|Data Collection Setting|Setting|Four community-based cardiac rehabilitation programs, three located in one urban/suburban environment (Halifax, Nova Scotia, Canada) and one in a more rural setting (Kentville, Nova Scotia, Canada) have been selected at intervention sites based on recruitment potential, adherence to the national guidelines for hyperacute and acute management of NDS and TIA [60], and availability of existing programs that could be adapted to meet the protocol for this trial.
PMC3024271|S95|3a|Trial Design|Study design|A multicenter randomised controlled three-armed study will be conducted to compare the effects of group exercise (on land or in a hydrotherapy pool), to a group of participants receiving no intervention.
PMC3033836|S126|12a|Statistical Methods for Outcome Comparison|Statistical analysis|The analysis will be performed in accordance with intention-to-treat principle.
PMC3037313|S37|3a|Trial Design|Study Design|This was an open label randomized controlled trial of parallel groups comparing the effect on QL of a specific educational program designed for the prevention of WMSD versus a general health orientation program.
PMC3039644|S182|11a|Blinding Procedure|Blinding|Because the primary and secondary end points of the study were laboratory measurements (qPCR and ELISpot) of blood samples with minimal opportunity for conscious or subconscious subjective bias, we felt that the benefit of blinding would be outweighed by its logistic difficulties, so no attempt at blinding was made.
PMC3042975|S56|4a|Eligibility Criteria|Patient selection|• Histologically proven adenoid-cystic carcinoma of the head and neck and Macroscopic or microscopic tumor rest (R1/R2) or           • Tumor stage >T3/T4 or           • perineural invasion and           • M0           • Written informed consent           • Age between 18 and 70 a           • Karnofsky-Index ≥ 70%           • adequate bone-marrow, liver, and kidney function           • effective contraception for patients in procreative age                             Exclusion criteria
PMC3045900|S52|3a|Trial Design|Study design|Patients were included from seven out of the nine psychiatric wards in The Capital Region of Denmark.
PMC3045987|S192|7b|Interim Analyses/Stopping Guidelines|Interim Analyses|Besides the planned analysis during the dose escalation, no further interim analyses are planned.
PMC3047537|S112|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Selected epidemiologic and biological variables were compared in linked and unlinked pairs, evaluating for statistical significance with the two-sided Fisher's exact test for categorical variables and Wilcoxon rank sum test for continuous variables.
PMC3050836|S117|4b|Data Collection Setting|Data collection|Information on the study variables will be collected on three occasions: when the woman enters to the study (baseline), once intervention is complete (at three months) and after three more months of follow-up (six months).
PMC3056734|S46|4a|Eligibility Criteria|Exclusion Criteria|-High-risk patient according to cardiological evaluation (e.g. necessary perioperative continuation of the ASA application shortly after coronary stent implantation, interfering bleeding disorders etc.)         -Emergency procedure         -Withdrawn or missing written consent         -Simultaneous participation in another clinical trial with interference of intervention and outcome         -Severe psychiatric or neurologic diseases or a mental condition rendering the patient incapable of understanding the nature, scope, and consequences of the trial.
PMC3072303|S57|12a|Statistical Methods for Outcome Comparison|Statistical methods|All statistical methods were performed using the R software package.
PMC3075234|S34|3a|Trial Design|Study design|We carried out a randomised, triple blind, placebo controlled clinical trial between April 2008 and June 2010 at the Instituto de Medicina Integral Prof Fernando Figueira (IMIP), Recife, a large tertiary teaching hospital in the northeast of Brazil.
PMC3076236|S45|4a|Eligibility Criteria|Inclusion and Exclusion Criteria|○ Patients who call 911, and are:           ○ Suspected by the paramedics to have ischemic chest pain for greater than 30 minutes but less than 6 hours, and           ○ 18 years of age or older           ○ Experiencing chest pain that fails to resolve with nitrates given as per protocol                             Exclusion Criteria
PMC3080737|S40|3a|Trial Design|Study design|We conducted a pragmatic27 cluster randomised trial28 of the effects of adding outreach education to a roll-out of decentralised nurse run HIV/AIDS/ART services at primary care clinics.
PMC3083383|S83|7a|Sample Size Determination|Sample Size|This was a pilot study and a sample size of ten patients in each of the randomised treatment arms was deemed to be sufficient after discussion with clinical experts and the trial statistician, No formal sample size calculation was performed for the pilot but the information from this study will informa power analysis for any larger trial.
PMC3086034|S49|3a|Trial Design|Trial design|This was a two-centre controlled trial of group CBT for fatigue self-management versus group information (usual care), with balanced randomisation (1:1), conducted in the UK.
PMC3095594|S40|4b|Data Collection Setting|Study Setting|The study was conducted at the Rockefeller University Hospital in New York City, USA.
PMC3097012|S46|4a|Eligibility Criteria|Subjects|A total of 30 periodontal healthy, non-smoking volunteers (16 males and 14 females, mean age: 43.9 ± 18.5 years) without medical disorders, and not undergoing any antibiotic or other antimicrobial therapy participated in the present study.
PMC3100239|S85|3a|Trial Design|Design|The EBP training program will be tested using a randomised controlled design, using a waitlist control group.
PMC3112165|S57|3a|Trial Design|Study design|The IMRT-HIT-SNT trial is a prospective, non-randomized phase II feasibility trial evaluating acute mucositis ≥ CTCAE°III as the primary endpoint.
PMC3112165|S72|4a|Eligibility Criteria|Patient selection|• Histologically confirmed or incompletely resected adenocarcinoma or squamous cell carcinoma of the nasal cavity or paranasal sinuses           • Inoperable tumour or refusal to undergo surgical resection           • Macroscopic or microscopic residual tumour (R2/R1) or           • ≥T3/T4 or           • written informed consent           • pts aged 18 - 80 years           • effective contraception for pts in childbearing age (<12 months post beginning of menopause)                             Exclusion criteria
PMC3117715|S94|8a|Random Allocation Sequence Generation|Sequence generation|The randomisation sequence is generated using a computer random number generator, in a 1:1 ratio, and a permuted block design with varying block sizes up to 6, stratified by prior care home residence.
PMC3118234|S70|6a|Outcomes|Measures|The following dependent and independent variables were examined in this study.
PMC3118359|S174|6a|Outcomes|Endpoints|- To evaluate feasibility and toxicity of intra-arterial gemcitabine therapy           - To establish the maximum tolerated dose                             Secondary Objectives
PMC3119027|S104|12a|Statistical Methods for Outcome Comparison|Data analysis|Holter data analysis will be done using Spacelabs Pathfinder Software Kit (version 9.019) and under supervision of a cardiologist of the Academic Medical Centre Amsterdam, The Netherlands.
PMC3123166|S70|4b|Data Collection Setting|Setting|Subjects will be enrolled in multiple academic and non-academic (teaching and non-teaching) hospitals in the Netherlands.
PMC3128457|S48|5|Interventions|Interventions|Participants were randomly allocated to receive a loading dose of 1 g tranexamic acid infused over 10 minutes, followed by an intravenous infusion of 1 g over eight hours, or matching placebo (sodium chloride 0.9%).
PMC3134460|S70|3a|Trial Design|Study Design|This was a prospective multi-country, randomized non-inferiority trial conducted in Ethiopia, Nepal, Nigeria, and Yemen to determine whether a scheme collecting two sputum specimens on the first day of consultation plus a morning specimen on the following day (SSM) had sensitivity and specificity that are non-inferior to the standard SSM scheme for the diagnosis of pulmonary TB (see Text S1).
PMC3134460|S81|4a|Eligibility Criteria|Inclusion and Exclusion Criteria|Patients ≥18 y old with cough ≥2 wk duration who had not received anti-TB treatment in the previous month presenting at the study site health service providers between 1 January 2008 and 30 March 2009 were eligible to participate.
PMC3141470|S69|3a|Trial Design|Design|The trial comprises three parts: the first is a test of the clinical effectiveness of the EBI, the second is an assessment of the patient's experience of the intervention using qualitative methods, while the third is an assessment of cost effectiveness of the BI.
PMC3142048|S48|6a|Outcomes|Outcome measures|The primary outcome measure was the percentage of patients with control of all three cardiovascular risk factors, defined as: BP <130/80 mmHg, LDL <100 mg/dL, and HbA1c <8.0%.
PMC3145214|S48|6a|Outcomes|Primary outcome|The primary outcome was the proportion of students who experienced an asthma                         exacerbation each month defined as one or more of the following: (1) a red                         (<50% of personal best) or yellow (50–70% of personal best) peak flow                         meter reading, (2) increased use of quick relief medication from baseline (≥                         4 puffs), or (3) a respiratory-related school absence [29].
PMC3145214|S56|4a|Eligibility Criteria|Study participants|Students who (1) attended one of the participating schools, (2) had physician                         diagnosed asthma, and (3) could use a peak flow meter were eligible for the                         study.
PMC3150341|S99|4a|Eligibility Criteria|Inclusion criteria|Patients meeting the following criteria will be considered for admission to the trial:           • All patients aged >18 years and <70 years after breast conserving surgery.
PMC3157892|S50|3a|Trial Design|Design|A partial factorial cluster randomized controlled trial design was used to assess rates of informed choice in women offered antenatal SCT screening.7
PMC3163575|S61|3a|Trial Design|Trial Design|This was a single centre, outcome assessor blinded, parallel group study with imbalanced randomisation [2∶1] conducted in Aberdeen, Scotland, UK (Trial registration: ISRCTN90101501; CONSORT checklist S1).
PMC3163575|S68|4b|Data Collection Setting|Study setting|The Clinical Research Facility of the University of Aberdeen, set up at the central hospital site for ambulatory clinical research such as clinical trials staffed with specifically trained research nurses.
PMC3163575|S70|5|Interventions|Interventions|Participants were randomly allocated to either a face-to-face group behaviour change intervention focusing on dietary and physical activity changes for weight loss, or a control group.
PMC3163575|S103|7a|Sample Size Determination|Sample size|The study aimed to recruit 90 participants as this gives precision of at least 5 percentage points on any estimated acceptability/feasibility proportion (i.e. the 95% confidence interval limits around the estimated proportion of, for instance, willingness to be randomised ±10%) [49].
PMC3165120|S64|4b|Data Collection Setting|Data collection|Study visits were conducted at the University Hospital of North Norway (Clinical Trial Unit and Department of Neurology).
PMC3169516|S105|6a|Outcomes|Outcome measures|Outcome measures were the impact of MDA on i) malaria morbidity by active and passive case detection; ii) asexual parasite prevalence and density by microscopy, rapid diagnostic test and molecular detection methods; iii) gametocyte prevalence and density by microscopy and molecular detection methods; iv) transmission intensity quantified by the entomologic inoculation rate.
PMC3170259|S131|11a|Blinding Procedure|Blinding|Blinding of investigators and patients is not feasible as it is immediately recognizable and impossible to conceal that only one group (Group A) receives saline intravenously.
PMC3170576|S33|3a|Trial Design|Study Design|This was a randomized, double blind, placebo controlled, parallel group interventional study.
PMC3170867|S35|3a|Trial Design|Trial design|This was a parallel group balanced (1:1) client randomized and single blind superiority controlled trial conducted in three health facilities in Iganga district, eastern Uganda.
PMC3170867|S37|4a|Eligibility Criteria|Eligibility criteria|Eligible participants consisted of all newly screened HIV-positive adult clients (>18 yrs) at the three recruitment centres at the start of the study, who were of sound mental status, and who were not under the prevention of mother to child transmission (PMTCT) program or bound to leave the district during the period of follow-up.
PMC3171708|S60|3a|Trial Design|Design|Randomised, open, general practice-based pragmatic clinical trial.
PMC3171716|S87|3a|Trial Design|Design|This is a pragmatic, two-arm, multi-centre, parallel, randomised controlled clinical trial.
PMC3176157|S60|4b|Data Collection Setting|Recruitment|Participating Clinicians were asked to recruit consecutive eligible patients from October to November 2006, and from late January to March 2007.
PMC3176208|S142|3a|Trial Design|Study design|The study was performed as a consecutive treatment, open label, follow-up study.
PMC3179718|S89|6a|Outcomes|Assessments|At baseline, the participants' socio-demographic information on education, employment, marital status, clinical diagnosis, suicide attempts, and earliest contract with psychiatric services will be collected.
PMC3180270|S91|3a|Trial Design|Design|Randomised, double-blind, placebo-controlled experimental trial to determine the efficacy of plant sterol esters as dietary supplement in reducing lipids.
PMC3182877|S60|3a|Trial Design|Trial Design|The STITCH trial has been designed as a prospective, multicenter, double-blind, randomized controlled trial, in which the large bites technique will be compared with the small bites technique.
PMC3182877|S108|6a|Outcomes|Primary outcome|• Primary outcome will be incisional hernia occurrence within one year after surgery, either clinically and/or ultrasonographically detected.
PMC3184060|S90|11a|Blinding Procedure|Blinding|It is not possible to blind participants to the intervention in this study, but outcomes will be collected by researchers who are blind to allocation and all analyses will be carried out blind to allocation.
PMC3190331|S47|4b|Data Collection Setting|Setting|Kenyatta National Hospital [Kenya], ENT department.
PMC3191725|S151|12b|Statistical Methods for Other Analyses|Subgroup analysis|Because we were interested in exploring the differential effect of the intervention on patients at higher compared with lower risk of functional decline, we did a post hoc analysis (using two way analysis of variance and its F tests) of differences in outcomes for patients who were at greater risk of functional decline (Sherbrooke postal questionnaire scores of 4-6) compared with those who were at lower risk of functional decline (scores of 2-3).
PMC3192673|S109|3a|Trial Design|Trial design|The study is a cluster-randomised, community intervention trial evaluating a participatory strategy, conducted by facilitators who collaborate with the local CHC staff and significant community members.
PMC3193831|S67|7a|Sample Size Determination|Sample Size|The original sample size of 500 patients had 80% power and 95% confidence to detect a 15% difference in the primary end point, assuming a 50% recurrence rate in the CQ group, allowing for up to 15% loss to follow-up by day 63.
PMC3207912|S64|3a|Trial Design|Design|Multicentre prospective cohort study with a follow-up to 1.5, 5, and 10 years from the participant inclusion in the study.
PMC3210772|S34|4a|Eligibility Criteria|Study Population|Children 6 months of age and older with JIA [8], kidney transplant recipients, RA [9], HIV-infected, and cancer patients 18 years of age and older, and elderly 60 years of age and older without any immunosuppressive condition, hereafter referred to as the elderly, were eligible to participate in the study (See Appendix S1 for full eligibility criteria).
PMC3216853|S53|3a|Trial Design|Design|We used a mixed-method design that is both exploratory (i.e., by developing the conceptual model of systems leader information and advice networks) and confirmatory (i.e., by testing the conceptual model) [23], achieving three types of integration of quantitative and qualitative data: (1) convergence: using both types of data to answer the same question; (2) complementarity: using each type of data to answer related questions, where the type of data is specific to the question asked (e.g., using qualitative data to generate hypotheses, provide depth of understanding, and focus on the function and context of social networks and quantitative data to confirm hypotheses, provide breadth of understanding, and focus on social-network structure and predictors of implementation stage); and (3) expansion: using one type of data to address questions raised by the use of the other type of data (e.g., using qualitative data to explain results of quantitative analyses) [18].
PMC3217058|S111|8b,10|Randomization Type,Randomization Implementation|Randomisation|Randomisation was performed by one of the investigators (MD) in advance by computer in blocks of 20 using the random number generator in MS Excel (Microsoft, Seattle, WA, USA).
PMC3217848|S48|3a|Trial Design|Study Design|The present study was in two phases: an initial study of practical utility and reliability of the cognitive outcome measures over three weeks, followed by a 10 week exploratory RCT.
PMC3219361|S76|7a|Sample Size Determination|Sample size calculation|By using a two-tailed test and assuming a 90% follow-up, it was calculated that 56 episodes would be needed (28 in each group) to detect a difference of 15% in the need of mechanical ventilation between the control group and intervention group, the one treated with corticosteroids (80% power, 5% significance level).
PMC3224456|S60|3a|Trial Design|Study design|This study is designed as a multicenter phase I/II trial evaluating the optimal dose for pazopanib (phase I) as well as activity and tolerability of a combination regimen consisting of pazopanib and metronomic cyclophosphamide in the palliative treatment of patients with recurrent, platinum-resistant, pre-treated ovarian cancer (phase II).
PMC3227809|S30|4b|Data Collection Setting|Setting|The trial was conducted in Goa, a state in West India, by a consortium of organisations led by Sangath, in collaboration with the Government of Goa’s Directorate of Health Services, the Voluntary Health Association of Goa, private general practitioners and the London School of Hygiene & Tropical Medicine.
PMC3227809|S89|11a|Blinding Procedure|Masking|Masking of the research assessor was maximised by: carrying out evaluations at home and by an independent research institution not associated with the intervention; randomly allocating unique participant IDs; and carrying out the primary outcome assessment prior to all other assessments.
PMC3233508|S37|3a|Trial Design|Study design|The study was conducted as a cluster-randomised controlled trial highly pragmatic in attitude including 40 Danish general practices and their diabetes populations.
PMC3239240|S39|7a|Sample Size Determination|Sample size|Based on our previous data on the mean serum 25(OH)D in Iranian diabetic patients (57.8 ± 47.8 nmol/L) [11], to detect a change in mean 25(OH)D of 1 standard deviation (SD; effect size of 1) and to have a power of 90%, the calculated sample size was 50 in each group.
PMC3249212|S54|5|Interventions|Intervention|The multi-faceted intervention was comprised of having the centralized coordinator, a physical therapist, follow-up with fracture patients and their physicians to provide evidenced-based recommendations about fracture risk and osteoporosis treatment and assist with arranging telehealth consultations to the Multidisciplinary Osteoporosis Program (MOP) [25] at a teaching hospital for complex patients if requested.
PMC3254637|S122|7a|Sample Size Determination|Sample size calculation|Based on a prior study of anakinra treatment for fatigue in RA [20], we estimated that 30 patients were needed to detect a difference in 25 points on the fatigue VAS with a power of 80% and a two-sided α of 0.05.
PMC3266346|S154|6a|Outcomes|Outcome measures|The primary endpoints were: 1) effectiveness measured as the number and proportion of patients correctly diagnosed (true positive + true negative) and treated; and 2) incremental cost per additional case correctly diagnosed and treated (incremental cost effectiveness ratio - ICER) defined as the change in costs over the change in effectiveness of moving from the presumptive strategy (the base case) to the next best alternative.
PMC3266384|S162|12a|Statistical Methods for Outcome Comparison|Statistical Analyses|Survival data were plotted using the Kaplan-Meier method and were compared by the log-rank test or Student's t-test as noted.
PMC3268742|S122|7a|Sample Size Determination|Sample Size|Sample size was not based on hypothesis testing, but instead on a reasonable estimation of the sample size necessary to 1) assess the feasibility of the intervention, and 2) determine the effect sizes for the main effects of the intervention.
PMC3277823|S60|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Given the exploratory nature of the study, all analyses were descriptive, with no formal statistical test performed on the data.
PMC3281013|S36|3a|Trial Design|Study design|The Cooperative Huntington Observational Research Trial (COHORT) is an observational study designed to collect phenotypic data and biological samples from individuals with HD and their family members.
PMC3282287|S105|6a|Outcomes|Primary outcome|Once a week, participants of both groups rated forearm pain intensity at its worst during the previous 7 days on a 100 mm Visual Analogue Scale (VAS), where 0 mm is ‘no pain at all’ and 100 mm is ‘worst possible pain’.17
PMC3283530|S123|8a|Random Allocation Sequence Generation|Sequence generation|The 16 PHCCs will be assigned to the intervention or the control group following a simple, computer-generated random sequence (EPIDAT 3.1).
PMC3295693|S70|4a|Eligibility Criteria|Exclusion criteria|Participants will be excluded if they:           A) have severe generalized skin conditions such as eczema, psoriasis, and atopy(hay fever, asthma)           B) have severe allergic reactions in the past           C) have taken oral anti-histamines or topical corticosteroids in the preceding 3 months           D) have any acute or chronic illness           E) have cardiovascular disease, liver or kidney disease           F) have allergies on soybean foods           G) have taken any prescribed or investigation medication during the 8 weeks preceding enrolment.
PMC3296686|S91|11a|Blinding Procedure|Blinding|Whereas patients and physicians allocated to the intervention groups were aware of the allocated arm, outcome assessors and data analysts of primary and secondary end-points were kept blinded to the allocation.
PMC3302845|S106|7a|Sample Size Determination|Sample Size|We estimated that a sample size of 2,314 women would have statistical power of 80% (two-tailed alpha level 0.05) to detect an increase of 2% in the risk of fetal death or liveborn infant death prior to discharge or serious infant outcome from 1.6% for planned ERC [24] to 3.6% for planned VBAC (Text S1) [13].
PMC3305518|S67|3a|Trial Design|Design|This phase I-II trial is a national multi-center dose-escalation study of low-dose oral cyclophosphamide in combination with a fixed dose of everolimus in patients with mRCC not amenable to, or progressive after, a VEGF-receptor tyrosine kinase inhibitor containing treatment regimen.
PMC3305518|S69|4b|Data Collection Setting|Setting|The study is initiated by the department of medical oncology of the VU University Medical Center and will be conducted within the context of the Netherlands Working Group on Immunotherapy of Oncology (WIN-O) with a present participation of 13 hospitals.
PMC3317867|S68|8b,10|Randomization Type,Randomization Implementation|Randomisation|Patients meeting the inclusion and exclusion criteria listed above were selected consecutively from those visited by the participating investigators.
PMC3324496|S66|6a|Outcomes|Study outcomes|We focused on three outcome domains: physician assessments of ICU eligibility, in-hospital and 6-month mortality, and changes in functional status ; where a change in functional status was defined as a minimum of one point change in at least one dimension of the ADL with respect to baseline during the 6 months following the ED visit.
PMC3325227|S82|6a|Outcomes|Outcomes|The main outcome measures were (1) clinical adverse events including mild, moderate and greater severity renal toxicities and serious adverse events, (2) willingness to use the study regimen, if shown to be effective, (3) adherence rates for daily and intermittent dosing, (4) change in HIV-associated risk behavior during trial participation, (5) the proportion of volunteers with HIV-specific immune responses as measured by Interferon-γ ELISpot.
PMC3328242|S81|5|Interventions|Interventions|Both intervention groups receive written information and education delivered during one-to-one sessions with a physiotherapist.
PMC3329851|S28|12a|Statistical Methods for Outcome Comparison|Statistical methods|Mixed models with repeated measures similar to the original analyses (5) were fitted separately to subgroups.
PMC3330821|S64|4a|Eligibility Criteria|Participants|Working men and women with subthreshold depression were recruited at 13 factories and offices of a large manufacturing company (19,742 employees) in Japan.
PMC3348027|S70|6a|Outcomes|Outcome measures|After discharge home directly from the PACU, patients were contacted by telephone to collect outcome data at 24 hours, 48 hours, and 12 weeks postoperatively using a structured interview.
PMC3348080|S54|3a|Trial Design|Trial design|A two-group randomized controlled clinical trial was undertaken.
PMC3352294|S122|12a|Statistical Methods for Outcome Comparison|Statistical analysis|A mixed multiple analysis of variance (MANOVA) (Group X Time) will be conducted to determine if there is a significant interaction between the between- group (Group) and within-group (Time) comparisons for:           Bone health (bone mineral density) at baseline and 12-month follow-up session;           HRQOL (FACT-P and SF-36), and physical function (FACT-Fatigue, ABC, SPPB, and 6MWT) at baseline, 3, 6, 9, and 12-month follow-up sessions.
PMC3353130|S112|11a|Blinding Procedure|Blinding|The study was single blinded with members of the study team assessing baseline and follow-up measurements blinded to group assignment.
PMC3361475|S64|3a|Trial Design|Study design|The REACT-2 trial is an international, multicenter randomized clinical trial in six high-volume trauma centers that will compare the effects of immediate total-body CT scanning in severely injured trauma patients with conventional imaging protocols.
PMC3376123|S157|4a|Eligibility Criteria|Exclusion Criteria|Participants were excluded if they were unable to complete the outcome measures, they had a diagnosis of Alzheimer’s disease or other dementia, if they were undergoing surgical procedures under regional anaesthesia or if they had delirium at 1 week post surgery.
PMC3378617|S55|3a|Trial Design|Design|An open label, parallel-arm multi-centre individually randomized controlled trial.
PMC3379583|S30|4a|Eligibility Criteria|Participants|Eligible participants were insulin-naïve adults (18–80 years) with type 2 diabetes treated for ≥3 months with ≥1,500 mg/day metformin and A1C values of 7.0–10.0% or with metformin and sulfonylurea (less than or equal to half of the maximum approved dose) and A1C values of 7.0–8.5% (Supplementary Data online).
PMC3387641|S41|4b|Data Collection Setting|Setting|The trial took place in the medical and surgical ICUs of the University Hospital of Basel, a tertiary care center.
PMC3388020|S58|12a|Statistical Methods for Outcome Comparison|Statistical Analyses|The quantitative bacterial counts of C. difficile and calculated CFU per gram of target organism group by real-time qPCR were log transformed, after which changes in each time of collection were compared between fidaxomicin and vancomycin treatments, using Wilcoxon signed-rank tests for nonparametric data (GraphPad Prism; GraphPad, San Diego, CA).
PMC3390274|S108|6a|Outcomes|Secondary outcome measures|Point smoking cessation at month 6 and/or month 12 confirmed by a urine cotinine test; self-declared smoking cessation at months 6 and 12; reduction in the number of self-declared cigarettes consumed when smoking cessation is not accomplished at months 6 and 12; variation in the phase of process of smoking cessation: from pre-contemplation to contemplation or preparation phase, or from contemplation to preparation phase, at months 6 and 12.
PMC3402741|S31|3a|Trial Design|Study design|A pragmatic randomised controlled trial, with nested process and economic evaluations (for full details, see published study protocol12).
PMC3402741|S61|7a|Sample Size Determination|Sample size|Sample size was determined to detect a difference in total minutes of weekly activity at 12 months, with 1052 participants in each group providing 90% power to detect an effect size of 0.15 with no loss to follow-up and, more realistically, 87% and 84% power to detect an effect size of 0.15 if 20% and 25%, respectively, of randomised participants who were lost to follow-up.
PMC3403849|S92|4a|Eligibility Criteria|Patients|Inclusion criteria: all participants must:         Â· be â‰¥65â€‰years of age         Â· be attending a primary healthcare centre for consultation on some medical matter         Â· provide their informed consent to be included         Â· have a serum B12 concentration of <179â€‰pg/ml.
PMC3412701|S39|3a|Trial Design|Design|This is a randomized-controlled, double-blind, double dummy multicentre trial assessing the comparative effectiveness of immediate vs. conditional antibiotic therapy in uncomplicated UTI.
PMC3414482|S82|6a|Outcomes|Primary Outcome Measures|We monitored the safety of BCG in advanced type 1 diabetes and its action on immune and pancreas outcomes, including levels of insulin-autoreactive T cells, Treg cells, autoantibodies (including GAD), and C-peptide, an indicator of endogenous insulin secretion.
PMC3419654|S69|6a|Outcomes|Measurements|The 130 participants who agreed to participate in the FU2 study were sent a package by mail containing a pre-programmed accelerometer and information on how and when to use it, a questionnaire and a prepaid envelope for return.
PMC3428286|S45|3a|Trial Design|Design|A two-year prospective follow-up study, carried out during the period from March 2008 to February 2010.
PMC3438078|S62|3a|Trial Design|Design|Two-arm, randomized, controlled trial.
PMC3440433|S102|8a|Random Allocation Sequence Generation|Randomization – sequence generation|Participants who provided informed consent were individually randomised to intervention or control groups via concealed centrally-allocated computer generated random numbers, with a 1∶1∶1 allocation ratio, without stratification or blocking on any variables.
PMC3440433|S104|9|Allocation Concealment Mechanism|Randomization – allocation concealment|The computer-based randomisation ensured that researchers and participants were not aware of allocated group.
PMC3441257|S54|3a|Trial Design|Study design|We conducted an open randomized, phase III clinical trial to compare the differences in efficacy and safety between thermotherapy and meglumine antimoniate.
PMC3447641|S89|4a|Eligibility Criteria|Inclusion criteria|· Weight at birth ranging: 700–1501 grams;         · Gestational age up to 25 weeks and 6 days;         · Written informed consent from parents or guardians.
PMC3448506|S63|7a|Sample Size Determination|Sample size|We intended to recruit forty patients in total, with ten patients sequentially allocated to each of the four study arms.
PMC3452182|S32|4a|Eligibility Criteria|Patients|Patients with refractory chronic CH were enrolled in the study according to the following inclusion criteria: chronic CH according to ICHD-II criteria [2]; disease duration over 3 years; resistance to pharmacological prophylactic treatment with adequate trials (verapamil up to 960 mg/day, lithium with plasma level from 0.6 to 1 mEq/l, association of both; in absence of adverse events); daily attacks; absence of substance abuse or dependence; age 18–65-year-old; normal findings on magnetic resonance imaging; no contraindications to surgery or anesthesia.
PMC3463860|S55|8b,10|Randomization Type,Randomization Implementation|Randomisation|The subjects were randomised corresponding to allocation codes generated for the diquafosol and the sodium hyaluronate using the permuted block method by the randomisation manager.
PMC3464250|S94|11a|Blinding Procedure|Blinding|This was an open label dose-escalating study, with both participants and those conducting clinical and laboratory assessments aware of the interventions received.
PMC3466198|S146|7a|Sample Size Determination|Sample Size|A total sample size of 36 (18 subjects in each arm) was selected a priori to allow 80% power to observe statistically significant equivalence of means if we assume that Acidform and HEC have no impact on anti-HSV activity and consider the mean difference of 1 standard deviation as the equivalence limit.
PMC3479093|S114|8b,10|Randomization Type,Randomization Implementation|Randomisation|After an initial baseline period hospitals were randomised into the intervention at two monthly intervals (Figure 1).
PMC3481364|S41|3a|Trial Design|Design|The present study has a double design; - an open intervention with stimulation therapy to which a randomised double blinded and placebo-controlled clinical trial (RCT) with donepezil is added, constituting a two-by-two factorial design.
PMC3482620|S56|4a|Eligibility Criteria|Patient selection|Patients who meet the following criteria are eligible to participate in the study:         (i) men and non-pregnant women > 18 years of age; (ii) implantation of an ICD or CRT-D for standard indications within 2–8 weeks; (iii) willing and able to be followed by the same medical centre throughout the study; and (iv) capable of understanding and completing the EQ-5D questionnaire.
PMC3483098|S35|3a|Trial Design|Study design|The study had a multicentre, randomised, controlled, crossover design.
PMC3493368|S37|3a|Trial Design|Trial design|This was a single-centre, single-blind, prospective randomised control trial.
PMC3493368|S48|5|Interventions|Interventions|Subjects were randomised to a 6-week home-based resistance-training (RT) exercise program, a 6-week home NMES program (NMES) or a control group (C) receiving standard care.
PMC3495200|S82|5|Interventions|Interventions|• Skin closure with metallic staples         • Skin closure with suture material – type of suture (non-absorbable or absorbable) and technique (simple, horizontal mattress, vertical mattress, subcuticular) at the discretion of the surgeon.
PMC3495200|S123|6a|Outcomes|Secondary outcome measures|Additional unscheduled episodes of care as defined by:            • Dressing changes by homecare/patient at home or self-reported visits to other healthcare professionals.
PMC3495760|S37|3a|Trial Design|Study design|The trial is designed as a prospective single-center one-armed phase I/II study to assess the efficacy and safety of a combination regimen consisting of neoadjuvant intensity-modulated dose-escalated radiation therapy followed by surgery and an intraoperative electron radiation therapy boost to the tumor bed in patients with gross resectable or borderline resectable soft tissue sarcomas of the retroperitoneal space.
PMC3503568|S73|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Student’s t and the Mann–Whitney U-tests were used for statistical analyses.
PMC3503734|S66|4a|Eligibility Criteria|Exclusion criteria|Age <18 years of         Abdominal discomfort without tenderness or rebound or clinical suspicion of appendicitis         Pregnancy         Patients with impaired consciousness         Patients not able to provide informed consent (Non-German Speakers)         Patients that will receive an appendectomy as part of another elective procedure         Patients who are unable to understand the study purpose.
PMC3504064|S36|4a|Eligibility Criteria|Study population|Twenty-one villages in Sibanor, Western Region, The Gambia, were selected as being representative of rural areas in The Gambia, as described previously [13].
PMC3506516|S79|3a|Trial Design|Design|The study is a cluster randomised controlled trial.
PMC3507889|S63|3a|Trial Design|Study design|This was an 18 months follow-up of an open, prospective comparative observational study.
PMC3516585|S70|4a|Eligibility Criteria|Inclusion Criteria|We adhered to the following inclusion criteria: (i) preschool-aged children (<6 years); (ii) written informed consent by parents/guardians; (iii) submission of at least one sufficiently large stool sample for duplicate Kato-Katz thick smears, and one urine sample for a 10 ml filtrate and a single point-of-care circulating cathodic antigen (POC-CCA) cassette test; (iv) no abnormal medical condition, as judged by the study physician on the day of the treatment; (v) no recent anthelmintic treatment (within the past 4 weeks) according to a parental questionnaire; and (vi) no participation in any other clinical trial.
PMC3517757|S130|6a|Outcomes|Measurements|Baseline descriptive data will be obtained by questionnaire and will include age, sex, weight, height, medication use and previous health problems.
PMC3522731|S170|11a|Blinding Procedure|Blinding|This study was not blinded.
PMC3525560|S55|8b,10|Randomization Type,Randomization Implementation|Randomization|Subjects were allocated unique identification codes and were randomly assigned to one of the three treatment groups using block randomization in blocks of 10 by reference to a statistical series based on random sampling numbers drawn up for each patient by the study staff; the details of the series were unknown to any of the investigators or to the coordinator and were contained in a set of sealed envelopes.
PMC3532978|S57|3a|Trial Design|Study design|Randomised controlled trial (RCT) allocating CRC patients to a CM intervention group or a control group (ratio 1 : 1).
PMC3534357|S42|3a|Trial Design|Study design|We conducted a cross-sectional analysis of participants visiting the Vancouver Falls Prevention Clinic ( http://www.fallsclinic.com) due to a fall from January 2009 through May 2011.
PMC3534357|S85|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Descriptive statistics were used to characterize the study sample.
PMC3534445|S47|3a|Trial Design|Design|An individually randomized controlled trial (RCT) [19].
PMC3538714|S42|3a|Trial Design|Trial design|A pilot randomised controlled trial using a PROBE design (prospective, randomised, open-label, blinded end point), compared two models of care: routine GP-led care or an onsite HF team.
PMC3548682|S69|3a|Trial Design|Design|The CHANGE-2 trial is a three arm cluster-randomized controlled trial that measures antibiotic prescription rates over three successive winter periods and reverts to administrative data of the German statutory health insurance company AOK.
PMC3551748|S93|12a|Statistical Methods for Outcome Comparison|Statistical analyses|Descriptive information on background characteristics, HIV and HCV status, sex risk, physical abuse, and feeling unsafe in the current relationship is presented in terms of frequencies and percentages or means and standard deviations.
PMC3551874|S68|4a|Eligibility Criteria|Study Population|The two groups were similar in age, sex, HAART-treatment, CD4-level, and viral load, at time of inclusion (Table 1).
PMC3552315|S109|7a|Sample Size Determination|Sample size|The trial was powered to detect an effect on the primary outcome of d = 0.45 with 80% power and alpha = 0.05 using a conservative simple post-treatment standardized difference method (d = M treatment − M control/SD).
PMC3555827|S36|3a|Trial Design|Study Design|This was a mixed-method study incorporating a randomised controlled trial (RCT) to assess the effectiveness of three different evidence summary formats with semi-structured follow-up interviews to explore panel members’ views of these formats, experience with appraisal, use of and engagement with the research evidence.
PMC3557164|S57|4a|Eligibility Criteria|Study subjects|Eligibility criteria included any child born to a mother who was HBsAg negative, aged between six and 10 weeks at the time of first vaccination, who did not present with any serious acute or chronic illness as determined by clinical or physical examination, medical history records or laboratory screening tests of haematology, and renal and hepatic function.
PMC3573973|S82|12a|Statistical Methods for Outcome Comparison|Statistical methods|The effect of aggressive antihypertensive treatment on the risk of the primary outcome was assessed adjusted for time-dependent systolic blood pressure using a Cox proportional hazards regression with combined stabilized weights (i.e., a marginal structural Cox model), as well as unadjusted for time-dependent systolic blood pressure using a Cox proportional hazards regression without weights (i.e., a standard time-dependent Cox model).
PMC3574826|S64|3a|Trial Design|Study design|A multicenter, randomised controlled trial will be conducted in the three Dutch burn centres: Beverwijk, Groningen and Rotterdam.
PMC3581561|S57|3a|Trial Design|Trial Design|Details of the EDIPS protocol were similar in each country, have been published for each trial cohort [5], [7], [8] and are described briefly here.
PMC3585698|S46|3a|Trial Design|Trial design|The APPAC trial has been designed as a prospective randomized controlled, open label, non-inferiority multicenter trial to compare antibiotic therapy (intravenous ertapenem) with emergency appendectomy in the treatment of uncomplicated appendicitis.
PMC3585832|S70|12a|Statistical Methods for Outcome Comparison|Statistical Methods|As a result of the early termination of POTENT due to poor patient enrollment, statistical tests were not applied to the observational data that were collected.
PMC3598789|S59|3a|Trial Design|Design|The study used a single center, randomized, parallel-group design at the outset, with the addition of a second site at a later stage to overcome recruitment problems.
PMC3599669|S55|3a|Trial Design|Design|A randomized, intervention study conducted in a human performance laboratory.
PMC3599669|S142|11a|Blinding Procedure|Blinding|Both participants and mechanical evaluation technicians were blinded with respect to the type of intervention applied, i.e. superficial or deep needle insertion.
PMC3599938|S45|3a|Trial Design|Design|A parallel group, randomized controlled trial.
PMC3610165|S51|3a|Trial Design|Study design|The ESCAPE trial is an open label randomized controlled, parallel, superiority multicenter trial.
PMC3620125|S48|4a|Eligibility Criteria|Participants|Healthy, HIV-negative subjects between the ages of 18 and 50 at the time of enrollment.
PMC3633984|S50|3a|Trial Design|Study Design|This was a prospective, non-controlled, multi-centre, observational, Phase IV cohort study conducted in 19 countries in three global regions: Asia Pacific (China, Indonesia, Malaysia, Pakistan, the Philippines and Singapore); Europe (Austria, France, Germany, The Netherlands and Romania); and the Middle East (Bahrain, Egypt, Jordan, Kuwait, Lebanon, Saudi Arabia, United Arab Emirates, Yemen).
PMC3646790|S50|3a|Trial Design|Study design|This study reports on results of the baseline measurements among the 66 women, who thereafter entered a randomized controlled trial (LEVA, Livsstil vid Effektiv Viktminskning under Amning; Lifestyle for effective weight loss during lactation).
PMC3651334|S111|6a|Outcomes|Outcome measures|We include one objective (Chair Stand Test) and two patient-reported outcome measures (pain and function subscale of the KOOS questionnaire) in this trial to test the effect of the intervention on lower extremity function (see Table 1).
PMC3664622|S67|3a|Trial Design|Study design|The present study is a triple blind randomized controlled trial.
PMC3667946|S201|3a|Trial Design|Study design|This was an open label, non-randomized, Phase I safety and immunogenicity clinical trial in healthy, previously BCG-vaccinated, adult subjects.
PMC3680082|S77|8b,10|Randomization Type,Randomization Implementation|Randomisation|Randomisation will be performed centrally by staff other than those of the research team, using a computer-generated random number sequence and after taking the baseline measurements.
PMC3681363|S95|4b|Data Collection Setting|Data collection|The following data were collected: gender, age in years, height in meters, weight in kilograms, body mass index (BMI), the Simplified Acute Physiology Score II (SAPS II), diagnosis on hospitalization, duration of mechanical ventilation prior to PCT (in days), indication for tracheostomy, anatomical palpation data (short neck, palpated goiter, deviation of the trachea, vessels, puncture site, and cricoid-manubrium distance in centimeters), US data (thyroid, tracheal deviation, aberrant vessels, puncture site, subcutaneous tissue thickness (in centimeters) defined by the distance between the skin and the anterior wall of the trachea measured perpendicularly to the skin at the puncture level, tracheal diameter in centimeters, and installation time in minutes), the duration of the tracheostomy defined by the time (in minutes) between the puncture of the trachea and the ventilation of the patient, difficulty in achieving US-guided PCT (rated on a simple numerical scale; 1: easy; 2: a few difficulties in identifying anatomical structures and in implementation; 3: moderate difficulties in identifying anatomical structures; 4: very difficult; and 5: impossible), hemodynamic data before and after the completion of PCT (blood pressure in millimeters of mercury and heart rate in beats per minute), and complications.
PMC3681669|S143|6a|Outcomes|Outcome measures|The primary outcome measures were the EA-level prevalence of TF and of Ct infection in 0–5 year olds at the 36 months survey.
PMC3681721|S111|8b,10|Randomization Type,Randomization Implementation|Randomization|Randomization follows a simple, non-adaptive variable-block length algorithm, which is stratified by clinical site and by gender and ethnicity (Non-Hispanic white versus other race/ethnic groups).
PMC3681783|S81|8b,10|Randomization Type,Randomization Implementation|Randomization|Participants were assigned to one of four groups based on a randomization schedule that was generated a priori by the study statistician that was not disclosed to the interviewers, ensuring that they were blind to group assignment.
PMC3682866|S50|11a|Blinding Procedure|Masking|Open-label study given the type of strategies used and given that an effect on their beliefs and the antibiotic use is expected.
PMC3687267|S61|6a|Outcomes|Outcome measures|The primary end point was HbA1c, and the secondary end points were mild and severe hypoglycemia, mean blood glucose, diabetes treatment satisfaction, quality of life, and patient preference for the IMI; all were measured 12 and 24 weeks after the run-in period.
PMC3691650|S50|4b|Data Collection Setting|Setting|The trial was carried out in 34 different IVF centers, 20 in Europe and 14 in North America.
PMC3691650|S52|4a|Eligibility Criteria|Participants|Women aged 18–36 years with a body weight from 60–90 kg, a body mass index of 18–32 kg/m2, a menstrual cycle length of 24–35 days and access to ejaculatory sperm and an indication for COS before IVF or ICSI were eligible.
PMC3696105|S102|4b|Data Collection Setting|Recruitment|Patients were recruited from general practitioners and psychiatrists, open wards at the local mental health centre and a few patients through advertisements.
PMC3698180|S80|4b|Data Collection Setting|Recruitment|Recruitment was conducted over a 14-month period between September 11 2010 and 29 December 2011.
PMC3710466|S103|7a|Sample Size Determination|Sample size|The required sample size was determined to be 246 (123 per treatment group) to detect a difference in VAS score of 10 mm (equivalent to 20% for a patient with a baseline VAS of 50 mm), assuming a 24 mm standard deviation, with significance level of 5% and power 90% using a 2-sided test.
PMC3718721|S68|7a|Sample Size Determination|Sample size|We assume that the average cluster size is 15000 population, considering a crude annual birth rate of 20 per 1000 population and estimated average perinatal mortality rate of 60/1000 with a coefficient of variation (k) between clusters of 0.125, an intracluster correlation coefficient of 0.05 and to detect a 20% difference in the mortality rates between intervention and control clusters, we would require at least 20 clusters, ten clusters per arm to provide the study with a power of 90% over a three-year intervention period.
PMC3720553|S94|7a|Sample Size Determination|Sample size|According a pilot study, a priori sample size calculation indicated 14 patients per group were required to detect a significant difference of 20% in fatigue analogue scale between the intervention and control group (Effect size d =1, alpha=0.05, beta=0.08).
PMC3720554|S52|4a|Eligibility Criteria|Study population|The study population will consist of working adults aged 30 to 50 years who are physically inactive, defined as not meeting the current physical activity recommendations [1].
PMC3722081|S54|4a|Eligibility Criteria|Eligibility criteria|Patients who were at least 18 years old, had signed informed consent and met all criteria listed in Table  1 were enrolled in the study.
PMC3724398|S70|6a|Outcomes|Outcome measures|Outcome measures were prescribing rates and proportion of non-penicillin V prescribing at the group level before and after the intervention, compared with equivalent data from the control arm.
PMC3742408|S47|3a|Trial Design|Trial Design|This study was an assessor-blinded randomized controlled trial (RCT; ISRCTN57754429) comparing a brief Internet-based early psychological intervention with a care-as-usual control group in two trauma centers (see Multimedia Appendix 1 for the CONSORT E-HEALTH Checklist of the trial).
PMC3746956|S42|3a|Trial Design|Study design|The Clinical and Cost Effectiveness of Collaborative Care for Depression in UK Primary Care Trial (CADET) was a multicentre, two group, cluster randomised controlled trial.
PMC3751087|S65|4a|Eligibility Criteria|Study population|To be eligible, the woman had to be at least 15 years old, in her first or second trimester of pregnancy, be eligible for coverage by Oregon Health Plan Plus (the state administered Medicaid program which provides medical and dental services to adults and children), and speak English.
PMC3751087|S136|7a|Sample Size Determination|Sample size|The sample size is 400 women with 80 to 120 women enrolled within any one county.
PMC3757993|S62|4a|Eligibility Criteria|Exclusion Criteria|Individuals who had suffered a previous MI, had coronary artery bypass graft (CABG) surgery, coronary angioplasty, or stroke, who were not permanent residents of Ontario, and who did not have an Ontario health card were excluded.
PMC3766220|S64|11a|Blinding Procedure|Blinding|Whereas patients and health personnel were not blinded after randomization, outcome assessors and data analysts will be blinded to the allocation, however for some of the secondary outcomes it is difficult for researchers to remain blind as the patients knew which group they were in.
PMC3774634|S50|3a|Trial Design|Study Design|The Feedback, Awareness and Behaviour (FAB) study was a parallel group, open randomised controlled trial in which eligible participants were allocated to receive either no personalised feedback about physical activity (control group), or one of three different types of feedback: simple, visual, or contextualised (intervention groups).
PMC3774818|S45|3a|Trial Design|Trial design|The trial used a randomised placebo-controlled double-blind crossover design in which each participant served as his/her own control.
PMC3774818|S47|4a|Eligibility Criteria|Participants|Eligible patients were recruited from primary care, had been diagnosed with rheumatoid arthritis, were adults (aged 18 or over), and reported chronic pain (≥3 months duration and ≥30/100 on a pain visual analogue scale) at the time of enrolment.
PMC3784050|S85|12a|Statistical Methods for Outcome Comparison|Statistical Methods|The data were analysed using descriptive statistics in Microsoft® Excel 2007.
PMC3784443|S83|6a|Outcomes|Outcomes|The main outcome measures were: (1) clinical adverse events including mild, moderate and greater severity renal toxicities and serious adverse events (2), adherence rates to daily and intermittent dosing (3), willingness to use the study regimen, if shown to be effective (4) change in HIV-associated risk behaviour during trial participation (5), the proportion of volunteers with HIV-specific immune responses as measured by interferon-γ ELISpot.
PMC3785997|S71|4a|Eligibility Criteria|Inclusion Criteria|The following inclusion criteria were established for this study: being a panel member of respondi; having computer/Internet literacy; having sufficient command of German; being 18 years or older; and having an unhealthy drinking pattern, which was defined as (1) not complying with the guideline recommending no more than 1 glass (women) or 2 glasses (men) of alcohol per day, (2) drinking on more than 5 days per week, (3) having a score higher than 7 on the Alcohol Use Disorders Identification Test (AUDIT) [49], or (4) currently trying to become pregnant, drinking alcohol while pregnant or breastfeeding (in relation to pregnancy), or trying to get one’s partner pregnant (for men).
PMC3787048|S77|7a|Sample Size Determination|Sample size|The required sample size (n = 76) was determined a priori, based on the ability to detect a difference (Δ) between the treatment groups equivalent to the previously determined minimum clinically important difference (MCID) of 0.5 points for the SSS symptom severity scale [19], and assuming a standard deviation of 0.56 [20], [21] with power set at 90% (alpha 5%), and allowing for a drop-out rate of 20%.
PMC3788129|S109|12a|Statistical Methods for Outcome Comparison|Statistical analysis|We analysed the outcome measures by the nonparametric Wilcoxon signed-rank test using SPSS version 20 as not all the data were normally distributed, and accepted p<0.05 as significant.
PMC3799568|S130|7a|Sample Size Determination|Sample Size|We targeted a sample size of 150 participants for feasibility reasons based on the project budget and timeline.
PMC3812203|S114|12a|Statistical Methods for Outcome Comparison|Statistical Analysis|Analyses were descriptive in nature, and no formal statistical comparisons were made.
PMC3816918|S34|4a|Eligibility Criteria|Inclusion and exclusion criteria|This study enrolled patients (aged ≥18 years; BMI ≤45 kg/m2) with inadequately controlled type 2 diabetes (HbA1c ≥7 to ≤10%) despite a diet and exercise program and a stable regimen (unchanged for ≥12 weeks prior to randomization) of metformin immediate release plus a sulfonylurea.
PMC3828227|S65|4a|Eligibility Criteria|Study population|All the enrolled patients were at least 18 years-old, HIV-1 infected adults with a CD4+ count <200/µL and/or CD4+ recovery ≤25% and HIV-RNA constantly <50 cp/mL who had been experiencing a HAART regimen for at least one year.
PMC3828622|S135|8a|Random Allocation Sequence Generation|Sequence generation|Group assignment will be determined using a password protected website, where randomization is in permuted blocks and participants will be stratified by gestational age (less than or greater than/equal to 32 weeks gestational age at birth) in order to ensure equal distribution across groups for all ages.
PMC3839936|S54|7a|Sample Size Determination|Sample Size|A sample of 270 in each arm was chosen so that, after allowing for 15% loss to follow up and using a significance level of 0·05, the following could be detected: a reduction by half in the proportion overall admitted under the MHA with 90% power (from 30% to 15%); a proportionate reduction for a pre-specified subgroup of interest, Black patients, with 80% power (from 40% to 20%), assuming that the overall sample would yield a subsample of 91 Black patients per arm.
PMC3840668|S148|6a|Outcomes|Outcome measures|The MM in Delphi as described in this article is designed to deliver information about needs in pharmacotherapy and to trigger activities to reduce these needs.
PMC3840772|S104|12b|Statistical Methods for Other Analyses|Subgroup analyses|In order to explore the consistency of the treatment effects with respect to baseline pain intensity (moderate versus severe pain) and type of anesthesia (spinal versus general) patients received for the surgery, subgroup analyses were performed for the 2 co-primary endpoints.
PMC3844512|S58|3a|Trial Design|Design|A randomised, controlled, equivalence trial at two tertiary hospitals (Austin Health and Alfred Health) in Melbourne, Australia.
PMC3849534|S48|4b|Data Collection Setting|Recruitment|Healthy male and female volunteers were recruited through advertisement at public institutions in Holstebro, Denmark.
PMC3853440|S51|4a|Eligibility Criteria|Subjects|Prior to pharmacokinetic analysis in rats, we demonstrated the radiation dose distributions in a head and neck cancer patient to show the dose-painting concept that low dose area generously deposited around high-dose target volume.
PMC3866585|S106|7a|Sample Size Determination|Sample size calculation|A priori sample size calculation for stage 2 indicated 15 patients per group were required in order to detect a significant difference of 25% in IPAQ [29] between the intervention and control group (Effect size d = 1, alpha = 0.05, beta = 0.08).
PMC3898271|S126|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Differences in participants’ demographic characteristics and baseline decisional conflict score across the three trial arms were assessed using one-way ANOVA (age of parent, age of child, decisional conflict) and chi squared analysis (relationship to child, ethnicity, marital status, education, employment).
PMC3898920|S48|3a|Trial Design|Study design|This study was a randomized, open-label, multi-dose, two-arm, cross-over trial, conducted in Vietnamese patients with HIV-associated tuberculosis - Clinical trial registry number: NCT00651066.
PMC3906401|S280|7a|Sample Size Determination|Sample size|The sample size was powered to detect a two day mean delay in patency in the immunized group compared with the infectivity controls (80% power, α = 0.05, one-sided).31
PMC3907139|S122|7a|Sample Size Determination|Sample size|We are seeking to detect a mean KASQ improvement two scores (8%) in the intervention arm and have estimated that with a power of 80% and significance level of p < 0.05, allowing for 15% attrition, deduced from previous studies, 144 participants will be required.
PMC3922504|S65|3a|Trial Design|Design|Pilot randomised controlled trial (RCT) with economic evaluation comparing peer support in addition to care as usual with usual care alone following discharge, with follow-up at one month and three months post-discharge.
PMC3922843|S43|3a|Trial Design|Trial design|The study is designed as a prospective randomized controlled trial.
PMC3923245|S114|6a|Outcomes|Secondary outcomes|Neck pain intensity, arm pain, headache, and dizziness, all measured with a Visual Analogue Scale (VAS) (0–100 mm) [34,38]; Pain distribution, measured on a drawing, where the patient indicates symptom locations [39]; Self-efficacy in daily activities, measured with the Self-efficacy Scale [40]; Symptom satisfaction, related to neck problems (how would the patient feel about experiencing the current neck symptoms for the rest of his/her life), rated on a seven-grade scale [41]; Psychological and psycho-somatic distress, measured with the Distress and Risk Assessment Method (DRAM) [42]; Coping strategies, measured with the Coping Strategies Questionnaire (CSQ) [43]; Work capability, measured with the Work Ability Index (WAI) [44]; Sick-leave, measured as the number of days off work; Health related quality of life, assessed with the EuroQol five dimensions self-report (EQ-5D) and Current health status, measured with the EuroQol vertical VAS (0–100 mm) [45]; Impact on social relationships, measured with the West Haven Multidimensional Pain Inventory, Swedish version (MPI-S), the MPI-S for impact on significant others, and open questions [46].
PMC3930556|S90|4a|Eligibility Criteria|Exclusion criteria|Patients are excluded from the virtual ward admission if they refuse to provide consent, or are unable to participate (e.g. language barrier).
PMC3930872|S28|4a|Eligibility Criteria|Study population|Patients with symptomatic persistent AF7 (>7 or <7 days requiring electrical or pharmacological cardioversion) refractory to at least one class I or class III antiarrhythmic drug were recruited.
PMC3931997|S75|4b|Data Collection Setting|Setting|The study will be conducted in three cardiac rehabilitation facilities in three NHS Boards across the UK: NHS Highland, Highland Heartbeat Centre, Raigmore Hospital; NHS Wales, University Hospital of Wales and Maindy Sports Centre, Cardiff; NHS Forth Valley, NHS Hub at the Peak sports and leisure complex, Stirling.
PMC3936853|S94|11a|Blinding Procedure|Blinding|Within the DREAM trial, it will not be possible to blind dentists, study personnel, and statisticians.
PMC3938821|S88|3a|Trial Design|Study design|For participating centres see the UPBEAT trial website: http://www.medscinet.net/upbeat/.
PMC3944885|S119|4a|Eligibility Criteria|Participants|The target population was school pupils leaving school for work, vocational training or with no definite plans for their future, according to their plans during their final term at school.
PMC3945996|S58|12a|Statistical Methods for Outcome Comparison|Analysis|The primary analysis of the data from this trial has been reported previously [6] using the original MED-QoL questionnaire [16].
PMC3961702|S59|4a|Eligibility Criteria|Participants|Eligibility requirements for the STC trial were intentionally broad and included age (18 years of age or older), completion of primary treatment at least four weeks prior, but not more than 5 years before joining the study, diagnosis with only one cancer and no recurrence, access to the Internet, and ability to read English.
PMC3972512|S118|3a|Trial Design|Design|Clinical trial, multicenter studies randomized, controlled, and randomized into two parallel groups.
PMC3979097|S65|6a|Outcomes|Outcomes|The following disease outcomes were assessed: (1) radiological damage - the onset of new erosions at 24 months and modified Larsen scores; (2) disease activity - disease activity scores on a 28-joint count (DAS28); (3) disability- Health Assessment Questionnaire (HAQ); (4) QoL- SF-36 physical (PCS) and mental (MCS) component summary scores and EuroQol.
PMC3983265|S39|3a|Trial Design|Study design|STEAL was an open-label, prospective, randomized, non-inferiority study that compared simplification of current NRTIs to fixed-dose combination TDF-FTC or ABC-3TC over 96 weeks in 357 adults with plasma HIV viral load <50 copies/mL [17].
PMC3985576|S108|6a|Outcomes|Outcome measures|The outcome measures tested in the study are summarized in Table 3.
PMC3994215|S134|4b|Data Collection Setting|Data collection|The variables will be assessed according to Table 1.
PMC3994215|S136|6a|Outcomes|Outcomes|Taking into account the recommendations of Barlow [57] and following analysis of the results of two recent meta-analyses [1,5], the following outcomes were defined (see Table 2).
PMC3994388|S53|4b|Data Collection Setting|Recruitment|Patients were consecutively recruited from the Dialysis Department and Outpatients’ Clinic of Renal Diseases, Holstebro Hospital All patients in our dialysis department were screened for participation.
PMC3994651|S75|12a|Statistical Methods for Outcome Comparison|Statistical methods|Statistical analyses were performed using R 3.01 with software package CMPRSK and SPSS software 19.0.
PMC3996065|S93|4b|Data Collection Setting|Data collection|Objective physiological as well as patient reported outcomes are collected at baseline and at the end of the intervention (6- 8 weeks).
PMC3997435|S58|4a|Eligibility Criteria|Study population|The research population includes all construction workers (i.e. blue collar workers) within the participating companies.
PMC4004141|S96|12a|Statistical Methods for Outcome Comparison|Data Analysis|Data analysis used SPSS 16.0 (SPSS Inc, Chicago, IL, USA) and included (1) descriptive numbers and percentages of patients who received SWAP-DM2–assisted prevention and newly diagnosed prediabetes and diabetes; and (2) comparison, using chi-square tests for percentages or t tests for quantitative ratings, between the baseline and 6-month follow-up assessments in terms of improvements in delivery of essential prevention procedures, knowledge about diabetes, lifestyle management practices, body mass index (BMI), and blood pressure, etc; and (3) narratives of qualitative data.
PMC4008389|S61|4b|Data Collection Setting|Recruitment|Headmasters at the selected schools will be contacted by a research team member, who will provide details about the study and invite the school to participate.
PMC4010491|S69|4b|Data Collection Setting|Setting|A nurse-led outpatient respiratory clinic in a large 600-bed general hospital in South West Wales, that serves an urban and rural population of around 600,000.
PMC4022155|S46|3a|Trial Design|Trial design|This paper reports on the internal pilot trial of a parallel-group RCT with a 1:1 allocation ratio.
PMC4022155|S94|8b,10|Randomization Type,Randomization Implementation|Randomisation|The randomisation sequence was generated in advance by a CTRU statistician who was not a member of the trial team, without stratification but using blocked randomization with randomly-selected block sizes.
PMC4022401|S92|7a|Sample Size Determination|Sample size|A priori analysis provided a sample size estimate of 18 per group which would allow 80% power to detect a difference for mean permeability between 0.015 and 0.045 assuming a standard deviation of 0.03.
PMC4024624|S33|4a|Eligibility Criteria|Study population|Our study is based on participants from the Danish part of the MONICA study [21], the Diet, Cancer and Health (DCH) study [22] and the INTER99 study [23], each of which are described in the following.
PMC4028934|S41|4b|Data Collection Setting|Setting|Participants for both groups were recruited from two Ontario Community Hospitals: Site I, a 40-bed unit in a 500-bed hospital, and Site II, a 20-bed unit in a 120-bed hospital.
PMC4030523|S191|12a|Statistical Methods for Outcome Comparison|Statistical analyses|Because of the low number of patients infected with HCV G4 in this study, no statistical analysis was performed and data were summarized descriptively.
PMC4045308|S79|12a|Statistical Methods for Outcome Comparison|Statistics|Sample size was driven by the dose-escalation scheme and descriptive statistics were employed.
PMC4050299|S50|5|Interventions|Treatment|Treatment and dose adaptation were as described previously (see also legend to Table 2) [14, 15].
PMC4054662|S245|11a|Blinding Procedure|Blinding|Apart from the independent statistician at the National Perinatal Epidemiology Unit who generated the sequence, all study personnel and the participants were blinded to allocation.
PMC4060440|S52|12a|Statistical Methods for Outcome Comparison|Statistics|All statistical calculations, including deriving means and SD, categorical data tests (that is, Chi square or Fisher’s exact test), and correlation analysis based on Pearson statistics were conducted with SAS 9.3 (Cary, NC, USA).
PMC4078101|S60|6a|Outcomes|Study outcomes|Four indicators of sexual behaviours were considered: 1) sexual activity (i.e. at least one sexual intercourse) in the past year; 2) multiple partnership (i.e. at least two sexual partners) in the past year; 3) unprotected sex at last intercourse in the past year; and 4) risky sex (defined as unprotected sex with a partner of HIV negative/unknown status) at last intercourse in the past year.
PMC4095608|S223|12a|Statistical Methods for Outcome Comparison|Statistics|Statistical analyses of experimental data were done in GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA) unless otherwise indicated.
PMC4096428|S94|3a|Trial Design|Study design|We will complete a multicenter double-blind, placebo-controlled randomized superiority clinical trial of oral Mg++ citrate supplementation.
PMC4100932|S43|3a|Trial Design|Study Design|This pilot study was a three-arm, parallel group, randomized controlled trial.
PMC4106208|S71|4a|Eligibility Criteria|Exclusion criteria|The following exclusion criteria were applied: (a) hysterectomized women with a history of pre-malignant lesions (AGUS ASCUS, LSIL, HSIL), carcinoma in situ or cervical-uterine cancer, HIV positive or other causes of immunosuppression (since these women follow a specific protocol); (b) non residents in the area for more than 6 months.
PMC4112648|S72|3a|Trial Design|Study design|The design is a multicenter, controlled, cluster-randomized, nonblinded clinical trial to evaluate the effectiveness of an intervention related to the prescription of cholesterol-lowering drugs in primary prevention, compared to usual clinical practice.
PMC4112648|S74|4b|Data Collection Setting|Setting|All individuals attended in 283 primary care center (PCC) managed by the ICS, which cover a population of 5.8 million urban, semi-urban, and rural residents of Catalonia.
PMC4120409|S44|3a|Trial Design|Trial design|This was an independent, investigator-initiated, multicentre, pragmatic, randomised, open, blinded-end point, parallel group study conducted in Japan (NCT00131846).
PMC4120409|S55|9|Allocation Concealment Mechanism|Concealment of assignment|We developed a web-based minimisation system that was controlled by the data centre and effectively concealed the assignment sequence from investigators assessing and recruiting patients.
PMC4143094|S40|4a|Eligibility Criteria|patients|This study was conducted in accordance with the Declaration of Helsinki and Japanese Ethical Guidelines for Clinical Research, and was approved by the Institutional Review Boards of each participating institute.
PMC4145236|S54|3a|Trial Design|Study design|We conducted a longitudinal comparative study to compare the changes of biomedical measurements, observed cardiovascular events and cardiovascular risks at 12 months follow-up using a difference-in-differences approach between the RAMP-DM group and the usual care group.
PMC4149271|S102|3a|Trial Design|Design|Exploratory randomised trial of the effectiveness and acceptability of the wellbeing intervention for common mental health symptoms in (a) elder patients (b) patients from ethnic minority groups, compared to treatment as usual (TAU).
PMC4149271|S124|7a|Sample Size Determination|Sample size|We estimated that 50 participants in each trial would be sufficient to assess feasibility, and estimate effect size for future trials.
PMC4150942|S67|5|Interventions|Intervention|A school-based family-focused pilot intervention focusing on reducing children’s sedentary behaviours in school and at home was developed and implemented over a six-week period.
PMC4154516|S113|6a|Outcomes|Primary outcome measures|Primary endpoint of the study is given by changes in the overall score of the Hamilton Rating Scale for Depression (HDRS [44]), from baseline (V0) to week 8 (v1) for each of the treatment groups.
PMC4155099|S120|6a|Outcomes|Primary outcome|The primary outcome is the proportion of regular smokers (smoking at least one cigarette per week) assessed by self-report at 24 months (final follow-up).
PMC4155866|S50|4a|Eligibility Criteria|Participants|Women between 30 and 70 years of age, with histologically confirmed endometrial hyperplasia according to WHO94 classification and D-score (see Additional methods) were eligible; excluded were women with hypersensitivity to progestin, active genital infection, a history of genital or mammary cancer, undiagnosed vaginal bleeding, liver disease, serious thrombophlebitis, or pregnancy.
PMC4158045|S90|4a|Eligibility Criteria|Participants|We include females aged 60 years and older with a distal radius fracture.
PMC4158199|S183|7a|Sample Size Determination|Sample size calculation|Using a power of 90%, p value of <0.05% (95% for one-sided CI and 90% for two-sided CI) a total of 310 events of hypokalaemia are required to reject the null hypothesis.
PMC4159508|S62|7a|Sample Size Determination|Sample size|A sample size of 500 per group was calculated to provide an estimated 86.4% statistical power to show meaningful differences in LOS, provided that the mean and standard deviation (SD) LOS were similar to those found in a previous study with similar outcome measures (mean [SD] of 8.75 [12.18] days in the quetiapine IR group compared with 6.91 [5.70] days in the quetiapine XR group) [11].
PMC4161875|S58|8b,10|Randomization Type,Randomization Implementation|Randomization|Patients who met the inclusion criteria were randomized in a 1:1 ratio with computerized block randomization to either the intervention group or the control group.
PMC4162545|S89|6a|Outcomes|Outcomes|Effectiveness – proportion of participants left at scene without conveyance to an Emergency Department and proportion referred to falls services                                         Safety – proportion of participants with adverse events (harm) up to one month (999 call, Emergency Department attendance, emergency admission to hospital, or death);                                         Cost-effectiveness – comparison of costs of implementation of CCDS for paramedics and its benefits in the form of patient utility modelled over 12 months.
PMC4163193|S68|7a|Sample Size Determination|Sample size|The study sample size calculations have already been described.14
PMC4163194|S33|3a|Trial Design|Study design|The prospectively collected medical records of a cohort of AMI patients were reviewed to assess the occurrence of chest pain and ischaemic atherosclerotic disease in any arterial bed in the 90 days prior to AMI.
PMC4169371|S58|3a|Trial Design|Study design|This was a prospective, multicentric, randomized, open-label, comparative Phase III study.
PMC4172821|S102|7a|Sample Size Determination|Sample size|Using Optimal Design software,24 we determined that a sample size of 252 schools with a minimum of 10 students for each school conferred 90% power, with an α of 0.05, intraclass correlation of 0.15, and explained variation by covariates (R2) of 0.50, to detect a difference of 0.20 standard deviations in endline math score between intervention arms and the control group.
PMC4176446|S69|12a|Statistical Methods for Outcome Comparison|Statistical Methods|Between-group comparisons were performed using a 2-sample t test with unequal variances.
PMC4177060|S80|4a|Eligibility Criteria|Study population|All pregnant women and their home- or facility-born live births within participating clusters will be eligible for enrollment in this study.
PMC4181733|S96|7a|Sample Size Determination|Sample size|A sample size of at least 84, divided into three groups, provides a power of 80% to detect the minimum effect size that was observed previously in a cardiovascular population13 with a two-sided α-value of 0.05.
PMC4188585|S50|8b,10|Randomization Type,Randomization Implementation|Randomization|Randomization was done by Herning Hospital Pharmacy according to a computer-generated randomization list (http://randomization.com/) and a block-size of four was used.
PMC4196118|S125|8b,10|Randomization Type,Randomization Implementation|Randomization|Patients will be randomized centrally for systemic treatment versus surgery of the primary tumour in a 1:1 allocation ratio, stratifying for number of metastatic sites (1 versus more), serum lactate dehydrogenase (LDH, normal versus abnormal), WHO performance status (0 or 1 versus 2) and institution.
PMC4196482|S98|6a|Outcomes|Outcomes|Primary birth outcomes were birth weight and rates of low birth weight.
PMC4207765|S46|12a|Statistical Methods for Outcome Comparison|Statistical analysis|All statistical analysis was performed using PASW Statistics for Windows, Version 18.0.
PMC4209067|S55|8b,10|Randomization Type,Randomization Implementation|Randomization|Participants will be randomly assigned to one of three groups: 1) a LMI-Lifestyle intervention physical activity group 2) a structured MVI-Exercise group or 3) a usual care control group.
PMC4209879|S42|8b,10|Randomization Type,Randomization Implementation|Randomization|Eligible patients were randomized via a central interactive voice-response system in a 1:1:2 ratio (high-ferritin FCM: low-ferritin FCM: oral iron), with randomization blocks distributed by country.
PMC4212133|S75|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Between-group baseline variables were compared using one-way analysis-of-variance (ANOVA) for continuous outcomes and chi-squared tests for dichotomous ones.
PMC4216866|S37|3a|Trial Design|Study design|This is a multicentre, prospective observational study of consecutive patients undergoing emergency intraperitoneal surgery that will be carried out by participants during 14-day, consecutive time periods of the individual participant's choice during a 5-month study period window.
PMC4222281|S140|6a|Outcomes|Outcomes|The list below represents the full range of outcomes relevant to the five intervention pairs being evaluated.
PMC4222281|S197|12a|Statistical Methods for Outcome Comparison|Analysis|A detailed Statistical Analysis Plan (SAP) will be developed and agreed by the Study Steering Committee (SSC) before the analysis is undertaken.
PMC4222435|S65|7a|Sample Size Determination|Sample size|A sample size of 60 randomised patients (26 analysed per arm, allowing for dropout) provided 80% power to detect a 2-point difference in mean distress at two-weeks between groups (SD = 2.5, alpha = 5%), with increased precision anticipated from adjustment for baseline.
PMC4222692|S91|4a|Eligibility Criteria|Patients|All practices were asked to identify patients with dementia by using electronic searches of their clinical record system updated by manual checks of the resulting list by medical and nursing staff.
PMC4222863|S46|3a|Trial Design|Study design|This is a prospective observational cohort study of patients with, or at risk for, HF.
PMC4223566|S55|3a|Trial Design|Study design|This is a randomised, double-blind (practitioner-patient blinding), placebo-controlled study performed in a single centre including four arms: treatment with penetrating needles (penetrating treatment), treatment with skin-touch placebo needles (skin-touch placebo treatment), treatment with no-touch placebo needles (no-touch placebo treatment) and control with no treatment (no-treatment control) [23-29].
PMC4225478|S63|12b|Statistical Methods for Other Analyses|Subgroup analyses|The proportion of patients achieving a ≥2-g dL−1 increase in Hgb at any time from baseline to Week 5 and the mean change in Hgb from Baseline to Week 5 were also analyzed in five predefined subgroups based on the patients' primary underlying cause of their IDA, as attributed by the investigators (i.e., patients with abnormal uterine bleeding (AUB), cancer, GI disorders, postpartum anemia, or other conditions [e.g., patients with nutritional deficiency, heart failure, and rheumatoid arthritis]).
PMC4227277|S120|4a|Eligibility Criteria|Eligibility criteria|The inclusion criteria are:           • women 18–45 years           • a singleton pregnancy           • 6–14 weeks of gestational age           • viable pregnancy           • delivery planned in the hospital where the study is performed           The exclusion criteria are:           • < 18 years or > 45 year           • multiple pregnancy           • known diabetes or treatment with metformin           • non-viable pregnancy (miscarriage)           • chronic medical condition (uncontrolled hypertension, severe heart disease, severe chronic liver disease, severe chronic kidney disease, chronic infections such as HIV and hepatitis)           • bariatric surgery           • gastro-intestinal surgery changing the absorption of glucose (e.g.
PMC4229898|S57|6a|Outcomes|Assessments|Methods used for tumor assessments and clinical outcomes have been published previously [10].
PMC4231609|S170|6a|Outcomes|Primary outcome|Changes in baseline DLL measures at 12 months postoperatively in both groups.
PMC4234129|S102|12a|Statistical Methods for Outcome Comparison|Statistical analysis|For the statistical analysis of data, JMP v9 software was used (SAS Inc.).
PMC4234276|S73|4a|Eligibility Criteria|Exclusion criteria|● Established critical limb ischaemia         ● Insulin dependent diabetes mellitus         ● Active leg ulceration         ● Open fractures         ● Serious concomitant disease - metastatic disease or terminal illness         ● Clinically substantial degenerative or inflammatory arthritis (in the ankle)         ● Unfit for general anaesthetic         ● Cognitive impairment - Mini-Mental State Exam (MMSE) of under 16/30 [27]         ● Patient unwilling to give informed consent.
PMC4236237|S58|6a|Outcomes|Assessments|A blinded research nurse performed standardized height/weight assessments at PCP sites and administered questionnaires, i.e., demographics, depression, stress, use of antidepressant medications.
PMC4236553|S43|3a|Trial Design|Design|A qualitative study exploring factors influencing the engagement of GPs in insulin initiation in a context where a support program is provided and exploring factors relevant for future program development.
PMC4236665|S38|3a|Trial Design|Study design|This is a prospective cross-sectional study which was carried out between March and June 2013 at the Radiology Departments of Aga Khan University (AKU) and Dow University of Health Sciences (DUHS).
PMC4236682|S166|3a|Trial Design|Trial design|Multicentre, randomised, masked, parallel controlled trial.
PMC4236797|S45|3a|Trial Design|Study design|This study is a pragmatic, randomised controlled clinical trial (RCT) of parallel groups.
PMC4239389|S57|3a|Trial Design|Study design|This is a multicenter prospective cohort study.
PMC4243579|S78|7a|Sample Size Determination|Sample Size|Assuming an expected response rate of 55% that is 20% higher than the threshold response rate (35%), 45 patients were determined as necessary to demonstrate that the lower limit of the two-sided 90% confidence interval (CI) of the response rate would exceed the threshold response rate with a power of 80%.
PMC4243941|S65|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Continuous variables were summarized as mean ± standard deviation (SD) or median (interquartile range).
PMC4245803|S78|4b|Data Collection Setting|Setting|Participating centers are Brest, Rennes, Nantes, Lille, Angers, Tours, Vannes, (France) - public funded specialist mental health services for adults in the Western and Northwestern regions of France.
PMC4247649|S40|3a|Trial Design|Design|This is a randomized, double-blind (patients and physician), placebo controlled multicenter study, which will be conducted in North America (Canada and United States) and Europe (Belgium, Switzerland and Germany), with an aim to enroll approximately 1,400 patients to evaluate the overall study hypothesis.
PMC4249962|S114|6a|Outcomes|Primary outcome|The occurrence of serious adverse events, defined as any event which resulted in death, was life-threatening, required initial or prolonged hospitalization, resulted in disability, or required intervention to prevent permanent impairment or damage to a volunteer (http://www.fda.gov/medWatch/report/DESK/advevnt.htm), or adverse events (including an abnormal laboratory or physical examination finding, symptom, or disease) defined as a new Grade II–IV toxicity using the FDA's Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials (Protocol S1), that were possibly/probably/highly probably related to administration of LGG.
PMC4251169|S76|12a|Statistical Methods for Outcome Comparison|Data analysis|In accordance with recommendations for the analysis of pilot trials,11 12 a formal power calculation was not carried out, the data analysis is descriptive and statistical comparisons between the randomisation groups have not been undertaken.
PMC4257733|S57|7a|Sample Size Determination|Sample size|We estimated that 300 patients would achieve at least an 85% power to detect a 15 percentage point or greater improvement in the proportion of patients who continued their medication and took it for at least 22 of the previous 28 days at a 5% level of statistical significance, assuming an adherence rate of 70% in the control group [4] and 20% loss-to-follow up.
PMC4258014|S39|3a|Trial Design|Trial design|The study was designed as a mono-centric, three armed, open label, randomized (1:1:1), controlled, phase IIb trial with tissue biopsy [19] without any amendments to the protocol after trial start.
PMC4269344|S40|4a|Eligibility Criteria|patients|Eligible patients were men with histologically or cytologically confirmed adenocarcinoma of the prostate and castrate levels of serum testosterone (<50 ng/dl), with ≤2 prior chemotherapy regimens, including ≥1 containing docetaxel.
PMC4271137|S68|4a|Eligibility Criteria|Patients|Complete patient inclusion and exclusion criteria are provided in Table 1.
PMC4287106|S50|12a|Statistical Methods for Outcome Comparison|Statistical analyses|Mean item and domain discomfort scores of the GSRS were calculated together with the corresponding 95% confidence intervals (CIs).
PMC4289564|S73|8b,10|Randomization Type,Randomization Implementation|Randomisation|After induction of anesthesia, but prior to the start of the surgery, patients were randomly assigned to the control group or the intervention group using sealed envelopes.
PMC4295396|S62|3a|Trial Design|Trial design|The trial design was a parallel-group study with balanced randomization 1:1.
PMC4299688|S38|3a|Trial Design|Study design|This study analyzed 110 subjects in the 4th year of follow up who were included in the longitudinal LOD-DIABETES study (NCT01065155) [31].
PMC4299688|S47|6a|Outcomes|Measurements|A detailed description has been published elsewhere regarding how the clinical data were collected, the anthropometric measurements were made, blood pressure was recorded, TOD was assessed, and the analytical parameters were obtained [31].
PMC4301623|S103|4b|Data Collection Setting|Data collection|The timing of data collection activities is outlined in Table 1 and described in more detail below.
PMC4304379|S80|12a|Statistical Methods for Outcome Comparison|statistical analysis|This paper describes the full, registered patient population, including all patients who signed the informed consent documents, up to the point of surgery.
PMC4304605|S50|3a|Trial Design|Design|A randomised controlled pilot study with nested quantitative and qualitative process evaluation.
PMC4309051|S91|8b,10|Randomization Type,Randomization Implementation|Randomization|Eligible participants were randomized by computer using a randomly permuted block method, stratifying by baseline 6‐minute walk performance.7
PMC4310398|S54|6a|Outcomes|Study Outcomes|The primary outcome of this study was to evaluate the effect of chocolate on endothelial function by FMD and on walking distance in PAD patients.
PMC4312114|S77|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Safety and efficacy data were summarized by descriptive statistics and reported using the safety population, which comprised patients who received ≥1 dose of eltrombopag or placebo.
PMC4318246|S58|3a|Trial Design|Study design|This study was a three-arm, open-labelled, randomized, controlled, non-inferiority trial comparing the efficacy, safety and tolerability of ASAQ and DHAP to AL in children aged six to 120 months following a 42-day follow-up period.
PMC4331517|S165|12b|Statistical Methods for Other Analyses|Subgroup Analyses|For the primary outcome only, interaction terms were added to the regression model to test whether the intervention effect varied between: men and women; different age groups; different BMI cut-offs; different disability levels; different levels of confidence in ability to exercise; and those taking part as a couple versus those taking part individually.
PMC4335123|S100|7a|Sample Size Determination|Sample Size|An a priori sample size estimate indicated 284 participants (142 per group) would be sufficient to detect a difference of 1 body mass index point with a two-sided 5 % significance level and a power of 80 %, given an anticipated dropout rate of 10 %.
PMC4337322|S45|3a|Trial Design|Study design|This was a prospective, randomized, double-blind placebo controlled trial of escitalopram in the prevention of PTSD symptoms in traumatized adults with full or partial ASD.
PMC4344956|S32|4a|Eligibility Criteria|Patients|We enrolled 142 patients with HeFH (n = 103) and HoFH (n = 38) taking maximally tolerated lipid-lowering therapy who had successfully completed a Phase 3 placebo-controlled mipomersen trial [NCT00607373-HoFH, n = 38 (86%); NCT00706849-HeFH, n = 94 (82%); NCT00794664-HeFH, n = 9 (100%)] had an acceptable safety profile [no significant liver blood test abnormalities that met stopping criteria or intolerable injections site reactions/flu-like symptoms (FLS)], no new or worsening conditions that interfered with study completion, and were willing to limit alcohol consumption to moderate amounts [males, 2 drinks (20 g) per day, 8 drinks (80 g) per week; females, 1 drink (10 g) per day, 4 drinks (40 g) per week] for the study duration.
PMC4352248|S61|12a|Statistical Methods for Outcome Comparison|Statistical methods|This was a non-interventional study, using a descriptive analysis approach to assess clinical management, clinical outcomes and healthcare resource use.
PMC4355145|S131|12a|Statistical Methods for Outcome Comparison|Analysis|Mean, standard deviation [SD] and proportions were used to describe time lapse, the flow of applications and meeting or not prerequisites or study criteria for applicants and candidates.
PMC4356153|S56|6a|Outcomes|Outcomes|We aimed to assess rates of death, dependence (measured according to patient-reported modified Rankin scale scores), and recurrent subarachnoid haemorrhage after neurosurgical clipping or endovascular coiling as part of the tertiary objectives of ISAT.
PMC4358851|S41|3a|Trial Design|Design|The TACIT (tumour necrosis factor inhibitors against combination intensive therapy) trial was an open label pragmatic randomised two arm non-inferiority trial carried out over 12 months in multiple centres.
PMC4359147|S90|3a|Trial Design|Design|A randomized, placebo-controlled, double-blind, double-dummy, superiority, three-arm trial with a six week follow-up study was conducted.
PMC4361143|S57|3a|Trial Design|Design|Randomised, parallel-group clinical trial in which a group of hypercholesterolaemic patients, undergoing a combined intervention targeted at improving treatment adherence and degree of lipid control as complementary measures in support of the intervention at the GP’s practice, will be compared to another group of hypercholesterolaemic patients who will solely receive routine GP care.
PMC4363667|S102|8b,10|Randomization Type,Randomization Implementation|Randomization|As the Guide was designed to be used with organizations, individual organizations were randomized to receive or not receive the Guide along with facilitation.
PMC4368731|S50|3a|Trial Design|Study design|This was a prospective matched case-control study designed to compare HIV replication and progression of clinical disease between patients co-infected with HIV and Wb infection and patients that were HIV-positive but without Wb infection.
PMC4370326|S52|6a|Outcomes|Outcomes|The primary outcome was the difference in mean fasting glucose levels by POC testing before breakfast between the supplement and no-supplement groups.
PMC4376964|S62|6a|Outcomes|Primary outcome|Increase in HCV antibody testing rate in prisons following introduction of DBST.
PMC4394418|S156|12a|Statistical Methods for Outcome Comparison|Statistical analysis|The analysis will be done according to the intention to treat analysis (all the patients will be included in the analysis in the group to which they were allocated independently of the treatment they finally received.
PMC4394557|S52|3a|Trial Design|Study design|A single-blind, randomized controlled trial to compare TAU alone with TAU and a psycho-educational intervention comprising six booklets delivered fortnightly to participants alongside follow-up phone calls.
PMC4410457|S143|7a|Sample Size Determination|Sample size|The sample size calculation was based on the primary outcome, RTW, and is reported elsewhere [15].
PMC4414283|S89|4a|Eligibility Criteria|Inclusion and exclusion criteria|Potential participants must meet the inclusion criteria of (i) DSM-V diagnosis of schizophrenia of schizoaffective disorder (ii) at least a mild level of depression as measured by scoring 14 or more on the Beck Depression Inventory-II [17] (iii) aged between 18 and 65 (iv) have a sufficient understanding of spoken English to engage with assessments and clinical intervention (v) are able and willing to provide informed consent (vi) do no exhibit an organic impairment which is considered to be the primary diagnosis and (vii) do not exhibit a learning disability.
PMC4422504|S148|6a|Outcomes|Assessments|The primary measure of the incidence study is psychotic caseness as ascertained by SCID (Kiddie SADS for adolescents who are 13–17 years old) assisted by the PANSS interview.
PMC4423483|S139|4b|Data Collection Setting|Data collection|Only partners of the women in the intervention group are asked to complete questionnaires regarding problems with sexuality and intimacy (male partner: IIEF [85], female partner: FSFI [86]), and relational functioning (PAIR Inventory [87], MMQ [84]) at the same points in time as the participants.
PMC4429324|S58|3a|Trial Design|Study design|This is a multicenter controlled randomized clinical trial in four parallel groups: a) healthy lifestyle psychoeducational program, b) focused program on positive affect promotion, c) brief intervention based on mindfulness and d) improved treatment as usual (ITAU) group in primary care.
PMC4429659|S44|4a|Eligibility Criteria|Participants|The eligible study population will consist of all consecutive adult patients who are planned for elective implant removal following fracture treatment of the foot, ankle and/or lower leg.
PMC4430584|S87|6a|Outcomes|Assessments|The CaMEO Study modules included validated instruments and surveys as well as original items developed based on the results of focus groups, expert opinion, and pretesting among target respondents.
PMC4431817|S40|3a|Trial Design|Trial Design|We conducted a randomized, double-blind, placebo-controlled, crossover study comparing the analgesic efficacy of amitriptyline tablets to inactive placebo tablets, with a three-week washout period between interventions.
PMC4442243|S56|3a|Trial Design|Study design|This study used qualitative, semistructured interviews to explore and understand participant experiences of dizziness self-management using booklet-based VR alone or with telephone support.
PMC4448287|S85|9|Allocation Concealment Mechanism|Randomisation-allocation concealment|After giving written informed consent and filling in baseline measures, the patients will be randomly assigned to the "early palliative care" group or the "standard care only" group using sealed envelopes prepared using a computer program by FRH co investigator not involved in the inclusion of the patients, in a 1:1 ratio without stratification and with randomized block sizes ranging from 4 to 6.
PMC4448287|S126|12a|Statistical Methods for Outcome Comparison|Statistics|To compare baseline characteristics and study outcomes of the patients between groups, Fishers’ exact tests, chi-square tests and the independent-samples t-test or the non-parametric equivalent Mann–Whitney u test will be used.
PMC4451719|S107|3a|Trial Design|Study design|The study was a feasibility study with a randomised design to assess the fidelity, feasibility and acceptability of the short-listed VBIs identified in Stage 1.
PMC4456169|S76|12a|Statistical Methods for Outcome Comparison|Statistical Analysis|Details on statistical analysis can be found in the online-only Data Supplement.
PMC4470524|S53|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Descriptive statistics were used to summarize the results according to HT use, reasons for use of HT, reasons for stopping HT, use of CAMs, and perceived helpfulness of CAMs.
PMC4472776|S57|6a|Outcomes|Endpoints|The final health outcome of the cost-effectiveness analysis is the number of CRBSIs avoided and the cost-effectiveness criterion is the cost per patient with CRBSI avoided resulting from chlorhexidine dressing use.
PMC4474364|S93|4a|Eligibility Criteria|Participants|The study population consisted of students who attended the following basic courses (vocational clusters in brackets):Car mechanicsCarpenter, bricklayer, painter or plumber (Construction)Electrician, data technician or frontline PC supporter (Electricity and information and computing technology (IT))Media graphic designer, graphic technician, web integrator or sign writer (Media production)Zookeeper, landscaper, farmer or greenhouse gardener (Agricultural)         Shaping the Social is designed to accommodate the fact that this was a heterogeneous population considerably more diverse than, for example, a typical Danish high school population.
PMC4476025|S91|6a|Outcomes|Secondary outcome measures|Secondary outcome measures included total opioid dose, opioid side effects, patients satisfaction with pain management, proportion of study period in moderate/severe pain (that is, with visual analogue scale >44 mm), proportion of study period spent sleeping, and length of hospital stay.
PMC4476026|S96|6a|Outcomes|Secondary outcome measures|Secondary outcome measures included total opioid dose, out of range vital signs, patients satisfaction with pain management, proportion of study period in moderate/severe pain (that is with visual analogue scale >4.4 cm), proportion of study period spent sleeping, and length of hospital stay.
PMC4476627|S29|3a|Trial Design|Study Design|This was a 12-week randomized, double-blind, placebo-controlled clinical trial conducted at Chung Shan Medical University Hospital (CSH-2012-C-023).
PMC4482316|S59|3a|Trial Design|Design|The study employed a repeated cross-sectional observational design embedded within a cluster randomised controlled trial, with the school as the unit of randomization [17].
PMC4489123|S70|5|Interventions|Treatment|After signing the informed consent form, women were given the antibiotic or anti-fungal treatment followed by EcoVag® vaginal capsules.
PMC4491841|S60|6a|Outcomes|Outcome measures|The outcome measures included the rate of successful blinding and the certainty in the participants’ beliefs in both treatment groups.
PMC4498531|S67|12a|Statistical Methods for Outcome Comparison|Statistics|Data were processed with SPSS version 22 for Mac and statistical analysis was made using descriptive statistics and repeated measures ANOVA, p values <0.05(two-tailed) were regarded as significant.
PMC4501099|S62|3a|Trial Design|Design|The OptEC trial, hence the internal pilot study was a multi-site, pragmatic, placebo controlled, superiority randomized trial [1].
PMC4501113|S98|12a|Statistical Methods for Outcome Comparison|Statistics|Nrf2 target gene data were analyzed with Sigmaplot 12.0 (Systat, Inc., San Jose, CA) by student’s t-test or by one way-analysis of variance (ANOVA) followed by Duncan’s Multiple Range post-hoc test with significance set at p < 0.05.
PMC4517398|S232|8b,10|Randomization Type,Randomization Implementation|Randomization procedure|The randomization procedure is explained in section 2a.
PMC4523042|S30|4b|Data Collection Setting|Setting|The study was conducted at seven sites: Carolinas Rehabilitation, Carolinas Health Care System in Charlotte, NC (lead site); Indiana University School of Medicine and Rehabilitation Hospital of Indiana in Indianapolis, IN; Kessler Institute of Rehabilitation in West Orange, NJ; Spaulding Rehabilitation Hospital and Harvard Medical School in Boston, MA; TIRR Memorial Hermann in Houston, TX; The Ohio State University in Columbus, OH; and University of Washington in Seattle, WA.
PMC4526282|S69|3a|Trial Design|Study design|The present study is a triple masked randomized controlled trial.
PMC4529153|S97|6a|Outcomes|Outcomes|Primary endpoints including safety and tolerability of the different prime-boost regimens, secondary endpoints assessing the qualitative and quantitative immune responses elicited by the different prime-boost regimens and ancillary endpoints were pre-defined.
PMC4531468|S39|3a|Trial Design|Study design|This study used baseline data from 450 randomly selected patients with established (multi-episode) psychosis recruited as part of the National Institute for Health Research-funded study: Improving Physical Health and Reducing Substance Use in Severe Mental Illness; a randomized controlled trial (IMPaCT RCT) (Gaughran et al. 2013).
PMC4531468|S41|4b|Data Collection Setting|Setting|The study took place in community mental health teams (CMHTs) in five Mental Health NHS Trusts, covering urban (Lambeth, Southwark, Lewisham, Croydon, Greenwich, Bexley, Bromley) and rural (Staffordshire, Somerset and Sussex) boroughs across England (Gaughran et al. 2013).
PMC4533950|S45|3a|Trial Design|Study design|Parallel randomized trial of two groups.
PMC4535739|S45|3a|Trial Design|Study design|We conducted a prospective cohort study to compare the risks of developing cardiovascular complications and all-cause mortality over 3 years between people with diabetes managed under RAMP-DM and those receiving usual primary care.
PMC4538259|S46|4b|Data Collection Setting|Setting|This is a diagnostic accuracy study in ambulatory care (defined as general practice, paediatric outpatient clinics or ED).
PMC4549128|S52|3a|Trial Design|Study design|This study was designed as a blinded, single-centre, parallel group feasibility RCT with a 1:1 allocation ratio (see Additional file 1 for CONSORT checklist).
PMC4549128|S73|6a|Outcomes|Outcomes|The study outcomes were as follows:Number of patients referred for elective AAA repair and the number and proportion eligible for the trial.Number of eligible patients approached to participate and reasons for non-approach.Number and proportion of eligible patients approached who consented to participate and reasons for non-consent.Success of blinding those not involved directly in administering the intervention.Impact of the intervention on delivery of care and time taken for anaesthesia (defined as the time from when the patient entered the theatre suite until surgical knife to skin).Participant follow-up to 6 months, numbers and reasons for loss to follow-upCompleteness of clinical outcome data and frequency of the these events, in particular, indices of acute renal injury within the first 48 hours after AAA repair, as defined by the AKIN criteria [26]; cardiac events, namely myocardial infarction (MI), new arrhythmias, electrocardiogram (ECG) changes and raised troponin T levels in the period prior to discharge; and complications, including stroke and death, up to 6 months after surgery.Staff and participant views on the intervention and study conduct.
PMC4549128|S85|11a|Blinding Procedure|Blinding|With the exception of the in-theatre anaesthetic team who administered the intervention, everyone (participants, surgeons, nursing staff and research nurses) was blinded to the intervention received.
PMC4551097|S51|3a|Trial Design|Trial design|This was a two-arm pilot cluster randomised controlled trial.
PMC4562360|S48|3a|Trial Design|Trial design|This multi-centre pragmatic randomised controlled non-blinded parallel arm trial assessed the effect of breathing training delivered over three 1 hour-long sessions at weekly intervals, or during a single session in the management of patients with refractory breathlessness due to intrathoracic cancer.
PMC4563922|S36|3a|Trial Design|Trial design|This was a multicenter, open-label, parallel group study conducted in France (10 sites).
PMC4563922|S43|5|Interventions|Interventions|After central randomization participants were assigned to either an intervention group including a pediatrician visit every 3 months, a nurse visit intercalated every month and phone calls every 2 weeks after each visit; or to the control group with a pediatrician visit only every 3 months.
PMC4569265|S82|3b|Changes TO Trial Design|Amendments/changes to the original study protocol|The authors made the following major changes to the initial study protocol: age range of eligibility was changed from 18–35 years to 18–40 years to reach a larger segment of the population; the criteria for classifying wound infections after circumcision was modified to be more specific and user friendly; and the initial enrollment number approved by the IRB was increased from 525 to 575 subjects.
PMC4569381|S52|3a|Trial Design|Study design|Randomized double-blind crossover controlled.
PMC4570037|S76|9|Allocation Concealment Mechanism|Allocation concealment|The sequence was concealed by a computer interface.
PMC4574984|S53|3a|Trial Design|Study design|The study was performed as a randomized, controlled, open-label, clinical prospective double-center interventional study, at two tertiary medical care university hospitals in Germany (Charité, Universitätsmedizin Berlin (3200 Beds), Klinikum der Universität München (KUM) (2244 beds)).
PMC4575303|S46|4b|Data Collection Setting|Recruitment|Patient recruitment methods for CANVAS (ClinicalTrials.gov Identifier: NCT01032629) have been previously described [20].
PMC4575534|S67|12a|Statistical Methods for Outcome Comparison|Statistical analysis|The log-rank test for survival and ANOVA or Kruskal–Wallis for comparison of treatment groups were used.
PMC4591592|S55|6a|Outcomes|Measurements|A detailed description has been published elsewhere of how clinical data were collected, including anthropometric measurements, blood pressure and TOD assessment [29].
PMC4593140|S66|4a|Eligibility Criteria|Inclusion criteria|Term and near term infants (36–43 weeks gestation) with evidence of neonatal encephalopathy and treated with therapeutic hypothermia at the participating neonatal units will be eligible for recruitment.
PMC4599153|S77|7a|Sample Size Determination|Sample size|Using a non-inferiority design with a margin of 1 in the OBPS, and assuming an SD of 2.6 (based on prior research at our centre), 107 patients would be required in each arm to achieve 80% power and a two-sided α of 0.05.
PMC4600219|S52|3a|Trial Design|Study design|Data were collected as part of the Pre-Empt study; a cluster randomised controlled trial with randomisation at the General Practice level [24].
PMC4605204|S162|7a|Sample Size Determination|Sample size|Our sample size calculation of N = 150 per arm provides 80 % power to detect a moderate effect size of 0.50 (Cohen’s d), with an estimated loss of 25 % due to the authors’ experience with dropout in similar settings, the additional expected dropout due to insecurity, and a moderate design effect of 1.5 given authors’ experience and a lack of other studies in the region.
PMC4606432|S255|11a|Blinding Procedure|Blinding|For the telephone bereavement interviews, social workers who are not involved in the study conduct the interviews and are blinded to the study arm of the patient and surrogate (intervention vs control).
PMC4606962|S116|12a|Statistical Methods for Outcome Comparison|Data analysis|To characterize the study sample and assess the success of randomization, the intervention and control group characteristics were compared using Chi square and two-tailed t-tests as appropriate for categorical and continuous variables.
PMC4611309|S65|3a|Trial Design|Design|An investigator-initiated, single-centre randomised superiority educational trial was previously described in a design article.36
PMC4616420|S31|3a|Trial Design|Study Design|This was a prospective observational study of 2000 individuals in 3 different groups of the society, and it was approved through expedited review by all participating hospitals’ institutional review boards.
PMC4617861|S43|3a|Trial Design|Design|A cross-sectional study design.
PMC4619336|S110|6a|Outcomes|Secondary outcome measures|Secondary measures for clinical measures, mobility (gait and balance), cognition and imaging domains are listed in Table 2.
PMC4620004|S46|3a|Trial Design|Study design|We carried out a multicenter, open, controlled, randomized, cluster, two-parallel arm trial (Experimental Group -EG- and Control Group -CG-) with a 12-month follow-up conducted in community health centers of the Spanish National Health System.
PMC4620004|S100|6a|Outcomes|Outcome measures|Variables collected during the visits were: age, sex, marital status, education level, social class, family status, family history of premature cardiovascular disease, comorbidity, current drugs consumption, snuff consumption (smoker, ex-smoker, non-smoker, number of cigarettes/day in case of smokers), and alcohol intake (basic units of alcohol/week), anthropometric data (weight, height, body mass index, waist circumference, blood pressure, heart rate), analytical data (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, glucose, creatinine, uric acid, GOT/GPT/GGT, glomerular filtration rate), abnormal ECG, cardiovascular risk (SCORE, Framingham) [23, 24], diet (diet questionnaire Mediterranean) [25], physical activity (IPAQ questionnaire) [26], and adherence to medications (Haynes-Sackett and Morisky-Green tests) [27, 28].
PMC4625526|S55|3a|Trial Design|Design|The study is a retrospective, observational study.
PMC4625526|S60|4b|Data Collection Setting|Data collection|Data was collected from the electronic patient records at UNN, including radiological images and scanned or transferred documents from referring hospitals.
PMC4635909|S119|7a|Sample Size Determination|Sample size|The sample size was contingent on the number of Malian subjects enrolled in the PHiD-CV unprimed group in study NCT00678301.
PMC4636652|S62|3a|Trial Design|Trial design|DRAGET is an ongoing multicentre prospective, open, transversal clinical trial with repeated measures.
PMC4643292|S27|4a|Eligibility Criteria|Study population|Female students of the School of Medicine from the Universidad Miguel Hernández of Elche (Spain) who suffer from PD.
PMC4644020|S40|3a|Trial Design|Trial design|This study was a prospective, interventional, double-blind randomized controlled trial.
PMC4647713|S139|11a|Blinding Procedure|Blinding|Research technicians not affiliated with the clinics carried out all assessments at the 3 and 9-month follow-up interviews and were blind to treatment group allocation.
PMC4654391|S138|7a|Sample Size Determination|Sample size|We believe that a sample size of 30 patients is appropriate for a pilot study and will allow estimation of percentage rates of recruitment and retention to within a SE of at most 10%.
PMC4655494|S50|3a|Trial Design|Design|We conducted a parallel-group, double-blind, randomized placebo-controlled monocentric study in a tertiary care hospital (Cochin Hospital, Paris, France).
PMC4656038|S40|6a|Outcomes|Outcomes|The primary efficacy end point was the mean change in Hgb from baseline to end of treatment (EoT), defined as the last one-sixth of time in the randomized stage (Stage 2) (average of all Hgb values obtained in the window) per patient.
PMC4660604|S44|3a|Trial Design|Study design|Open randomized controlled prospective clinical trial with subsequent development of a conception of evolution of AS based on systematic review of scientific databases.
PMC4663447|S75|3a|Trial Design|Study design|Pragmatic, blinded, parallel-group, superior, randomised, placebo-controlled trial.
PMC4664262|S43|4b|Data Collection Setting|Recruitment|Subjects were invited to participate in the trial during hospital visits, through trial posters on bulletin boards in hospitals, newspaper and Internet advertisements.
PMC4667406|S58|4b|Data Collection Setting|Setting|Center of Chronic Pelvic Pain and Gynecologic Endoscopy of the Universitary Hospital, Ribeirão Preto Medical School, University of Sao Paulo.
PMC4667406|S97|8a|Random Allocation Sequence Generation|Sequence generation|Block randomization, consisting of ten blocks of six subjects each, with three patients in each group of treatment, was generated online (http://www.randomization.com).
PMC4674978|S55|4a|Eligibility Criteria|Patients|Eligible patients were ≥30 years old, l-dopa responsive, met UK Parkinson's Disease Society Brain Bank diagnostic criteria, and had severe motor fluctuations defined as ≥3 hours of daily off time at baseline (confirmed by the PD symptom diary), despite optimized treatment with available PD medications.
PMC4680117|S81|12a|Statistical Methods for Outcome Comparison|Statistical analysis|See online supplementary text.
PMC4684233|S78|6a|Outcomes|Measurements|All the measurements and questionnaires were administered by the same expert interviewers, who were blinded to the allocated study group in both sessions (baseline and at the end of the intervention).
PMC4693437|S53|3a|Trial Design|Study design|This was a cross-sectional descriptive study of catatonia in NS patients in Northern Uganda and an open label pilot study of using one or two doses of lorazepam as a catatonia test.
PMC4693437|S110|6a|Outcomes|Primary outcome measures|Our primary outcomes were: (a) the proportion of children and adolescents with NS who met clinical criteria for pediatric catatonia; and (b) a positive catatonia test (>50 % reduction in catatonia symptoms and signs) on the responses of the children and adolescents with NS and catatonia to test doses of oral LZP.
PMC4710982|S67|3a|Trial Design|Design|This is a randomized double blinded placebo-controlled non-inferiority trial with parallel assignment and treatment allocation ratio of 1:1.
PMC4712500|S97|6a|Outcomes|Outcome measures|All analyses were carried out using the full analysis set, thus permitting a paired analysis of results.
PMC4712571|S31|3a|Trial Design|Study design|This was a multi-center (9 sites in Korea) open-label, single-arm, phase 4 study conducted from April 2012 to October 2012.
PMC4716164|S67|8b,10|Randomization Type,Randomization Implementation|Randomisation|Allocation of CSR teams to either an intervention or control cluster was carried out once teams had been recruited and given consent to participate by a local clinical trials unit via simple randomisation at 1:1 ratio without matching.
PMC4716206|S96|12b|Statistical Methods for Other Analyses|Subgroup analysis|We repeated the two subgroup analyses performed in the original trial, among the two groups of patients that were hypothesised to derive greater benefit from surgery: (1) patients with less severe radiographic disease (KL grade 2), and (2) patients reporting mechanical symptoms of catching and/or locking.10
PMC4716214|S69|8b,10|Randomization Type,Randomization Implementation|Randomisation|Randomisation of individual participants to a particular treatment arm was undertaken using an automated online randomisation system.
PMC4716214|S86|6a|Outcomes|Outcomes|Trial outcomes used to assess the feasibility and acceptability of the intervention were consent rate, reasons for declining to participate, adverse events, intervention adherence, evaluation of training.
PMC4718147|S63|7a|Sample Size Determination|Sample size calculation|A sample size of 600 patients and a significance level of 0.05 were required for a power higher than 85% to detect the differences in change of SPID8 between dexketoprofen/tramadol and each single component.A standard deviation of 94 mm h and a between difference of at least 35 mm h was assumed based on data from a previous phase II study (Scartoni S and Nizzardo A, unpublished observations).
PMC4722555|S85|6a|Outcomes|Outcomes|For this study, the primary clinical outcome of interest was the results of the head CT scan (positive/negative) among patients with the first blood sample drawn within 6 h of injury.
PMC4724076|S71|4a|Eligibility Criteria|Participants|Study participants will be enrolled consecutively from Aarhus University Hospital (OUH) and Odense University Hospital (AUH) in Denmark.
PMC4734771|S56|11a|Blinding Procedure|Blinding|Blinding was not possible in this study, but the data collectors were not aware of the arm to which each patient had been allocated.
PMC4748545|S166|11a|Blinding Procedure|Blinding|Randomisation status will not be blinded since the assigned treatment involves a surgical procedure.
PMC4751474|S38|4a|Eligibility Criteria|Study Subjects|At each clinical intervention site, study subjects were selected if they met the following criteria: 1) they were 18–75 years of age; 2) they met study criteria for diabetes before study enrollment (13,14); 3) they had received clinical care at a designated clinic or medical center involved in this study for at least 15 months before study enrollment; and 4) they were prescribed a new class of medication (not filled in the past 180 days) for A1C, BP, or LDL cholesterol uncontrolled at the time of medication prescription (A1C ≥8% [64 mmol/mol], systolic BP [SBP] ≥140 mmHg, or LDL cholesterol ≥100 mg/dL).
PMC4751747|S55|3a|Trial Design|Study design|In this prospective multicenter outcome study data were collected during the inclusion phase of an ongoing randomized controlled clinical trial (RCT) in a multi-center setting described in detail elsewhere [50].
PMC4755561|S125|6b|Changes to Outcomes|Changes to Outcomes|There were no changes to any of the outcomes.
PMC4762100|S55|3a|Trial Design|Trial design|This was a two arm, pragmatic, cluster randomised trial, with general practices as clusters allocated in a 1:1 ratio to each arm.
PMC4771926|S72|8b,10|Randomization Type,Randomization Implementation|Randomisation process|Randomisation at a ratio of 1:1 was by pre-prepared sealed opaque envelopes under the supervision of the study statistician.
PMC4773183|S159|3a|Trial Design|Design|The JIKI trial was a multicenter proof-of-concept non-comparative trial conducted in four Ebola treatment centers in Guinea.
PMC4779564|S73|4b|Data Collection Setting|Study setting|The study will be conducted in HIV clinical sites across Australia, including general practice clinics, public hospitals and sexual health centres.
PMC4801182|S83|12a|Statistical Methods for Outcome Comparison|Statistical analysis|All statistical analyses were performed using a one-tailed paired T-test or one-way ANOVA with Prism software (GraphPad).
PMC4802895|S37|3a|Trial Design|Study design|This is a cross-sectional study of a random sample of people with established psychosis, recruited at baseline to the NIHR funded Improving Physical health and reducing substance use in Psychosis (IMPaCT) randomised controlled trial (RCT) [20].
PMC4803456|S43|3a|Trial Design|study design|Patients were randomized 1:1 (stratified by KPS, presence of liver metastases, and geographic region) to receive nab-P 125 mg/m2 plus Gem 1000 mg/m2 on days 1, 8, and 15 every 28 days for 56 days or Gem alone 1000 mg/m2 on days 1, 8, 15, 22, 29, 36, and 43 every 56 days (cycle 1) and then on days 1, 8, and 15 every 28 days (cycle ≥2).
PMC4806770|S43|4a|Eligibility Criteria|Eligibility Criteria|Participants included children meeting the following eligibility criteria: aged 4 to <17 years with T1D duration of at least 1 year and in good general health.
PMC4815218|S105|3a|Trial Design|Study design|Controlled before-after (CBA).
PMC4826492|S64|4b|Data Collection Setting|Data collection|Preoperative patient data (age, weight, height, sex, BIA, European system for cardiac operative risk evaluation [EuroSCORE], diagnosis, preoperative myocardial infarction within 24 hours [MCI], history of asthma bronchiale, chronic obstructive pulmonary disease [COPD], insulin or non-insulin-dependent diabetes mellitus [IDDM, NIDDM], history of chronic kidney disease [CKD], dialysis, left ventricular ejection fraction [LVEF], stable and unstable angina pectoris, cardial decompensation, peripheral arterial obstructive disease [PAOD], and arterial hypertension), surgery-related factors (kind of operation, duration of anaesthesia and surgery duration of CPB and aortic cross-clamp [AoCC], unplanned insertion of assist devices, amount of fluids [cristalloids or colloids], need of catecholamines [noradrenalin, dobutamin, levosimendan, vasopressin, or milrinon], and need of blood products [erythrocytes, fresh frozen plasma, or thrombocytes] or coagulation factors [fibrinogen, prothrombin complex concentrate, desmopressin, or recombinant factor VIIa]), intraoperative diuresis and postoperative data (use of catecholamines, BIA, length of stay on intensive care unit [LOS-ICU], length of mechanical ventilation, or need of extracorporeal membrane oxygenation [ECMO]) were collected by a case report form.
PMC4836189|S60|4b|Data Collection Setting|Setting|The setting of the study is the Department of General, Endocrine and Transplantation Surgery within the Medical University of Gdansk, Poland.
PMC4838709|S93|7a|Sample Size Determination|Sample size calculation|We estimated that a trial among a minimum of 2266 patients would allow us to detect a 25% reduction in attendance with RTIs (20% vs 15% requires 906 per group, with completed outcomes or 2266 allowing for 20% loss to follow-up; for α=0.05 and β=0.2), and a 0.2 standardised effect size for continuous outcomes.
PMC4845257|S81|11a|Blinding Procedure|Blinding|Patients, EMS personnel and physicians treating the patient were aware of the allocated arm; however, outcome assessors, the adjudication committee, and data analysts were blinded to the allocation.
PMC4855643|S52|3a|Trial Design|Design|TARDIS is an international collaborative multicenter parallel‐group prospective randomized open‐label blinded‐end‐point phase III controlled trial.
PMC4862805|S83|4b|Data Collection Setting|Recruitment|In May 2013, we placed advertisements in four community newspapers and sent emails to relevant groups (e.g., health professional associations) and placed posters in the local neighborhood library and community center.
PMC4865998|S72|6a|Outcomes|Measurements|A detailed description has been published elsewhere regarding how the clinical data, drugs therapy, anthropometric measurements, and analytical parameters were obtained from patients [18].
PMC4869283|S94|5|Interventions|Intervention|Both groups will attend an initial 60-min session comprising the following content: CPGs—what they are and where to find them; information on and presentation of the GuiaSalud website and a link to the guidelines library; and instructions for downloading guidelines.
PMC4875600|S41|3a|Trial Design|Trial design|The NEUROS study is a prospective two-arm randomized controlled multicenter clinical trial with a follow-up period of 12 months per patient.
PMC4881951|S26|3a|Trial Design|Design|We performed a multicenter prospective controlled cluster-randomized trial in community and academic hospitals.
PMC4881951|S65|7a|Sample Size Determination|Sample size|With the study design assuming 30 participating centers divided into two groups of 15, an intra-cluster correlation of 0.01, a 5% combined rate of VTE or major bleedings in the control group, a total of 16,170 patients with 8,085 in each group were required to detect a 1.5 percentage absolute difference between the two groups, with 3.5% in the intervention group, at a power of 80% and significance level of 5%.[13]         Considering that approximately 15% of patients would be hospitalized for less than 48 hours and 5% would be lost to follow-up, we planned to enroll a total of 20,000 patients.
PMC4884619|S46|3a|Trial Design|Design|A controlled trial will be conducted involving a random assignment of clusters (patients registered with the same primary care physician) to two study groups: a) control group undergoing usual care; and b) treatment group, where participants will undergo a program for the integrated management of chronic pain and depression (Fig. 1).
PMC4896022|S49|3a|Trial Design|Design|The study design involved repeated baseline and intervention phases, with each of eight consecutive periods lasting two weeks:         A: Baseline: standard 300 ml glass used         B: Larger 370 ml glass replaced standard glass         A: Standard 300 ml glass used         C: Smaller 250 ml glass replaced standard glass         B: Larger glass         A: Standard glass         C: Smaller glass         A: Standard glass         The primary outcome was the daily volume of wine (ml) purchased in ‘Larger glass’ and ‘Smaller glass’ intervention periods compared to baseline (all ‘A’ periods).
PMC4898635|S47|12a|Statistical Methods for Outcome Comparison|Statistical analysis|PATENT-1 and CHEST-1 were not designed to show statistically significant differences in subgroup populations; the subgroup data presented here were therefore analysed descriptively.
PMC4909487|S37|3a|Trial Design|Study Design|A Phase I, randomized, double-blind, dose-escalation study was conducted at Saint Louis University (SLU), following Declaration of Helsinki principles and approved by SLU and Aeras Institutional Review Boards.
PMC4909487|S39|4a|Eligibility Criteria|Participants|After giving written informed consent, 24 HIV-negative, BCG-naïve, mycobacteria-naïve, 18–40 year old healthy subjects were sequentially assigned to study groups.
PMC4915048|S108|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Analysis of pre-treatment and post-treatment biomarker analytes was performed using paired student-t tests.
PMC4916576|S55|3a|Trial Design|Study design|This study is a prospective study nested within the Newhints cluster-randomised controlled trial.
PMC4916576|S91|6a|Outcomes|Outcomes|Two main indicators were used to measure newborn access to care: referral compliance defined as the percentage of families who took their babies to health facilities after CBSV referrals and overall care seeking defined as the percentage of newborns taken to a hospital/clinic among those reported by the mother in the first surveillance visit (usually up to 56 days) after birth as having had severe illness.
PMC4916610|S54|3a|Trial Design|Study design|A cross-sectional health facility assessment was conducted to study health worker competence in emergency obstetric care, and linked to population-based surveillance data on place of birth.
PMC4929566|S162|4a|Eligibility Criteria|Participants|We screened healthy, male volunteers between 18 and 50 years of age, with a body weight between 60 and 100 kg, and a body mass index between 19 and 30 kg/m2, as detailed in Supplementary Methods.
PMC4939832|S35|4b|Data Collection Setting|Setting|This prospective single-center observational study was performed during a 9 months period in 2013/2014 in an 18 bed neurosurgical ICU in a tertiary teaching hospital.
PMC4944308|S50|3a|Trial Design|Study design|The study was a randomised, placebo-controlled, double-blind intervention trial conducted over a twelve-week period (Sheffield University Breakfast Study – SUBS).
PMC4944495|S42|3a|Trial Design|Trial design|This phase 2 clinical trial (NCT00137852) was a single arm study evaluating the efficacy and safety of perioperative celecoxib and neoadjuvant chemoradiation with weekly cisplatin plus irinotecan followed by surgery in locally advanced esophageal and gastroesophageal junction cancer patients.
PMC4945817|S45|4a|Eligibility Criteria|Study Population|Eligible participants included English-speaking parents or guardians (subsequently “parents”) of children aged 6-12 years, who received treatment at a participating practice, had an asthma diagnosis at the time of recruitment, and had an office visit during the past 12 months.
PMC4956069|S84|11a|Blinding Procedure|Blinding|The study was single-blinded (investigators and gastroenterologists) since the placebo aqueous solution was not identical to the PEG 3350 ASC.
PMC4959921|S50|6a|Outcomes|assessments|Tumor response was assessed by investigators and independent central review (RECIST v1.1) every 6 weeks for the first 24 weeks, and every 8 weeks thereafter [10].
PMC4964056|S103|4a|Eligibility Criteria|Participants|The study population included nonsmoking male and female volunteers from 18 to 55 years of age with a body mass index between 18.5 and 30.0 kg/m2 who were judged to be healthy based on a medical history, electrocardiogram (ECG), laboratory evaluation, physical examination, vital sign measurements, pulse oximetry, spirometry, radiography, being capable of providing consent, and having normal lung function (forced expiratory volume in 1 second [FEV1] ≥ 80 % of predicted and FEV1, forced vital capacity >70 %).
PMC4965058|S57|4a|Eligibility Criteria|Study subjects|Patients suffering from untreated localized mild-to-moderate chronic periodontitis were initially included into the study [14].
PMC4966861|S92|4a|Eligibility Criteria|Eligibility criteria|The inclusion and exclusion criteria are summarized in Table 1 and depend on time of inclusion.
PMC4966871|S89|4a|Eligibility Criteria|Participants|Down syndrome                                               Aged 50 years and over                                                                    Exclusion criteria
PMC4966871|S95|6a|Outcomes|Outcome measures|Recruitment and retention:Numbers screened and recruited each monthThe proportion of participants retained 12 months after randomisationThe number of participants recruited per base general population size                                                                    Secondary measures
PMC4967304|S93|6a|Outcomes|Measurements|The patients were referred to a baseline examination which included a tender-point examination [2] by a physician, performance-based tests of physical capacity conducted by physical therapists, and a battery of self-reported questionnaires [32].
PMC4977887|S60|3a|Trial Design|Design|To reach the study aim, a multicentre prospective cohort study is set up among women visiting Dutch STI clinics.
PMC4985830|S68|3a|Trial Design|Study design|A multinational and multicentre retrospective, observational cohort study which will involve the collection of data on hospitalised patients from 1 January 2013 to 31 December 2014.
PMC4987207|S112|12a|Statistical Methods for Outcome Comparison|Statistical Methods|Mean changes in SM levels from baseline to 26 weeks were measured by computer morphometry and assessed for statistical significance (P<0.05) using the unpaired Student t test (GraphPad PRISM, version 5.0, GraphPad Software).
PMC4994157|S40|3a|Trial Design|Study design|ORTHODIAB is a French collaborative multi-centre randomized, open label trial, with a blinded end points evaluation by an adjudication committee according to the Prospective Randomized Open Blinded End-point (PROBE) method [19].
PMC4997752|S74|11a|Blinding Procedure|Blinding|Due to the nature of the intervention, participants, service providers, and research staff involved with collecting and assessing outcome data will not be blinded (i.e. they were aware of group assignment to either the intervention or the TAU group) for the duration of the study.
PMC5002157|S59|7a|Sample Size Determination|Sample size calculation|We estimated that a sample size of ten patients per group was required to detect an effect size of 0.6 with a power of 80 %, assuming a balanced allocation to treatment groups, and a 5 % type I error probability.
PMC5010693|S53|3a|Trial Design|Study design|A waitlist RCT design was used to examine the feasibility, acceptability, and effectiveness of the iPeer2Peer program in adolescents with JIA.
PMC5018181|S122|12a|Statistical Methods for Outcome Comparison|Statistical analyses|Table 2 Statistical findings shown as change from baseline at week 8 and 12                         Secondary outcome measures
PMC5025541|S40|3a|Trial Design|Study design|This 12-week, open-label, noncomparative, observational study of bimatoprost 0.01 % in consecutive patients with OAG (including NTG) or OHT (ClinicalTrials.gov identifier: NCT01814761, registered on March 18, 2013) was conducted between May 2013 and August 2014, in accordance with the Guidelines for Good Clinical Practice and all applicable Taiwanese laws.
PMC5028942|S46|3a|Trial Design|Design|The study relied in the comparison of three independent samples, in three experimental conditions: 1) control situation with no specific FOP nutrition label on products; 2) intervention n°1: introduction of the 5-CNL as a FOP nutrition labelling on all food products with no additional information for the consumer; 3) Intervention n°2: introduction of the 5-CNL FOP nutrition label on all food products with consumer information.
PMC5041900|S232|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Unpaired student T-test and Chi-squared test were used to compare continuous and categorical data respectively.
PMC5043601|S48|3a|Trial Design|Trial Design|This was an open-label clinical trial in which participants were randomized to one of three treatments: (1) Lorcaserin 10 mg by mouth twice a day for 12 weeks; (2) LLLT administered for one hour once a week for 12 weeks; or (3) combination therapy with lorcaserin and LLLT for 12 weeks.
PMC5045594|S50|6a|Outcomes|Outcomes|The primary end point was a triple composite of the time from the date of group assignment to the date of kidney disease progression, as indicated by dialysis initiation, kidney transplantation, or doubling of the sCr level, whichever occurred first.
PMC5053167|S66|4a|Eligibility Criteria|Participants|Mentally competent ambulatory outpatients of any age > 18 years with advanced lung cancer were eligible to participate whether or not they were receiving specific anti-cancer therapy, with the following exceptions: current use of any vitamin D supplement equivalent to > 1000 IU per day, current therapy with any dose of calcitriol, a recent history of extensive sunlight exposure (>30 min of summer sunlight exposure more than 5 days per week), non-fluency in French or English and no capable neutral translator available, current diagnosis of primary hyperparathyroidism, existing nephrocalcinosis, hypercalcemia, current or suspected tuberculosis, histoplasmosis, sarcoidosis or other granulomatous disease, pregnancy, or anticipated death within 2 months.
PMC5068191|S52|3a|Trial Design|Design|This study had an exploratory design with a qualitative phenomenological lifeworld approach.
PMC5069403|S104|3a|Trial Design|Trial Design|Further details regarding study recruitment, inclusion and exclusion criteria, the screening process, randomization, assessments, baseline and follow-up interviews, and institutional review board approval are presented in Part 1 of this study [23].
PMC5070122|S54|3a|Trial Design|Design|A 16 week randomised controlled trial with focus on feasibility and acceptability, and with blinded outcome assessors.
PMC5070581|S59|3a|Trial Design|Design|An open label, randomized control design was used.
PMC5072601|S36|3a|Trial Design|Study design|This is a single-center, 5-year follow-up study (MYSTAR-5-YEAR, clinicaltrials.gov NCT01395212) including patients who participated in the MYSTAR trial at the Medical University of Vienna (clinicaltrials.gov NCT00384982) (Fig 1) [5].
PMC5073433|S161|6a|Outcomes|Outcome measures|All primary and secondary outcomes are presented in Table 5 below.
PMC5074347|S99|12a|Statistical Methods for Outcome Comparison|Statistical Methods|Standard statistical methods (Data Supplement) were used to assess significance for associations between ASCO-CAP FISH groups and HER2 protein expression (Friedman tests and χ2 tests) and clinical outcomes (log-rank tests) in BCIRG-00519,25 and BCIRG-006.4,26
PMC5079020|S45|3a|Trial Design|Study Design|This is an observational, single‐center cohort study based on data from the SMURF (Symptom burden, metabolic profile, ultrasound findings, rhythm, neurohormonal activation, hemodynamics, and health‐related quality of life in patients with AF) study.21
PMC5080708|S136|6a|Outcomes|Outcomes|Major cardiovascular events are defined as:Sudden cardiac death (SCD) defined as a sudden pulseless condition out of the hospital (most probably due to arrhythmia).
PMC5097372|S107|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Changes in RQLQ and IgE were compared to the first time point (T0; before first herbal plaster) via a paired Student’s t-test and a Mann Whitney U-test, respectively.
PMC5107191|S45|4a|Eligibility Criteria|Subjects|Subjects enrolled in the registry included individuals of any age who used pnfC1-INH for any reason, irrespective of regionally approved product indication.
PMC5113831|S90|4b|Data Collection Setting|Data Collection|After baseline information was collected during screening, subjects used diaries to record pain intensity (rated at 15 minutes, 30 minutes, 1 hour, and 2 hours after treatment), attack duration, rescue medication use, AEs, device perceptions, and blinding questionnaire responses for each attack.
PMC5114779|S71|6a|Outcomes|Measures|Potential prognostic factors were assessed by means of the CINS questionnaire at baseline assessment (t0) which included Norwegian versions of instruments, covering a broad range of factors including demographic variables, physical variables, individual- and work related psychological variables and social support.
PMC5115705|S47|4a|Eligibility Criteria|Inclusion criteria|CF Individuals older than six years were included with persistent S. aureus airway cultures one year before recruitment.
PMC5120535|S128|12b|Statistical Methods for Other Analyses|Subgroup analyses|Subgroups will be analyzed with an interaction term for each subgroup by treatment allocation and reported as subgroup-specific estimates with 95% confidence intervals, displayed in a forest plot.
PMC5123258|S80|6a|Outcomes|Outcome measures|The study assessor who collected the outcome measurements was blinded to the study hypotheses and group allocation.
PMC5125136|S60|12a|Statistical Methods for Outcome Comparison|Statistical Analyses|All the analyses were descriptive and performed using SAS® 9.4 software (Cary, NC, USA).
PMC5125453|S49|8b,10|Randomization Type,Randomization Implementation|Randomization|Clusters were randomized (2:2:1:1: PHiD-CV 3+1, PHiD-CV 2+1, control 3+1, control 2+1) using a blocking scheme, stratified according to cluster size (below/above average), urbanity (urban/rural), and Tampere University Vaccine Research Centre trial enrollment.
PMC5127234|S53|4a|Eligibility Criteria|Participants|Couples were eligible if patients, with a willing partner able to speak and read English, met the following criteria: had a diagnosis of type 2 diabetes for >1 year (diagnosis confirmed by medical record and/or A1C level); baseline A1C level of ≥7.5% (58 mmol/mol); ≥21 years of age; able to speak and read English; in a self-defined committed relationship for ≥1 year; no severe medical or psychiatric conditions that might interfere with participation; and telephone access.
PMC5128772|S114|4b|Data Collection Setting|Data collection|Each data collector received training for data collection and was required to use an adapted standardised protocol for data collection, an optimised version of the one used in the Hutchinson Smoking Prevention Project, which was discussed with and provided by the original authors.19
PMC5136691|S80|7a|Sample Size Determination|Sample size|The sample size of 75 patients (25 in each arm) was calculated assuming an SD of 0.25 with the aim to detect a minimum difference of 0.2 logMAR units at the 5% significance level (two-sided) with 80% power.
PMC5136691|S86|11a|Blinding Procedure|Masking|The research orthoptist who delivered the treatment was aware of the patient allocation but not of visual acuity measurements which were performed by an independent orthoptist who was masked to the treatment allocation.
PMC514552|S81|12a|Statistical Methods for Outcome Comparison|Statistics|All analyses were done on SPSS for Windows (Release 11.5.1)-statistical package (SPSS Inc., Chicago, Illinois).
PMC5154028|S82|4b|Data Collection Setting|Study setting|Participants will be recruited from the inpatient unit and day hospice at an 18-bed specialist palliative care unit in Northern Ireland.
PMC5174793|S46|3a|Trial Design|Study design|The study was a single-center, one-visit, single-blinded trial in people with type 2 diabetes, investigating skin PF, pain, and SBP during needle insertion into the subcutis on the abdomen with different needle designs.
PMC5198985|S104|7a|Sample Size Determination|Sample size calculation|To detect a 0.50 effect size when comparing the change in the primary outcome between two groups with 80% power using a two-tailed 0.05 hypothesis test, and considering a 0.6 correlation between repeated measures in two time points, 50 patients per group were needed.[40] However, the study ended after recruiting 50 participants when funding was received to continue the study as a multicenter RCT with slightly different participants’ criteria (Trial registration NCT01610908).
PMC5215218|S50|4a|Eligibility Criteria|Patients|Individuals aged >6 months with a body weight >5 kg with slide-confirmed P. vivax monoinfection, parasite density between 250 and 100 000 parasites/µL, and axillary temperature ≥37.5°C or history of fever in the last 48 hours were considered eligible.
PMC5223491|S125|11a|Blinding Procedure|Blinding|Research technicians not affiliated with the study clinics carried out all assessments at the follow-up interviews and were blind to treatment group allocation.
PMC5223544|S138|6a|Outcomes|Measures|Outcome measures were assessed at baseline, at post-intervention (immediately after the intervention) and at follow-up (6 months post-intervention; 9 months after baseline) (Fig. 1).
PMC5223743|S60|4a|Eligibility Criteria|Eligibility criteria|Residents of England aged 16–24 who had received either a positive chlamydia test result or reported unsafe sex in the last year (defined as more than one partner and at least one occasion of sex without a condom), were literate in English and who owned a personal mobile phone were eligible.
PMC5225209|S72|12a|Statistical Methods for Outcome Comparison|Statistical analysis|A linear multiple regression model was used to assess the relationship between AUC0–τ normalized to the administered dose/m2 at steady state and age, gender and drug formulation using the lm function in R statistical software package (The R Foundation for Statistical Computing, http://www.R-project.org).
PMC5225252|S69|12a|Statistical Methods for Outcome Comparison|Statistical Methods|The statistical methods are described in the Supplementary Materials.
PMC5228098|S74|6a|Outcomes|Primary outcome|The primary outcome in this analysis was bacterial resistance of uropathogens in children with spina bifida on clean intermittent catheterization to commonly used antibiotics.
PMC5237147|S125|11a|Blinding Procedure|Blinding|Due to the nature of the study, GPs and patients could not be blinded to the intervention.
PMC5240256|S40|3a|Trial Design|Study design|FIND-CKD was a 56-week, open-label, multicenter, prospective, randomized, three-arm study undertaken during December 2009 to January 2012 at 193 nephrology centers in 20 countries (ClinicalTrials.gov NCT00994318) [25].
PMC5253594|S51|4b|Data Collection Setting|Study setting|The study is conducted in a diabetes and obesity care centre affiliated with a 400-bed private tertiary care hospital in São Paulo, Brazil.
PMC5259892|S142|7a|Sample Size Determination|Sample size|Considering a 20% recurrence rate within 3 years in most collaborating centres for BC cases specified in Table 2, and a predicted rate of 10% in the high intensity arm, with power of 80% and two-sided alpha of 0.05, the number of subjects are 506 (n = 253 in each arm).
PMC5264217|S96|12a|Statistical Methods for Outcome Comparison|Statistics|This Phase I trial was not powered for comparative hypothesis testing and basic descriptive statistics are used to summarise outcome data, demographic and operational information.
PMC5267380|S88|3a|Trial Design|Study design|A prospective 2-site parallel intervention trial using mixed qualitative and quantitative methods has been selected to facilitate in-depth exploration of whether and why Fit For Dialysis works (or fails) in a particular setting, and for whom, including the actual degree of adoption and the extent to which the adoption occurred as intended.
PMC5286692|S57|8b,10|Randomization Type,Randomization Implementation|Randomization|An independent statistician unconnected with clinical practice prepared randomization lists of patients with T2D using computer generated random numbers (SPSS for Windows v.21.0: An IBM Company, Armunk, NY).
PMC5294772|S61|4b|Data Collection Setting|Study setting|The study centre, testing and exercise clinic are located at Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden.
PMC5306527|S69|4b|Data Collection Setting|Setting|The RCT was conducted in 10 maternity centres in the UK in order to assess realistic recruitment rates and acceptability across different types of units.
PMC5309971|S63|11a|Blinding Procedure|Blinding|All laboratory-based tests, including UPLC-MS, were conducted and interpreted by technicians blinded to POCT results.
PMC5312926|S68|6a|Outcomes|Secondary outcomes|Secondary outcomes were cardiovascular mortality and cancer mortality, and were available in all cohort studies except NHS.
PMC5315068|S96|12a|Statistical Methods for Outcome Comparison|Statistics|Safety, efficacy, and pharmacokinetics were summarized by descriptive statistics.
PMC5319045|S49|12a|Statistical Methods for Outcome Comparison|Statistical analysis|The median values of the 12-month change (from 12 to 24 months) and 24-month change (from 12 to 36 months) in strain, LV EF and LGE during this open-label extension phase (from 12 to 36 months) were compared between the eplerenone and placebo groups, using two-sample Wilcoxon rank-sum tests.
PMC5319062|S66|3a|Trial Design|Study design|The study was a prospective randomized controlled trial that compared the effectiveness of a face-to-face structured patient-specific smoking cessation program conducted by trained ambulatory pharmacists with brief unstructured pharmacist-delivered advice on smoking cessation rates.
PMC5320746|S49|5|Interventions|Intervention|Patients were randomly divided into one of the two groups: (1) patients in group LR received intraoperative placebo lactate Ringer’s at a dose of 7.5 mL/kg; (2) patients in group HES received 6% HES 130/0.4 at a dose of 7.5 mL/kg during the first hour of surgery, followed by administration of 5 mL/kg lactate Ringer’s until the end of the surgery.
PMC5322619|S212|12a|Statistical Methods for Outcome Comparison|Statistical analyses|All primary analyses are based on intention-to-treat principles in full accordance with CONSORT guidelines [45].
PMC5324684|S46|4a|Eligibility Criteria|Participants|Key enrollment criteria included the following: 21 to 65 years of age; body weight > 45 to ≤ 110 kg and body mass index 18 to 32 kg/m2; good general health with no clinically relevant abnormalities based on medical history, physical examination, clinical laboratory evaluations, and 12‐lead electrocardiography; surgically sterile or using adequate contraception; not taking medications (other than allowable oral and implanted contraceptives) unless approved by the sponsor and the investigator; and no vaccination within 30 days before baseline.
PMC5327511|S44|3a|Trial Design|Study design|This is a prospective multi-center longitudinal cohort study of H&N cancer patients who receive high-dose RT.
PMC5330620|S41|3a|Trial Design|Design|A multiple case study design was used starting with an analysis of PFs’ narrative reports to categorize barriers and enablers (Yin, 2009).
PMC5340586|S40|3a|Trial Design|Study Design|This was descriptive, cross-sectional formative research, drawing on a qualitative approach to collect data through semi-structured interviews and focus group discussions with both Option B+ patients and HCWs.
PMC5341443|S71|12a|Statistical Methods for Outcome Comparison|Data analysis|The six phases for thematic analysis identified by Braun and Clark [15] were followed; data familiarisation, generation of initial coding, emerging themes, analysis and connecting themes, development and naming of each theme and telling the story of the data in a coherent way.
PMC5347830|S75|4b|Data Collection Setting|Recruitment|Healthy volunteers were recruited by advertising in public institutions and private companies.
PMC5353290|S61|3a|Trial Design|Study design|RELIEF is a large, multicentre, randomised, international, single blind, pragmatic trial, with patients randomly assigned to either restrictive or liberal fluid groups, stratified by site and by planned high dependency unit (HDU) or intensive care unit (ICU) admission.
PMC5363087|S37|4a|Eligibility Criteria|Study population|Patients were eligible for the study if they were ≥18-year-old, and had HCM based on the two-dimensional echocardiography identification of an hypertrophied, nondilated left ventricle (wall thickness with septal-to-posterior wall thickness ratio of ≥1.3:1) in the absence of another cardiac, or systemic disease capable of producing this magnitude of wall thickening.[7] They were ineligible for the study entry if they had (1) ongoing use of statin therapy or intolerance to it, (2) hypertension, (3) a myectomy or septal ablation, (4) use of calcium channel blocker or angiotensin receptor blocker at baseline for <3 months[8] or had a dose change within the 3 months prior to randomization, (5) indication for statin therapy for primary or secondary prevention of coronary artery disease, or (6) current or anticipated indication in ≤1 year for implantable cardioverter-defibrillators or other metallic devices preventing cardiac magnetic resonance imaging (CMR).
PMC5364323|S52|3a|Trial Design|Trial Design|We performed an open-label randomized controlled trial to assess the effectiveness of InsuOnline as a method for education of PCPs on insulin therapy for diabetes, as compared with a “traditional” onsite educational activity with the same content and same duration.
PMC5364323|S54|4a|Eligibility Criteria|Eligibility Criteria|Subjects were eligible if they were medical doctors with an active register at a regional Council of Medicine in Brazil, were not specialists in Endocrinology or diabetes, were currently working at a public health care unit as a primary care physician (PCP), and were directly involved in the treatment of patients with diabetes in those facilities, with any degree of computer or gaming literacy.
PMC5368996|S55|8b,10|Randomization Type,Randomization Implementation|Randomization|Participants were randomized to a physical activity or health education program via a secure web-based data management system using a permuted block algorithm (with random block lengths) stratified by field center and sex.
PMC5372063|S88|12b|Statistical Methods for Other Analyses|Subgroup analysis|In 26 cases and 26 controls, we undertook a subanalysis of glucocorticoid duration, grouping patients according to duration of steroid treatment, since the data were insufficient to allow for overall exposure to be calculated.
PMC5379647|S92|5|Interventions|Intervention|26-week vitamin D supplementation (1200 IU) in obese children presenting with low serum concentrations of 25OHD3 at enrolment to the integrated weight-loss programme.
PMC5380494|S28|3a|Trial Design|Study Design|This post hoc analysis was based on pooled data from four 26-week, placebo-controlled, phase 3 studies (N = 2313) that evaluated canagliflozin 100 and 300 mg in patients with type 2 diabetes (ClinicalTrials.gov Identifiers: NCT01081834, NCT01106677, NCT01106625, NCT01106690).
PMC5383936|S27|3a|Trial Design|Study design|This was a prospective single-arm phase II trial conducted at 20 centres in Germany registered at clinicaltrials.gov (NCT 00989352).
PMC5391707|S44|4a|Eligibility Criteria|Subjects|Eligible subjects were ≥18 years old with histologically or cytologically confirmed, unresectable and/or metastatic GIST with investigator-assessed objective progression after, or intolerance to, treatment with at least both imatinib and sunitinib; measurable disease (RECIST 1.1); and Eastern Cooperative Oncology Group performance status 0–2.
PMC5395117|S27|4a|Eligibility Criteria|Patients|Eligible patients were aged ≥18 years, had documented CD20+ FL with no prior systemic therapy, were deemed in need of treatment by the investigator, had ≥1 bi-dimensionally measurable lesion (>1.5 cm at its largest dimension by computed tomography scan), had a life expectancy >12 weeks, an Eastern Cooperative Oncology Group performance status of 0–2, and no disease transformation based on lymph node biopsy or re-biopsy within 5 months of the start of treatment.Key exclusion criteria included central nervous system lymphoma, a history of malignancy within 2 years of study entry, and evidence of significant, uncontrolled comorbidities.All patients provided written informed consent.
PMC5401691|S106|12a|Statistical Methods for Outcome Comparison|Statistical analysis|The statistical significances between the rates from vitrified/warmed and fresh oocytes were evaluated by z-test with p > 0.05 and 0.01.
PMC5402635|S41|3a|Trial Design|Study design|We conducted a secondary analysis of data of all 100 patients enrolled from the African site (Mbarara, Uganda) within the Rifatox Trial [16].
PMC5404992|S41|4b|Data Collection Setting|Setting|This study took place in a New York City large urban public hospital and an affiliated neighborhood health center.
PMC5405840|S86|7a|Sample Size Determination|Sample size|Sample size was selected to provide 95% power to detect an absolute difference of 0.65 in the change from Baseline at Week 8 on the IPR-V3 scale between the ETA + PEM group (using pooled PEM dose groups) and the ETA + placebo group, assuming a standard deviation of 0.80, using a two-sample t-test and a two-sided α = 0.05 significance level and allowing for ∼10% dropout.
PMC5414382|S58|3a|Trial Design|Study design|This was an exploratory, within-subjects cross-over study.
PMC5435222|S112|7a|Sample Size Determination|Sample size|We intended to include 420 early MV-children and 210 controls based on detecting a 10% reduction of pneumococcal colonization among MV-children, from 85% to 75%, with a power of 80% and significance level α = 0.05.
PMC5443329|S68|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Microsoft Excel for Mac (version 15.27) was used to tabulate data and calculate odds ratios, confidence intervals, and perform Student t tests.
PMC5446025|S29|4a|Eligibility Criteria|Patients|Patients were aged 18–75 years, had active RA despite MTX treatment, and had inadequately responded or been intolerant to previous treatment with anti-TNF agents (see online supplementary material B and C for details of study methods).
PMC5464088|S37|4a|Eligibility Criteria|Participants|Eligible subjects were healthy, 6 week-old, full-term infants, attending well baby clinics for their first polio vaccinations.
PMC5466785|S74|11a|Blinding Procedure|Blinding|All sociodemographic, clinical characteristics, food consumption and anthropometric measurements, biochemical markers and cytokines measurements were performed in a blinded fashion by the same single evaluator.
PMC5466785|S76|7a|Sample Size Determination|Sample size|Considering a prevalence of 60% of inadequate omega-3 PUFAs intake [26], IFNγ values of 3986 (738) pg/mL at baseline and IFNγ values of 2922 (1275) pg/mL after omega-3 PUFA supplementation [27], and assuming 80% of power and 5% of significance level, the minimum estimated sample size was 40 patients (20 in each group).
PMC5483256|S43|3a|Trial Design|Design|This was a multicentre, double blind, randomised controlled trial (RCT).
PMC5488108|S56|12a|Statistical Methods for Outcome Comparison|Statistical Analysis|Exploratory, descriptive analyses of demographic, safety, and efficacy data were planned based on the treated set (all patients who were dispensed medication and were documented to have taken ≥1 afatinib dose), with two subgroups divided by previous TKI exposure.
PMC5493124|S76|11a|Blinding Procedure|Blinding|Other than for the random selection process, no blinding was used due to the pragmatic nature of the research question “Is treatment by a homeopath effective for self-reported depression?” No blinding of assessment (statistical analyses) was used, as group allocation would become obvious due to the 1:2 randomisation ratio.
PMC5498984|S49|3a|Trial Design|Study design|Quasi-experimental longitudinal field study with an intervention and a control group.
PMC5502144|S33|4a|Eligibility Criteria|Patients|Patients were eligible for enrollment if they had a histologically or cytologically confirmed adenocarcinoma of the prostate that was castration resistant, had not received cytotoxic chemotherapy or abiraterone acetate, had an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (no symptoms or ambulatory but restricted in strenuous activity), and were asymptomatic or mildly symptomatic per the Brief Pain Inventory Short Form question 3 (i.e., pain score 0–3).[22] Patients with conditions that could lower the seizure threshold (i.e., brain metastases, history of seizure, concurrent medications) or those with a history of chemotherapy were excluded.
PMC5508629|S58|3a|Trial Design|Design|The study was a two arm, parallel group pilot randomised controlled trial with outcome assessments at baseline (T1), and subsequent blinded outcome assessment at the end of the intervention (T2) and at 3 months (T3) and 6 months (T4) after the end of the intervention.
PMC5512940|S46|3a|Trial Design|Design|A two-site randomized controlled trial (RCT) was completed with community-dwelling MWC users in Québec City, QC, Canada, and Vancouver, BC, Canada.
PMC5512940|S49|4a|Eligibility Criteria|Participants|≥50 years of ageLived in the communityCould self-propel a MWC an average of 1 h per dayHad self-proclaimed wheelchair mobility goalsWas cognitively able to engage in the WheelSeeU program (Modified Mini-Mental Status Exam (MMSE) score of ≥24) [23]                              Exclusion criteria
PMC5513124|S49|4a|Eligibility Criteria|Exclusion criteria|Pregnant femaleAny significant lab abnormality of neutrophil count, hemoglobin, platelets, aspartate aminotransferase (AST), or alanine aminotransferase (ALT) (Defined as Grade ≥ 3 by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0, Nov.
PMC5530971|S49|3a|Trial Design|Study design|An observational study that analyzed the motor control system by evaluating the performance in a computer task in individuals with CP and in a control group of typically developed individuals.
PMC5531217|S67|3a|Trial Design|Study design|A UK multicentre, prospective, blinded study comparing surveillance intervals determined by NBI-assisted optical diagnosis and histological assessment in patients referred for colonoscopy.
PMC5537518|S60|8b,10|Randomization Type,Randomization Implementation|Randomisation|Participants were randomised 1:1 to the two arms and balanced for sex after baseline assessment independently of the investigators by the Health Services Research Unit University of Aberdeen.
PMC5541637|S75|5|Interventions|Interventions|Combined physical activity and dietary restriction programmes.
PMC554986|S82|12a|Statistical Methods for Outcome Comparison|Data analysis|The data was analysed by a blinded assessor, to reduce any biases and increase the rigour with which a de-identified and coded dataset was probed.
PMC5558668|S66|4b|Data Collection Setting|Recruitment|Eligible ADPKD patients were recruited from the Outpatient Nephrology Clinic of the Department of Medicine at Holstebro Hospital, Denmark.
PMC5565792|S42|3a|Trial Design|Design|We conducted a parallel-group, controlled trial in order to compare the effectiveness of domiciliary VR-based therapy versus domiciliary occupational therapy (OT) in inducing functional recovery and cortical reorganization in chronic stroke patients.
PMC5569270|S70|7a|Sample Size Determination|Sample size|The sample size was based on the primary outcome,10 and accounting for possible dropouts the sample was 60 participants.
PMC5569491|S85|3a|Trial Design|Study design|This is a double blind placebo-controlled phase III multicenter study conducted at the University Hospitals Leuven, the University Hospitals of Antwerp, the Centre Hospitalier Universitaire de Liège in Belgium and at the Medical and Health Science Center at the University of Debrecen in Hungary.
PMC5569491|S175|11a|Blinding Procedure|Blinding|Both patients and investigators are blinded to study medication and vitamin D levels.
PMC5569551|S117|4a|Eligibility Criteria|Study population|Diabetic patients with LVH will be identified for this study and all potential participants who meet the following criteria will be eligible for the trial:         Inclusion criteria:Diagnosed with type 2 diabetes mellitus based on the current American Diabetes Association guidelines.Aged 18–80 yearsBody Mass Index ≥ 23 kg/m2 HbA1c 48-85 mmol/mol [last known result within in the previous 6 months]BP < 145/90 mmHg.
PMC5574738|S41|3a|Trial Design|Study Design|This was a prospective, open-label, single-arm, observational and multicentre study.
PMC5576126|S56|6a|Outcomes|Outcomes|The endpoints for this investigation are as follows:Establishment of bicarbonate and acetate levels in the blood and dialysate before, during and after HD when using NaturaLyte® and GranuFlo® acid dialysate compositions.Investigation of the associations during and after HD in blood bicarbonate increases using NaturaLyte® and GranuFlo® acid dialysate compositions.
PMC5576372|S137|8a|Random Allocation Sequence Generation|Sequence generation|ProACT randomizes at the patient level, with 1:1 study arm allocation using a computer generated, permuted block design, stratified by center, race, and age (Table 5).
PMC5576733|S49|3a|Trial Design|Study design|This secondary analysis used the dataset from the original GOPCABE trial population and specifically assessed the influence of female sex on perioperative outcome and the impact on predictive accuracy of commonly calculated risk scores (logistic EuroSCORE and the KCH score).
PMC5584045|S61|8b,10|Randomization Type,Randomization Implementation|Randomization|Randomization will be controlled by an independent third party, the hospital Clinical Evaluation Center, using the SAS system (Version 8.2 for Windows) to assign the eligible participants at a 1:1 ratio to receive either topical compound TwHF gel or placebo.
PMC5587887|S60|4a|Eligibility Criteria|Patients|The French authorities have made available the instructions for analyzing I-Satis questionnaire [30], and according to these recommendations, the study was restricted to patients whose LOS included at least two consecutive nights.
PMC5588959|S69|3a|Trial Design|Design|Multicentre, pre- and post-intervention feasibility study with process evaluation.
PMC5601301|S47|6a|Outcomes|Measures|Based on the CFIR and our research questions, we explored the following baseline variables as predictors of CRC screening among participants at follow-up.
PMC5608866|S66|8b,10|Randomization Type,Randomization Implementation|Randomization|Participants in the present study were randomized to either the intervention or wait list condition, with a ratio of 1:1 using the randomization function in the IBM SPSS Statistics for MacOS X, Version 22 (IBM Corp, Armonk, NY, USA).
PMC5618936|S145|7a|Sample Size Determination|Sample size|The study described herein will enroll 290 patients to accrue sufficient PFS and OS events to provide 80% power at two-sided α = 0.05 (74% at two-sided α = 0.025 for two-arm comparison) to detect a statistically significant difference between veliparib plus carboplatin/paclitaxel and placebo plus carboplatin/paclitaxel or between veliparib plus TMZ and placebo plus carboplatin/paclitaxel, assuming a true HR for PFS of 0.58 and 0.61 for OS (favoring the experimental treatment groups).
PMC5622424|S97|6a|Outcomes|Assessments|Assessments (Table 2) will be conducted at baseline, 3, 6, and 12 months by research assistants blinded to group assignment.
PMC5625129|S143|7a|Sample Size Determination|Sample Size|We aimed to recruit 30 participants to allow for a sample size of 24 participants (12 per arm), with a 20% allowance for dropouts, which would allow 90% power (alpha=.05) to detect a difference of 14% in ICP (assuming a standard deviation of 10% for ICP).
PMC5625709|S42|3a|Trial Design|Design|We plan to conduct a prospective observational cohort study.
PMC5625709|S44|4b|Data Collection Setting|Setting|The study is conducted in the critical care unit in a tertiary care centre in the United Kingdom.
PMC5628800|S47|8b,10|Randomization Type,Randomization Implementation|Randomization process|We used random number tables in terms of the time they enrolled into the study and stratified by nasal SA carrier status.
PMC5629663|S66|4b|Data Collection Setting|Data collection|The following clinical/laboratory parameters and patient reported outcomes are collected as per routine care at baseline and at all follow-up visits, with suggested assessments every 6 months given that this is within acceptable practice patterns for patients with active PsA: morning (AM) stiffness, swollen joint count (SJC28), tender joint count (TJC28), patient’s global assessment (PtGA) and physician’s global assessment of disease activity (MDGA), Health Assessment Questionnaire (HAQ), patient’s assessment of pain, C reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
PMC5635483|S47|3a|Trial Design|Study design|Prospective observational study carried out from December 2014 to December 2015.
PMC5640048|S45|3a|Trial Design|Study design|A multicentre observational study.
PMC5640225|S70|6a|Outcomes|Outcomes|The primary outcomes of this study were to determine the serotype-specific serum IgG antibody geometric mean concentrations (GMC) pre- and 1month post-challenge with a 0.1mL dose of PPV23 at 3–5 years of age for serotypes contained in PCV7 (4, 6B, 9V, 14, 18C, 19F, 23F) and PPV23 serotypes 1, 2, 3, 5, 7F, 19A; and the proportion of children with serotype-specific serum IgG antibody levels ≥ 0.35 μg/ml and ≥ 1.0 μg/ml before and after a PPV23 low-dose challenge for the above serotypes.
PMC5645978|S70|6a|Outcomes|Endpoints|The endpoints assessed were mean changes in the SF-36v2, EQ-5D-3L, and the WPAI:SHP from screening period to the end of titration period (open-label titration period), from randomization baseline to the end of study (double-blind treatment period), and from screening period to the end of double-blind treatment period (overall study period).
PMC5649052|S55|6a|Outcomes|Outcomes|All measurements in both the exercise group and control group were performed at the following time points, i.e., before TKA operation (pre-operation), before exercise (pre-exercise), at 12 weeks after the beginning of the circuit training program (mid-exercise), and after completion of the circuit training (post-exercise).
PMC5654468|S53|3a|Trial Design|Study design|This was a multicentre, two-arm, parallel (1:1), double-blind, randomised controlled trial.
PMC5664395|S40|4a|Eligibility Criteria|Patients|Eligible patients were aged 18–80 years with untreated histologically confirmed CD20+ DLBCL, International Prognostic Index (IPI) 1–5 or IPI 0 with bulky disease (one lesion ≥7.5 cm), had at least one bidimensionally measurable lesion ≥1.5 cm at its largest dimension by computed tomography (CT), positron emission tomography-CT (PET-CT), or magnetic resonance imaging (MRI), had adequate hematologic function, and Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (detailed inclusion/exclusion criteria are supplied in the Online Supplementary Appendix).
PMC5664395|S42|8b,10|Randomization Type,Randomization Implementation|Randomization|Patients were randomized 2:1 via a centralized interactive voice/web response system to receive rituximab SC or IV, and were stratified according to age (<60 or ≥60 years), IPI risk category (low, low-intermediate, high-intermediate, high), and chemotherapy regimen (CHOP-14, CHOP-21).
PMC5665270|S57|6a|Outcomes|Measures|Data collected in the self-administered survey included: age (years); education level (at least secondary or higher than secondary); sexual identity (homosexual or gay; bisexual; heterosexual; transgender; other); sexual role during anal intercourse with men (ie, activo, pasivo, moderno); transactional sex (ie, exchange of money/items of value for sex, ever, yes/no); sex and concomitant drug and alcohol use (past month, yes/no); cigarette use (ever, yes/no); age at first anal intercourse (years); oral sex (given) with a man (ever, yes/no); condom use during anal intercourse (last, yes/no); HPV knowledge (‘Have you ever heard of HPV or human papilloma virus prior to participating in this study?’, yes/no).
PMC5669010|S38|3a|Trial Design|Study design|We conducted a single arm, open-label study of regimen simplification to E/C/F/TDF plus darunavir 800 mg daily from stable therapy including two nucleoside/nucleotide reverse transcriptase inhibitors, a ritonavir-boosted protease inhibitor (atazanavir or darunavir), and raltegravir or dolutegravir.
PMC5683376|S58|4b|Data Collection Setting|Setting|Hospitalized patients were consecutively recruited from a geriatric ward at Aalborg University Hospital, North Denmark Region, Denmark, between the 29th of February and the 14th of April 2016.
PMC5684768|S67|3a|Trial Design|Design|This was a secondary analysis of a parallel group RCT on the effect of 6-month long Schroth PSSE intervention added to standard of care compared to standard of care alone (observation or bracing) on the change in Cobb angle in patients with AIS.
PMC5685761|S46|6a|Outcomes|Outcomes|The primary endpoints of this study were rate of PVR ≤ 50 ml and proportion of patients in which the catheter was removed successfully on postoperative day 4.
PMC5693395|S39|3a|Trial Design|Design|This is a prospectively registered, two-arm, open-label, randomized controlled trial.
PMC5693395|S174|11a|Blinding Procedure|Blinding|Due to the nature of the interventions, it is not possible to blind patients and therapists, and due to lack of human resources, the outcomes of this trial will be collected by an unblinded outcome assessor.
PMC5695321|S52|4b|Data Collection Setting|Setting|This prospective, multicentre, open-label RCT will be conducted in four French university hospitals.
PMC5695321|S55|4a|Eligibility Criteria|Participants|We will include patients with the following conditions:Lung cancer (or high suspicion for malignant tumour) eligible for resection surgery (lobectomy or pneumonectomy with video-assisted thoracic surgery or open thoracotomy)COPD stages from 2 to 4 by the Gold classification (FEV1/FVC<70%, FEV1<80% of predicted value)Exertional dyspnoea stage mMRC (modified Medical Research Council) ≥1Receiving written information and giving signed consentAffiliated with the French social health insurance                             Non-inclusion criteria
PMC5697864|S42|3a|Trial Design|Trial design|This was a cluster-randomized, investigator-masked, controlled trial.
PMC5698198|S46|4a|Eligibility Criteria|Patients|Eligible patients were aged 18 years or older and had been prescribed MAL DL-PDT as part of their routine medical care to treat mild to moderate AK on the face and/or scalp.
PMC5698198|S48|5|Interventions|Treatment|A single treatment of MAL DL-PDT was administered.
PMC5698198|S56|12a|Statistical Methods for Outcome Comparison|Statistical Methods|All collected variables were descriptively summarized without replacement of any missing values (observed data only).
PMC5702785|S93|6a|Outcomes|Outcomes|The primary endpoint was safety measured as (i) occurrence of solicited symptoms during a 3-day follow-up period after each immunization; (ii) occurrence of unsolicited symptoms during a 30-day follow-up after each vaccination; (iii) occurrence of abnormal laboratory results during study period; and (iv) occurrence of serious AEs throughout the study period.
PMC5704365|S102|4a|Eligibility Criteria|Patient selection|Inclusion criteria according to the protocol are:Histologically confirmed cervical or endometrial cancerIndication for postoperative radiotherapyKarnofsky Index ≥70Age between 18 and 80 yearsWritten informed consent          Exclusion criteria are the following:patients refusal or incapability of informed consentimplanted active medical devices lacking approval for ion beam radiationmetallic implants in the radiation field, e.g. hip prosthesesprior pelvic irradiationparticipation in another clinical trial which might influence the results of the APROVE trial          Simultaneous chemotherapy is NOT an exclusion criterium.
PMC5715643|S71|8b,10|Randomization Type,Randomization Implementation|Randomization|Randomization assignment used variable block lengths, was stratified by clinical site, sex, and ethnicity (non-Hispanic white/other), and was implemented through a web-based data management system.
PMC5718081|S79|4a|Eligibility Criteria|Inclusion criteria|Diagnosis of psychosis established by the clinicians using ICD10 criteria (including schizophrenia, schizoaffective disorder, or delusional disorder using ICD-10 research criteria).Individuals aged 18–65 years.Being a resident of Karachi.The participant could give informed consent (written).
PMC5721778|S49|4b|Data Collection Setting|Setting|The British Hypertension Society Research Network of academic investigators recruited participants from both primary and secondary care.
PMC5722079|S53|4a|Eligibility Criteria|Patients|All patients aged ≥18 years who attended the participating practices during the study period were eligible for the trial, but those known by the GPs to suffer from severe psychiatric disorder, alcohol dependence, serious visual impairment or terminal illness were excluded, as were those judged to have inadequate command of the Italian language.
PMC5726104|S155|6a|Outcomes|Outcomes|All outcome measures assessed in this study are presented in table 4.
PMC5736091|S74|4b|Data Collection Setting|Study setting|The study was conducted in the paediatric cardiac intensive care unit (PCICU) at Aga Khan University Hospital, Karachi, Pakistan.
PMC5745974|S46|3a|Trial Design|Study design|This was a Phase 1, open-label, non-randomized, multicenter, multiple-dose study of tofacitinib (BID for 5 days) (A3921103; ClinicalTrials.gov: NCT01513902) in pediatric patients with JIA, conducted at nine Pediatric Rheumatology International Trials Organization and Pediatric Rheumatology Collaborative Study Group centers [18] in Germany, Poland, Slovakia, and the United States between March 2013 and December 2015.
PMC5751814|S40|3a|Trial Design|Study design|Cross-sectional study (PreCo survey) using an online survey.
PMC5753454|S100|7b|Interim Analyses/Stopping Guidelines|Interim analysis|The interim analysis for safety parameters will be done as soon as 20 patients have been treated and observed for at least 6 months.
PMC5756334|S103|12a|Statistical Methods for Outcome Comparison|Statistics|Survival rates were calculated using the Kaplan-Meier method in the statistical software R (version).
PMC5760813|S29|4a|Eligibility Criteria|Patients|Preoperative exclusion criteria included the following: pacemaker implantation, atrial fibrillation, infective endocarditis, pericardial disease, infiltrative myocardial disease, ischemic heart disease, limited mitral annular motion,14 LVEF < 50% in preoperative transthoracic echocardiography (TTE) or contraindications to transesophageal echocardiography (TEE).
PMC5761198|S76|3a|Trial Design|Study design|We designed a randomized, placebo-controlled, three-arm parallel-group, double-blind trial comparing the efficacy of Curamin with that of CuraMed and placebo (PL, negative control) (Fig. 1).
PMC5761198|S107|9|Allocation Concealment Mechanism|Allocation concealment|The Treatment Randomization Code was kept by the QP at the investigational product manufacturing site (at sponsor) until the study was finalized.
PMC5761717|S46|3a|Trial Design|Trial design|We performed a prospective, randomised, sham-controlled, blinded (physician, researcher) clinical trial.
PMC5761717|S103|12a|Statistical Methods for Outcome Comparison|Analysis|ECGs were analysed in the Glasgow ECG Core Laboratory by a blinded analyst (P.McC.) for PR duration, QRS duration, corrected QT interval (QTc, defined as the QT interval corrected for heart rate using Bazett's formula), presence of atrioventricular block and ST-segment deviation.
PMC5771152|S46|6a|Outcomes|Study outcomes|ECHO study outcomes include:         Primary study endpoint: HIV infection as measured by documented HIV seroconversion (defined by the study HIV algorithm) occurring post-enrolment (see Supplementary materials, Appendix 7);         Secondary endpoints: Pregnancy, method-related serious adverse events, method related adverse events resulting in method discontinuation, and method discontinuation;         Tertiary endpoints: include a) HIV infection by age (<25 years versus ≥25 years) and b) by HSV-2 status; and c) HIV plasma viral load and CD4 count.
PMC5771152|S54|3a|Trial Design|Study design|The ECHO Trial is a multi-centre, open-label, randomised clinical trial designed to compare the benefits and risks, including HIV acquisition, between women randomized to one of three commonly used, effective contraceptive methods.
PMC5771152|S63|4b|Data Collection Setting|Study setting|The study includes women from settings with high HIV incidence and high use of hormonal contraception (particularly DMPA IM) in four countries (South Africa, Kenya, Zambia and Swaziland) across eastern and southern Africa.
PMC5771578|S33|3a|Trial Design|Design|This was a parallel, individual participant 1:1 randomized, superiority, multicenter, double-blind placebo controlled trial.
PMC5771578|S85|7b|Interim Analyses/Stopping Guidelines|Interim analyses|No interim analyses or stopping rules were described.
PMC5771578|S93|11a|Blinding Procedure|Blinding|The trial was described as “double-blind” and this presumably means that patient and clinicians were blinded to group assignment.
PMC5771578|S95|11b|Similarity of Interventions|Similarity of interventions|According to the clinical study report, “the placebo tablets were of identical in size, shape, taste, and color” as the doxylamine-pyridoxine tablets and only the lot number differed.
PMC5776758|S97|7a|Sample Size Determination|Sample size|Calculation of sample size for this study has been previously detailed [10].
PMC5779025|S58|6a|Outcomes|Primary Outcome|The primary outcome was excess mortality at 6 months, 1 year, and 5 years following hospitalization with AMI.
PMC5779750|S81|11a|Blinding Procedure|Masking|The study will be blind for the trial participants, investigators of the project and data managers, but will not be blind to the physicians.
PMC5781264|S39|3a|Trial Design|Design|We conducted a prospective, unblinded, parallel group, block randomized phase II pilot trial in six ICUs in Australia and New Zealand.
PMC5786115|S94|4b|Data Collection Setting|Data collection|The data were collected from the pilot study’s clinical database,22 examination of patient clinical records and IUCPQ-UL financial databases, as well as discussions with healthcare staff to provide us with information about some resources used to deliver various clinical activities to hospitalised patients with COPD (see the details in online supplementary appendix 1).
PMC5788360|S49|3a|Trial Design|Design|This was a non-randomized, single group, prospective interventional study with no comparison group.
PMC5791175|S46|4a|Eligibility Criteria|Study population|Patients aged > 18 years treated with meropenem and receiving SLED during daytime were eligible for study inclusion.
PMC5793401|S54|3a|Trial Design|Study design|A secondary analysis of interview data collected with individuals who had been newly diagnosed with T2DM and were participants in the Early ACTID (Early ACTivity In Diabetes) trial.
PMC5797349|S74|3a|Trial Design|Study design|This was a quasi-experimental study which adopted a multisite nonequivalent control group pre- and post-test design (Clinical trial registry: CREC Ref.
PMC5799088|S88|12b|Statistical Methods for Other Analyses|Subgroup analysis|Subgroup analysis was undertaken based on race (Caucasian vs non-Caucasian), comorbid anxiety (none vs mild or moderate defined by Generalized Anxiety Disorder-7 score), comorbid depression (none vs mild or moderate defined by Patient Health Questionnaire-9 total score), body mass index (< 18.5 kg/m2 vs 18.5 to < 25 kg/m2 vs 25 to < 30 kg/m2 vs ≥ 30 kg/m2), history of acute headache medication overuse (yes vs no), age (18 to < 25 years vs 25 to ≤65 years vs > 65 years), use of oral preventive treatment for headache at baseline (yes vs no), previous use of preventive treatment for headache (yes vs no), and country (United States, Australia, and South Korea).
PMC5806270|S154|7a|Sample Size Determination|Sample size calculation|An a priori power calculation based on a two-sample t test and using pilot data from 19 subjects indicated that a sample size of n = 18 per group would provide 80% power at α = 0.05 to detect a clinically meaningful 6-point difference in mean ANTS scores between the ‘hot-seat’ and ‘observer’ groups.
PMC5810183|S92|7a|Sample Size Determination|Sample size|This study was purely exploratory, thus no prospective sample size calculation had been done.
PMC5813371|S54|4a|Eligibility Criteria|Patients|The specific inclusion criteria were as follows: (1) age between 18 and 85 years, (2) pleural effusion occupying at least one third of the ipsilateral hemithorax in posteroanterior chest radiograph (CXR), (3) no contraindications for therapeutic thoracentesis, (4) general health condition allowing prolonged procedure of therapeutic thoracentesis.
PMC5813708|S54|4b|Data Collection Setting|Setting|Participants were recruited from community stroke services by National Institute for Health North East Stroke Local Research Network clinical trial officers, stroke health professionals, or advert.
PMC5813708|S88|8b,10|Randomization Type,Randomization Implementation|Randomization|An allocation sequence to randomize to either the exercise or the control group was created using a computer “true” random number generator (www.random.org) and delivered after screening by an administrator not associated with the trial.
PMC5816269|S30|3a|Trial Design|Study Design|A prospective, open-label, single-arm clinical trial.
PMC5816352|S81|4b|Data Collection Setting|Setting|Recruitment will be from locality-based, secondary-care memory clinics, and therapy delivered in the participant’s home.
PMC5816399|S94|7a|Sample Size Determination|Sample size calculation|Our pilot RCT sample size (n = 115) was calculated such that we would be able to estimate our protocol adherence rate within a margin of error of ± 5%, with 95% confidence, with an adherence rate of 90%; or ± 7%, with 95% confidence, with an anticipated adherence rate of 80%.
PMC5816732|S44|4b|Data Collection Setting|Setting|Sixty-five German ICUs participated in this registry.
PMC5817351|S126|6a|Outcomes|Outcomes|The primary outcome was all-cause post-neonatal under-5 child mortality, the secondary outcome was all-cause under-5 child mortality, and intermediate outcomes included the coverage of the campaign (as measured by the proportion of mothers who reported listening to the campaign) and family behaviours targeted by the campaign as listed in table 1 (as measured by the proportion of mothers who reported a given behaviour during interviews and the number of attendances at primary health facilities).
PMC5828327|S61|6a|Outcomes|Outcomes|Superiority of one of the active comparator treatment arms in patients after surgery for prevention of hypoactive, hyperactive or mixed delirium, which is assessed by 2-point drop in MMSE score when assessed during one of the 3 postoperative days.
PMC5828327|S186|7b|Interim Analyses/Stopping Guidelines|Interim analyses|No interim analyses are planned for this study.
PMC5838153|S40|3a|Trial Design|Study design|Integrated allelic influences of the position and type of PKD1 mutations on renal survival were examined in 410 patients with documented PKD1 or PKD2 mutations.
PMC5845153|S71|12b|Statistical Methods for Other Analyses|Subgroup analysis|In order to estimate cost-efficacy of ECLS based on indication patients will be categorized into six different subgroups: respiratory – bridge to recovery, respiratory – bridge to transplant, cardiac – bridge to recovery, cardiac – bridge to transplant, cardiac – post-cardiotomy, and extracorporeal cardiopulmonary resuscitation.
PMC5845205|S122|6b|Changes to Outcomes|Changes in trial outcomes after trial commencement|No changes in trial outcomes were made after trial commencement.
PMC5848207|S93|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Please see Supplementary Methods.
PMC5849098|S32|4b|Data Collection Setting|Setting|Emergency department and trauma center in an urban 689-bed university hospital.
PMC5849098|S36|4a|Eligibility Criteria|Subjects|Adult patients requiring phlebotomy for blood culture due to clinical suspicion of serious infection.
PMC5850181|S44|4a|Eligibility Criteria|Subjects|Healthy men and nonpregnant women (aged 18–45 years) with a body mass index of 18 to 32 kg·m−2 were enrolled.
PMC5856000|S59|3a|Trial Design|Study design|The study is a phase II single center, one-arm open-label clinical trial for patients with metastatic CRC.
PMC5858550|S70|4a|Eligibility Criteria|Patient Selection|Key inclusion criteria were refractory solid tumors (in dose escalation phase) and RR-SCLC (in dose expansion phase), not more than three prior lines of cytotoxic therapies, age ≥18 years, ECOG performance status 0–1, adequate organ/marrow function, and life expectancy >3 months; key exclusion criteria included LVEF <50%, lifetime cumulative doxorubicin dose >150 mg/m2, untreated, symptomatic brain metastases, known serious cardiac illness including, but not limited to clinically significant atrial and ventricular arrhythmias and heart block, QTc >470 ms, strong inhibitors, or inducers of CYP 3A4 or 2C19 and known allergic or hypersensitivty reactions to taxanes.
PMC5869734|S94|3b|Changes TO Trial Design|Protocol changes|The trial protocol was amended with respect to the eligibility criteria (the maximum time between delivery and randomization was increased from 7 months to 9 months), the vildagliptin dose regimen (from 100 mg once daily to 50 mg twice daily), a change to diagnostic criteria (use of the ADA 2012 criteria [21] as an alternative primary efficacy outcome), the inclusion of IGT and/or IFG as additional efficacy outcomes, and the decision to perform an interim (futility) analysis in November 2015.
PMC5877900|S53|6a|Outcomes|Study outcomes|The main study outcomes are: (1) the proportions of CC and trial participants by age group, gender, ethnicity, educational level, type of trauma and matching postal codes; and (2) the acceptability and beliefs of CC participants toward the proposed EFIC research protocol.
PMC5879797|S69|7a|Sample Size Determination|Sample size|We aimed to recruit 120 (60 intervention and 60 control) participants in order to be able to assess feasibility objectives allowing for a loss to follow-up of 10% with precision of ±1% at 95% CI.22
PMC5891970|S167|7a|Sample Size Determination|Sample size|A total of n = 50 subjects (25 patients per treatment arm) will be included in the analyses.
PMC5891981|S38|3a|Trial Design|Study design|The current study is an analysis of the baseline characteristics of participants enrolled in “Exercise and Activity Guidance in Older Adults with Diabetes”, a randomized controlled trial to improve PA in sedentary older adults with type 2 diabetes.
PMC5898946|S39|3a|Trial Design|Study design|RESPITE was a 24-week, prospective, exploratory, open-label, multicentre, uncontrolled, single-arm study including patients from nine countries in Europe and North America (ClinicalTrials.gov Identifier NCT02007629) [30].
PMC5903590|S70|8b,10|Randomization Type,Randomization Implementation|Randomization|We used restricted randomization balanced on zone and health area estimates of (1) population size, (2) prior 6-month likelihood of mRDT-negative febrile children (number of children mRDT negative/under-5 population), and (3) geographic distance from CHW to zonal health center to allocate the 28 health areas (and all the CHWs and the children they enrolled within these areas) to either universal or conditional follow-up advice (also see sample size section below) [16].
PMC5910048|S42|8b,10|Randomization Type,Randomization Implementation|Randomization|Participants were randomized 1:1 into the first treatment phase, stratified by site, to CGM using the Dexcom G4 PLATINUM (San Diego, CA), stand-alone system or conventional therapy.
PMC5937864|S65|6a|Outcomes|Secondary Outcome Measures|Change in Walking Impairment Questionnaire (WIQ, rating 0–100 from worst to best) [17], ABI, and absolute walking distance was measured by a standardized treadmill test (speed 3 km/h, without incline, maximum duration 20 min or 1000 m) between baseline and 24 months.
PMC5937973|S76|11a|Blinding Procedure|Blinding|Due to the decision of IRB and Ethical Committee, blinding in the planned study was not considered appropriate from the ethical positions, so the study protocol did not include it.
PMC5950698|S52|3a|Trial Design|Study design|Five matched retrospective case–control analyses were performed, nested within the Hopkins Lupus Cohort.
PMC5954607|S89|3a|Trial Design|Design|This is a randomized controlled trial with a follow-up.
PMC5964734|S75|6a|Outcomes|Outcomes|The outcome measures were in-hospital death, limb amputations and resource consumption (number of surgeries, length of hospitalization).
PMC5964900|S122|4b|Data Collection Setting|Data collection|We will collect worksheets and clinical note templates (which contain adherence checklists) from clinicians who have varying degrees of CBT expertise in a variety of settings The data sets will include variability in population characteristics and clinician training/education level.
PMC5968034|S102|6a|Outcomes|Outcomes|The primary outcome measures were fasting serum LDL-C and TG concentrations, secondary outcomes included fasting TC, HDL-C, lipoprotein (a) (Lp(a)) and safety and tolerance of the study products and tertiary (exploratory) outcomes were fasting non-HDL-C, remnant cholesterol (remnant C), glucose and insulin, and postprandial TG, TC, LDL-C, HDL-C, glucose and insulin response after a mixed meal challenge.
PMC5975048|S116|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Because of the small number of participants, absence of sham surgery control, and the fact that it was an open-labeled study design, we did not perform statistical analysis to compare the outcome measures of the low- and high-dose hUCB-MSC recipients.
PMC5991106|S39|3a|Trial Design|Trial design|We performed a randomised, controlled, double-blind, pilot study between July 2012 and June 2016 that was approved by the Medical Research Ethics Committee (MREC) of the University Medical Centre of Utrecht and registered at ClinicalTrials.gov, number NCT01362959.
PMC5992821|S76|3a|Trial Design|Study design|This is a single-centre, parallel group double blind-RCT.
PMC6013880|S105|6a|Outcomes|Outcome measures|The assessments were conducted at pretreatment, and at 8, 16, and 32 weeks since the trial initiation (i.e. at post-treatment, 8 weeks post-treatment and 24 weeks post-treatment).
PMC6024481|S89|7a|Sample Size Determination|Sample size calculation|For a sensitivity of 0.75, a precision of 0.15 and an alpha risk of 5%, the number of subjects required is 33 patients with ACS.
PMC6029138|S46|3a|Trial Design|Study design|REGATTA is a double-blind, randomized, controlled comparative effectiveness trial with active control and parallel groups comparing initial herbal treatment of uncomplicated UTI with immediate antibiotic therapy.
PMC6034233|S99|12a|Statistical Methods for Outcome Comparison|Statistical analysis|Statistical differences in liver and spleen volumes, as a percent of body weight (BW), at 52 weeks, relative to baseline, and differences in shoulder extension and flexion at 26 weeks, relative to baseline, were evaluated with the Paired T-Test and a two-tailed P value (GraphPad, La Jolla, CA).
PMC6042276|S70|3a|Trial Design|Study design|A prospective, single-centre, observer and patient blinded (double blinded), fixed design randomised trial.
PMC6042543|S70|3a|Trial Design|Study design|The NeuroVISION Study is a multicentre, prospective cohort study being conducted in 12 tertiary hospitals from 10 countries on 5 continents.
PMC6045886|S52|3a|Trial Design|Study design|This study was an open, nonblinded explorative study.
PMC6057099|S94|8b,10|Randomization Type,Randomization Implementation|Randomization|After completion of all the screening evaluations (compliance with all the inclusion criteria and none of the exclusion criteria) and signature of the informed consent forms, all eligible patients will be randomly assigned (2:2:1) to the three arms using minimisation technique, as follows:The “mFOLFIRINOX” arm: neo-adjuvant chemotherapy – surgical resection– adjuvant chemotherapyThe “FOLFOX” arm: neo-adjuvant chemotherapy – surgical resection– adjuvant chemotherapyThe “Standard” arm: immediate surgical resection, followed by adjuvant chemotherapy (according to current guidelines)         Centralized randomization using minimisation technique will be stratified according to the study centre, the topography of tumor (uncinate/head/neck versus body/tail), bilirubin level (< 1.5 N vs. > 1.5 N) and the CA19–9 level (≤200 U/ml vs. > 200 U/ml).
PMC6078324|S61|3a|Trial Design|Study design|This is an open-label, randomized, non-comparative, two armed exploratory study to evaluate the safety, and efficacy of two regimens of Anfoleish.
PMC6083620|S31|4a|Eligibility Criteria|Inclusion criteria|Clinical stage T3–4 N + M0 gastric cancer or Siewert II/III esophagogastric junction carcinoma; pathologically confirmed adenocarcinoma; 18–75 years old, male or female; Karnofsky score ≥ 70; white blood cell count ≥4 × 109/L; platelet count ≥100 × 109/L; serum creatinine ≤1× upper limit of normal, total bilirubin ≤1× upper limit of normal, alanine aminotransferase and aspartate aminotransferase ≤2.5× upper limit of normal, and alkaline phosphatase ≤5× upper limit of normal.
PMC6090834|S64|3a|Trial Design|Study design|This was a multicentre, qualitative study which was embedded within a trial.
PMC6090922|S48|3a|Trial Design|Design|This is a three-arm parallel randomized controlled trial which recruited adults (18–60 years) participants classified as overweight or obese (body mass index – BMI > =25 kg/m2) and who had the intention to lose weight.
PMC6090922|S66|7a|Sample Size Determination|Sample size|Based on a 90% power to detect a significant difference of 4 kg weight loss between groups, assuming the SD of weight is 6.0 and using a two-sided significance level of 0.05, and a 40% attrition rate, a sample size of 90 participants was calculated for each group [7].
PMC6102814|S47|3a|Trial Design|Trial design|Multicenter descriptive and analytic cross sectional survey of acutely admitted patients for risk factors and carriage of MRB.
PMC6102814|S56|5|Interventions|Interventions|There are no interventions in this study.
PMC6102814|S138|3b|Changes TO Trial Design|Protocol amendments|Important protocol modifications like changes in eligibility criteria or outcome will be communicated to the relevant parties, i.e. sponsor, trial registry and scientific ethical committee.
PMC6107186|S36|3a|Trial Design|Study design|We conducted a multicenter, randomized controlled trial, which enrolled mechanically ventilated patients with COPD in southern Brazil.
PMC6107292|S97|12a|Statistical Methods for Outcome Comparison|Statistical analysis|GraphPad Prism 6 was used to compare group means by student’s T test and analysis of variance and group proportions by Fisher’s exact test, and to determine Spearman’s correlation coefficients to evaluate RLU and CFU correlations.
PMC6114254|S55|4a|Eligibility Criteria|Eligibility criteria|Inclusion and exclusion criteria for the PATH-2 trial are presented in Table 2.
PMC6125258|S55|4a|Eligibility Criteria|Patients|Hospitalized adult patients > 18 years of age with CF were included in the study if they had a clinical indication for NIV at the time of admission based on at least one of the following criteria [4, 21] and had been stabilized with NIV as set by respiratory therapists, medically optimized with antibiotics and bronchodilators as necessary according to their treating physician before entering the study (in order to minimize the risk of abrupt decompensation):Signs of clinical respiratory distress: respiratory rate > 24/min or accessory muscle usePartial pressure of arterial carbon dioxide (PaCO2) level > 45 mmHg from the time of hospital admissionNocturnal hypoventilation treated by NIV but requiring daytime NIV because of clinical worsening defined as either of the two conditions aboveDiurnal hypercapnia (PaCO2 > 45 mmHg) or PtcCO2 > 40 mmHg in patients who have persistent elevation of serum bicarbonate level (HCO3− ≥ 32 mmol/L).
PMC6133462|S36|4a|Eligibility Criteria|Patients|Adult patients with ≥1-year history of active moderate-to-severe RA disease activity (DAS28-ESR ≥3.2; ≥6 tender joint count [TJC], and ≥6 swollen joint count [SJC] or ESR ≥28 mm/h; and C-reactive protein [CRP] ≥3.5 mg/L), nonresponsive to prior MTX (≥10 mg/wk for ≥12 wks) were included in the study.
PMC6137116|S35|3a|Trial Design|Trial Design|The study was a multicenter, randomized, open-label, controlled clinical trial among patients admitted at 2 hospitals in southeastern Bangladesh, Thailand: Ramu Upazilla Health Complex (primary subdistrict hospital) and Chittagong Medical College Hospital (CMCH; tertiary referral hospital).
PMC6137925|S46|3a|Trial Design|Study design|A RCT, with a PA intervention programme of 9 months duration, comprising a walking group of 120 min/week, supervised, and with socio-cultural activities.
PMC6144397|S46|3a|Trial Design|Study design|A pragmatic parallel observer-blinded RCT nested in a school-based open cohort.
PMC6145341|S116|8b,10|Randomization Type,Randomization Implementation|Randomisation|Potential participants identified from GP lists as eligible were randomly allocated to receive the control PIB or intervention (user-tested PIB) and GP covering invitation letter at a 1:1 ratio using the recruitment-tracking software developed by the Health Informatics Centre, University of Dundee, and the TCTU.
PMC6153611|S44|4a|Eligibility Criteria|Patients|Patient eligibility criteria for the randomized controlled PRIME study have been previously described (Douillard et al. 2010).
PMC6158889|S51|4a|Eligibility Criteria|Participants|The target population was underserved minority children entering kindergarten through fifth grade and their adult caregiver from underserved neighborhoods in Columbus, Ohio [13].
PMC6162005|S50|3a|Trial Design|Study design|The study has a cross-sectional design.
PMC6172755|S42|4a|Eligibility Criteria|Study population|The sample included community advisory board members (CAB); healthcare providers (henceforth “providers”); and patients registered with an urban primary HIV clinic in Kampala, Uganda, an area that is largely representative of other areas in the capital and includes lower-income market areas as well as upscale shopping areas.
